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Summary 
 
 
Huntington’s disease (HD) is a devastating neurodegenerative disorder 
caused by an expanded CAG repeat in the IT15 gene, which encodes for 
huntingtin. The disease is classically characterized by accumulation of 
huntingtin in neuronal intranuclear inclusions, a progressive degeneration of 
neurons in the striatum and the cerebral cortex, which leads to progressive motor 
and cognitive deterioration, and inevitably death. Since the discovery of the 
mutation responsible for HD, several transgenic rodent models have been 
generated. The most widely studied are the R6 lines that express exon 1 of the 
IT15 gene with 115 (R6/1) or 145 (R6/2) CAG repeats. The work presented in 
this thesis further characterizes these transgenic HD rodent models (particularly 
the R6 mice) and describes, for the first time, a number of novel histological and 
functional changes in HD. 
The first part of this thesis evaluates changes in neurotransmitter systems, at 
the level of glutamate receptor stimulation (Chapter 2) and dopamine (DA) 
release (Chapter 3). More precisely, the work presented in Chapter 2 
demonstrates that, unlike R6 mice that are known to be resistant to excitotoxic 
insults, a newly generated HD transgenic rat (which expresses 22% of the IT15 
gene with 51 CAG repeats) is not resistant to this damage. These results, 
together with previous research, suggest that the response of transgenic HD 
rodent models to excitotoxicity is dependent on the length of the transgene 
expressed. On the other hand, Chapter 3 describes an impairment in the release 
of DA in R6/1 mice, as determined by in vivo microdialysis upon membrane 
depolarization-induced exocytosis and DA transporter-mediated efflux. In 
support of this result, a reduction in whole striatal DA levels and basal levels of 
DA metabolites were also observed. These results suggest a dysfunction of the 
dopaminergic nigrostriatal pathway in HD. 
The second part of this thesis explores the involvement of nonstriatal brain 
regions, namely the lateral hypothalamus (Chapter 4) and the dentate gyrus 
(DG) of the hippocampus (Chapters 5 and 6), in the neuropathology of the R6/2 
HD mouse. 
Chapter 4 describes, for the first time, loss of specific neuronal populations 
in the lateral hypothalamus of R6/2 mice. Two major neuronal populations were 
affected: orexin-containing neurons (which regulate the sleep/wakefulness cycle) 
and melanin-concentrating hormone-containing neurons (which play a role in 
maintaining energy homeostasis). Importantly, the progressive loss of orexin 
neurons was accompanied by the development of narcoleptic-like symptoms in 
R6/2 mice, which closely resemble the deficits reported in orexin knockout mice 
Summary 
 6 
by other researchers. In conjunction with the loss of these neurons we also 
observed decreased levels of orexin in the cerebrospinal fluid of end-stage R6/2 
mice. Interestingly, we also found loss of orexin neurons in samples of the 
lateral hypothalamus of HD patients. Overall, these results clearly implicate the 
lateral hypothalamus in the pathology of HD. 
Finally, Chapters 5 and 6 describe, for the first time, a dysfunction in yet 
another nonstriatal brain region, the DG of the hippocampus, in R6/2 mice. The 
DG constitutes one of the regions in the adult mammalian brain where 
neurogenesis (i.e., generation of new neurons) occurs. R6/2 mice show a 
progressive decrease in the number of proliferating cells and neurons in the DG 
when compared to wild-type littermate controls. Moreover, this decrease can be 
detected as early as 2 weeks of age, when the R6/2 mice do not show any clear 
behavioral symptoms. Finally, treating the R6/2 mice with asialoerythropoietin 
(an erythropoietin analogue) did not reverse the decreased rate of neurogenesis 
nor had any effect on the neuropathology or the development of motor 
symptoms. 
Overall, the results presented in this thesis provide new evidence that 
corroborates the implication of excitotoxicity and dopaminergic dysfunction in 
the HD striatum. It also demonstrates pathological changes and morphological 
dysfunction in nonstriatal structures, such as the lateral hypothalamus and the 
DG of the hippocmapus. Moreover, this data further contributes to our 
understanding of the transgenic rodent models used in HD research by 
expanding our knowledge of their neuropathology. We speculate that this work 
may be instrumental in the design and screening of new therapies to treat this 
devastating neurodegenerative disorder. 
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Resumo 
 
 
A doença de Huntington (HD, do inglês ‘Huntington’s disease’) é uma 
doença neurodegenerativa causada pela expansão de repetições do trinucleotídeo 
CAG no gene IT15 que codifica a proteína huntingtina. Esta doença é 
classicamente caracterizada pela formação de inclusões nucleares de huntingtina 
em células neuronais e pela progressiva degenerescência dos neurónios do 
estriado e do córtex cerebral. Clinicamente, a HD manifesta-se pela deterioração 
progressiva das capacidades motoras e cognitivas, resultando na morte do 
paciente. Desde a descoberta da mutação responsável pela HD, vários modelos 
transgénicos têm vindo a ser gerados em rato e ratinho, entre os quais se 
destacam as linhas R6 que expressam o exon 1 do gene IT15 com 115 (linha 
R6/1) ou 145 (linha R6/2) repetições do trinucleotídeo CAG. O trabalho 
apresentado nesta tese caracteriza alguns destes modelos transgénicos (em 
particular os ratinhos R6) e descreve, pela primeira vez, alterações morfológicas 
e funcionais que poderão contribuir para a patologia da HD. 
Na primeira parte desta tese são avaliadas as alterações nos sistemas de 
neurotransmissão, em particular a activação de receptores de glutamato 
(Capítulo 2) e a libertação de dopamina (DA) (Capítulo 3). Deste modo, o 
trabalho apresentado no Capítulo 2 demonstra que o modelo transgénico para a 
HD que foi recentemente gerado em rato (e que expressa 22% do gene IT15 com 
51 repetições do trinucleotídeo CAG) não apresenta alterações na 
susceptibilidade dos neurónios do estriado a lesões excitotóxicas. Estes 
resultados, juntamente com estudos anteriores, sugerem que a resposta dos 
vários modelos transgénicos para a HD a insultos excitotóxicos é dependente do 
tamanho do transgene. Por outro lado, no Capítulo 3 são apresentadas novas 
evidências que suportam uma desregulação na libertação de DA em ratinhos 
R6/1. A libertação deste neurotransmissor foi detectada por microdiálise in vivo 
após exocitose induzida por despolarização da membrana plasmática e após 
indução da libertação de DA através do seu transportador membranar. Para além 
disso, um decréscimo dos níveis totais de DA no estriado e dos níveis basais dos 
metabolitos de DA foram observados em ratinhos R6/1. Estes resultados 
confirmam o envolvimento de uma disfunção da via dopaminérgica nigro-
estriatal na patologia da HD. 
A segunda parte desta tese explora o envolvimento de algumas regiões 
cerebrais não estriatais, o hipotálamo lateral (Capítulo 4) e o giro dentado (DG, 
do inglês ‘dentate gyrus’) do hipocampo (Capítulos 5 e 6), na neuropatologia do 
ratinho R6/2. 
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O Capítulo 4 descreve, pela primeira vez, a perda de populações neuronais 
no hipotálamo lateral de ratinhos R6/2. Os neurónios afectados contêm orexina 
(um peptídeo que regula o ciclo diurno/nocturno) ou a hormona concentradora 
da melanina, que desempenha um papel importante na manutenção da 
homeostase energética. A perda progressiva dos neurónios que contêm orexina é 
acompanhada pelo desenvolvimento de sintomas do tipo narcoléptico nos 
ratinhos R6/2, semelhantes aos sintomas descritos em ratinhos que não 
expressam o gene da orexina. Para além disso, os níveis deste peptídeo no 
líquido cefalorraquidiano de ratinhos R6/2 também se encontram reduzidos, e a 
perda de neurónios que contêm orexina também foi detectada em cérebros de 
doentes com HD. Estes resultados reforçam a importância do hipotálamo lateral 
na patologia da HD. 
Finalmente, os Capítulos 5 e 6 descrevem, pela primeira vez, a disfunção de 
outra região cerebral não estriatal, o DG do hipocampo, no ratinho R6/2. O DG 
constitui uma das regiões no cérebro adulto de mamíferos onde ocorre a 
formação de novos neurónios, um processo designado por neurogénese. Os 
ratinhos R6/2 apresentam um decréscimo progressivo no número de células 
proliferativas e de novos neurónios nesta região cerebral, quando comparados 
com ratinhos controlo da mesma idade. Para além disso, este decréscimo pode 
ser detectado às duas semanas de idade, uma altura em que os ratinhos 
transgénicos ainda não apresentam quaisquer sintomas. Por fim, o tratamento de 
ratinhos R6/2 com asialo-eritropoietina (um análogo da eritropoietina) não teve 
qualquer efeito na redução da proliferação celular observada no hipocampo 
destes animais, bem como na neuropatologia e no desenvolvimento dos sintomas 
motores.  
Conjuntamente, os resultados apresentados nesta tese corroboram o 
envolvimento da excitotoxicidade e da disfunção dopaminérgica na HD, e 
demonstram, ao nível morfológico e funcional, o envolvimento de estruturas 
cerebrais não estriatais na patologia da HD. Para além disso, estes resultados 
contribuem para uma melhor caracterização dos modelos transgénicos mais 
usados na investigação da HD e descrevem novos aspectos da sua 
neuropatologia, possibilitando o desenvolvimento de novas terapias para esta 
doença neurodegenerativa. 
 
Chapter 1 
Introduction 
 9 
 
 
 
 
 
 
 
Chapter 1 
 
 
General Introduction 
 
Huntington’s Disease and in vivo Transgenic Models 
Used to Study this Neurodegenerative Disorder 
 
 
 
Chapter partially based on the following reviews: 
 
Gil J, and Rego AC (2006): “Mechanisms of neurodegeneration in Huntington’s 
disease”, (Manuscript in preparation). 
 
Petersén Å, Gil J, and Brundin P (2006): “Revolutionizing Huntington’s disease 
research: the R6 transgenic mice”, (Manuscript in preparation for Brain Res Rev). 
 
 
  10 
Chapter 1 
Introduction 
 11 
1.1. Polyglutamine Diseases 
 
The expression of unstable trinucleotide repeats is known to be the 
underlying cause of several neurological disorders. Nine of these diseases are 
caused by the expansion of cytosine-adenine-guanine (CAG) repeats (which 
code for the amino acid glutamine) on specific genes, leading to the expression 
of a glutamine track in the respective proteins. Hence, these disorders are 
referred as polyglutamine diseases (for review see Gusella and MacDonald, 
2000; Zoghbi and Orr, 2000; Ross, 2002; Gatchel and Zoghbi, 2005). 
The polyglutamine diseases include Spinal and Bulbar Muscular Atrophy 
(SBMA; also called Kennedy Disease), DentatoRubral and PallidoLuysian 
Atrophy (DRPLA), Spino-Cerebellar Ataxia (SCA) types 1, 2, 3 (also called 
Machado-Joseph Disease), 6, 7, and 17, and Huntington’s Disease (HD), the 
most common of these neurodegenerative disorders. In all 9 diseases, the first 
symptoms normally appear in midlife. They then progress over time and are 
caused by dysfunction and eventual loss of specific neuronal populations. Death 
of affected individuals occurs 10 to 20 years after the appearance of the first 
symptoms. With the exception of SBMA (which has a X-linked recessive pattern 
of inheritance), polyglutamine expansion diseases are dominantly inherited. 
Interestingly, the age of onset and the severity of the disease are inversely 
correlated with the number of CAG repeats. Each disorder shows a characteristic 
threshold for the length of the glutamine tract (Table I), below which symptoms 
are not manifested and above which a progressive decrease in the age of onset is 
observed. Excessively large expansions result in severe juvenile-onset cases, 
characterized by widespread neurodegeneration and cell death. However, the age 
of onset and progression of polyglutamine diseases may be determined by 
factors other than the CAG expansion, since for a given CAG repeat there is a 
great variation in the age of onset. 
The CAG repeats show both somatic and germline instability, causing 
intergenerational instability (i.e., variation of the number of repeats from 
generation to generation). This is frequently observed in paternal transmissions 
and may result in anticipation of the disease characterized by earlier age of 
onset, increase in the severity of the symptoms and faster progression of the 
disease in the next generation (for review see Gusella and MacDonald, 2000; 
Zoghbi and Orr, 2000; Gatchel and Zoghbi, 2005). Interestingly, for most 
polyglutamine diseases (including HD) alleles with CAG repeats within the 
upper limit of the normal range are less stable during transmission through the 
germline than shorter alleles. Therefore, these are believed to constitute the 
allele pool from which the pathologic mutations are generated. As a result, there 
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is a positive correlation between the frequency of “long normal alleles” and the 
disease prevalence in any given population (for review see Ho et al., 2001). 
 
 
Table I – Features of the various polyglutamine neurodegenerative diseases. 
Polyglutamine 
Disease 
Mutated 
Protein 
Expanded 
CAG Repeat 
Affected Brain Regions Main Clinical 
Symptoms 
SBMA 
(Kennedy Disease) 
Androgen 
Receptor 
38-62 Anterior horn and bulbar 
neurons, dorsal root 
ganglia 
Motor weakness, 
swallowing difficulty, 
hypogonadism 
DRPLA Atrophin-1 49-88 Cerebellum, cerebral 
cortex, basal ganglia, 
Luys body 
Ataxia, epilepsy, 
choreoathetosis, 
dementia 
SCA-1 Ataxin-1 40-82 Cerebellar Purkinje cells, 
dentate nucleus, brain 
stem 
Ataxia, slurred speech, 
spasticity, cognitive 
impairment 
SCA-2 Ataxin-2 32-200 Cerebellar Purkinje cells, 
fronto-temporal lobes, 
brain stem 
Ataxia, decreased 
reflexes, 
polyneuropathy, motor 
neuropathy 
SCA-3 (Machado-
Joseph Disease) 
Ataxin-3 61-84 Cerebellar dentate 
neurons, basal ganglia, 
brain stem, spinal cord 
Ataxia, parkinsonism, 
severe spasticity 
SCA-6 α1A-voltage-
dependent Ca2+ 
channel 
20-29 Cerebellar Purkinje cells, 
dentate nucleus, 
inferior olive 
Ataxia, dysarthria, 
nystagmus, tremor 
SCA-7 Ataxin-7 37-306 Cerebellum, brain stem, 
macula, visual cortex 
Ataxia, retinal 
degeneration 
SCA-17 TATA-binding 
protein (TBP) 
47-63 Cerebellum, caudate 
nucleus, putamen, 
thalamus, frontal and 
temporal cortex 
Ataxia, behavioural 
changes or psychosis, 
intellectual 
deterioration, seizures 
HD Huntingtin 35-121 Striatum (caudate 
nucleus and putamen), 
cerebral cortex, 
hypothalamus 
Movement 
abnormalities, chorea, 
dystonia, cognitive 
decline, dementia 
(Adapted from Gusella and MacDonald, 2000; Zoghbi and Orr, 2000; Gatchel and 
Zoghbi, 2005). 
 
The genes carrying the expanded CAG repeat that are responsible for these 9 
disorders share no homology except for the CAG repeat itself. As a 
consequence, the proteins that they code for are unrelated to each other (Table 
I). Therefore, it has been suggested that the expanded polyglutamine track on 
each of these unrelated proteins is directly responsible for the neurodegeneration 
seen in polyglutamine expansion disorders. On the other hand, the affected 
proteins have been suggested to play an indirect modulatory role on some of the 
disease-specific characteristics, such as which specific brain regions become 
affected, the number of CAG repeats necessary for the manifestation of disease 
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symptoms, and the rate of disease progression (for review see Gusella and 
MacDonald, 2000; Ross, 2002). 
Another interesting feature common to most polyglutamine diseases (SBMA, 
DRPLA, SCA-1, -3, -7, -17, and HD) is the localization of the respective mutant 
proteins into ubiquitinated neuronal inclusions. These inclusions are thought to 
result from the accumulation of misfolded mutant proteins that are not degraded 
by the proteasome despite the presence of ubiquitin residues, which are known 
to target proteins for proteasomal degradation. In addition, these inclusions may 
also contain several different intracellular molecules with which the mutant 
proteins establish aberrant interactions. Therefore, protein aggregation appears to 
be a critical event in most polyglutamine diseases (for review see Zoghbi and 
Orr, 2000; Gatchel and Zoghbi, 2005). 
 
 
1.2. Huntington’s Disease 
 
HD is the most common and well studied polyglutamine neurodegenerative 
disorder. It has a prevalence of 3 to 10 affected subjects per 100,000 individuals 
in Western Europe and North America (for review see Vonsattel and DiFiglia, 
1998; Ho et al., 2001). 
The disorder was first described in the 19th century by George Huntington, 
who identified both its clinical features and pattern of familial transmission. 
However, it was not until 1993 that a multicenter consortium, organized by the 
Hereditary Disease Foundation, discovered the actual HD gene mutation. This is 
an unstable expansion of CAG repeats within the coding region of the 
“Interesting Transcript 15” (IT15) gene, which is located on the short arm of 
chromosome 4 (4p63) and encodes huntingtin, a protein of yet unknown 
function. The mutation results in a stretch of glutamine residues located in the 
NH2-terminal of huntingtin (The Huntington’s Disease Collaborative Research 
Group, 1993). Although the abnormal protein is ubiquitous expressed throughout 
the organism, cell degeneration appears to be restricted to the brain (for review 
see Vonsattel and DiFiglia, 1998). 
 
 
1.2.1. Clinical Manifestation 
Mutant huntingtin is expressed throughout life. However, in most cases the 
onset of the disease occurs in midlife, between the ages of 35 and 50 years. 
When intergenerational instability and anticipation occur, the first symptoms can 
appear during early childhood, leading to rare and more severe infantile or 
juvenile cases. The disease progresses over time and is invariably fatal 15 to 20 
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years after the onset of the first symptoms. In juvenile cases the progression is 
faster, leading to death 7 to 10 years after the onset of symptoms (for review see 
Ho et al., 2001). 
Classically described as Huntington’s Chorea (the Greek word for dance), 
the first signs of the disease are subtle: clumsiness, difficulties with smooth eye 
pursuit, and slight uncontrolled and awkward movements. These motor 
disturbances, with the loss of voluntary movement coordination, progress 
slowly. The involuntary movements of the proximal and distal muscles become 
more severe and the patients gradually lose their capacity to move and 
eventually communicate. In late stages of the disease, the chorea tends to be 
replaced by bradykinesia and rigidity, where death soon follows due to heart 
failure or aspiration pneumonia. In juvenile patients the symptomatology is 
considerably different, being characterized by bradykinesia, tremors, rigidity and 
dystonia, where the chorea may be completely absent. Affected children may 
also suffer epileptic seizures (for review see Vonsattel and DiFiglia, 1998; 
Gusella, 2001; Ho et al., 2001; Petersén and Brundin, 2002). 
The majority of patients also suffer from inexplicable muscle wasting and 
weight loss, despite constant caloric intake (Sanberg et al., 1981; Kirkwood et 
al., 2001; Djousse et al., 2002). The cause of these peripheral symptoms is still 
unclear. A number of endocrine abnormalities have also been reported in HD 
patients, including increased levels of corticosteroids (Heuser et al., 1991; 
Leblhuber et al., 1995; Björkqvist et al., 2006a) and reduced levels of 
testosterone (Markianos et al., 2005). Furthermore, 10-25% of HD patients 
exhibit diabetes mellitus (Farrer et al., 1985). 
The cognitive capacities are also severely affected during the course of HD, 
which can be classified as subcortical dementia. The slowing of intellectual 
processes is the first sign of cognitive impairment in HD patients. Chronic 
depression sometimes occurs years before the onset of motor symptoms. 
Cognitive impairments progress over time and late-stage HD patients show 
profound dementia. Manic-depressive behaviour and personality changes 
(irritability, apathy, and sexual disturbances) are often part of the psychiatric 
syndrome (for review see Vonsattel and DiFiglia, 1998; Gusella, 2001; Ho et al., 
2001; Petersén and Brundin, 2002). 
Based on the above features, the criteria used for the diagnostic of HD 
include: (1) a family history of HD; (2) progressive motor disability with chorea 
or rigidity with no other cause; and (3) psychiatric disturbances with progressive 
dementia with no other cause (for review see Vonsattel and DiFiglia, 1998). 
Currently, all individuals showing these symptoms are submitted to genetic 
testing in order to screen for the HD mutation and confirm the diagnosis. 
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1.2.2. Neuropathology 
The pathological hallmark of HD is the gradual atrophy of the striatum 
(caudate nucleus and putamen), which can be observed in 95% of all HD cases 
(Figure 1.1). 
 
Figure 1.1. – (A) A schematic representation of the human basal ganglia from a 
three-dimensional and coronal perspectives. The basal ganglia includes the striatum, 
which comprises the caudate nucleus and putamen. Adapted from Kolb and Whishaw, 
2006. (B) Macroscopic photographs of HD and normal control brains in coronal view. 
Note that the striatum is severely atrophied in the HD brain. Adapted from the web-page 
of the Harvard Center for Neurodegeneration & Repair: 
http://www.hcnr.med.harvard.edu/visitorInfo/huntingtons.php 
 
 
The most commonly used grading system to assess the severity of HD 
degeneration was developed by Vonsattel and colleagues (1985). It is based on 
the pattern of striatal degeneration in post mortem tissue and classifies HD cases 
into five different severity grades (0 to 4): Grade 0, which comprises 1% of all 
HD brains, superficially appears indistinguishable from normal brains after gross 
Chapter 1 
Introduction 
 16 
examination. However, with histological examination, a 30-40% neuronal loss 
can be detected in the head of the caudate nucleus. Grade 1 occurs in 4% of all 
HD brains and comprises atrophy in the tail, and in some cases the body of the 
caudate nucleus. Neuronal loss and astrogliosis are evident in the head (50% 
loss), tail, and to a less extent, in the body of the caudate nucleus. Grade 2 
comprises 16% of the cases, with gross striatal atrophy that is more pronounced 
than that detected in grade 1 brains. Grade 3 comprises 54% of all HD brains, 
with severe gross striatal atrophy. Grade 4 includes 25% of all HD cases, with 
severe atrophy of the striatum and up to 95% neuronal loss (Vonsattel et al., 
1985). 
Interestingly, the degree of striatal atrophy also correlates with the 
degeneration of other nonstriatal brain structures. For instance, in grades 1 and 2 
nonstriatal structures are generally spared or only show a slight atrophy; 
whereas, in grades 3 and 4 the cerebral cortex (particularly layers III, V, and 
VI), globus pallidus, thalamus, subthalamic nucleus, substantia nigra, white 
matter, and cerebellum can be markedly affected (for review see Vonsattel and 
DiFiglia, 1998). Recent studies have also indicated that the hypothalamus can be 
significantly atrophied in HD patients (Kassubek et al., 2004), which is in 
agreement with previous findings of loss of somatostatin-positive neurons in the 
lateral tuberal nucleus of the hypothalamus (Kremer et al., 1990, 1991). Because 
of the generalized cerebral atrophy observed with the most severe cases, the 
overall brain weight can decrease by up to 40% (Figure 1.1; for review see 
Gusella, 2001). 
Within the striatum, the most afflicted neuronal populations are the medium-
sized projection spiny neurons, which correspond to 80% of the striatal neuronal 
population. These neurons use the inhibitory transmitter γ–aminobutyric acid 
(GABA), and either enkephalin, dynorphin, or substance P as co-transmitters. 
These neurons are in part regulated by the dopaminergic inputs emanating from 
the substantia nigra in the brain stem, and project back to the substantia nigra 
and to the globus pallidus. Since these medium-sized spiny neurons exert an 
inhibitory effect, it is believed that the loss of their inhibitory input is the 
underlying cause of the uncontrolled movements characteristic of HD (for 
review see Gusella, 2001). 
Interestingly, different degrees of degeneration can be observed within the 
striatal spiny neuronal population, with enkephalin-containing neurons being 
more susceptible than substance P-containing neurons. Conversely, medium-
sized aspiny interneurons (containing somatostatin, neuropeptide Y, or NADPH-
diaphorase), cholinergic interneurons, and parvalbumin-containing GABAergic 
neurons are relatively spared in HD brains. Since striatal neurons receive 
glutamatergic input from the cerebral cortex, it has been suggested that the 
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degree of degeneration of the various striatal populations results from their 
glutamate receptor composition, which in turn can modulate their susceptibility 
to glutamate stimulation. Thus, the most vulnerable spiny neurons are those that 
express ionotropic N-methyl-D-aspartate (NMDA) receptors predominantly 
formed by NR1 and NR2B subunits; whereas, the less vulnerable aspiny neurons 
express mainly the NR2D subunit (see section 1.4.1). However, the aspiny 
neurons also demonstrate increased vulnerability in late stages of the disease (for 
review see Vonsattel and DiFiglia, 1998; Davies and Ramsden, 2001). 
HD is also characterized by the presence of neuronal intranuclear inclusions 
(NIIs) (DiFiglia et al., 1997a) and protein aggregates in dystrophic neurites 
(Sapp et al., 1999) in striatal and cortical neurons, which is a feature of several 
other polyglutamine diseases (section 1.1). These inclusions are present in 1 to 
5% of all striatal neurons and in 3 to 6% of all cortical neurons (DiFiglia et al., 
1997a). Interestingly, the frequency of neurons bearing NIIs is drastically 
increased in juvenile cases of HD, reaching a frequency of 38 to 52% in the 
cerebral cortex (DiFiglia et al., 1997a). 
NIIs appear before the loss in brain weight, which in turn, is known to 
precede the loss of body weight and the onset of neurological symptoms (for 
review see Vonsattel and DiFiglia, 1998). These events suggest that the 
abnormal accumulation of mutated protein is one of the initial pathologic events 
during the development of HD. Moreover, the number of cortical inclusions 
correlates well with the length of the CAG repeat expansion and the age of 
disease onset (Becher et al., 1998), further indicating that the development of 
NIIs is a good predictor of the disease state. 
 
 
1.2.3. Genetics  
As mentioned above (section 1.2), the mutation responsible for HD 
constitutes a stretch of uninterrupted CAG trinucleotide repeats located near the 
5’-end in exon 1 of the IT15 gene coding sequence, which comprises 67 exons. 
Consequently, the mutated protein (huntingtin) bears a tract of consecutive 
glutamine residues in its NH2-terminal, 17 amino acids downstream from the 
initiator methionine (The Huntington’s Disease Collaborative Research Group, 
1993). 
The disease is inherited in an autosomal dominant manner. The normal and 
mutant alleles are transmitted from generation to generation in a Mendelian 
fashion. The mutant allele is unstable during meiosis, changing in length in the 
majority of intergenerational transmissions, with either slight increases of 1 to 4 
units or decreases of 1 to 2 units. In rare occasions, larger size increases occur in 
parental transmissions, which reflects a particularly high mutation rate during 
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spermatogenesis (The Huntington’s Disease Collaborative Research Group, 
1993; for review see Gusella, 2001). 
The number of CAG repeats (i.e., glutamine residues) is the primary and 
major determinant of disease severity, accounting for about 60% of the variance 
in the age of onset of the first symptoms. The remaining variance is attributable 
to other genetic features and environmental factors. Normally, asymptomatic 
individuals have less than 35 CAG repeats; whereas, HD is manifested when the 
number of repeats exceeds this threshold. Alleles with 35 to 39 repeats are 
associated with later onset of the disease, although incomplete penetrance has 
been observed in some individuals who have shown no symptoms or 
neuropathological signs. Alleles of 40 to 50 units give rise to the most common 
adult-onset form of the disease; whereas, the longest repeats (normally 
associated with high allele instability during parental transmission) are 
responsible for the severe juvenile and infantile cases (The Huntington’s Disease 
Collaborative Research Group, 1993; for review see Gusella, 2001). 
Importantly, there is a positive correlation between the number of CAG 
repeats and the Vonsattel grades of neuropathological severity (section 1.2.2), 
with greater CAG repeat lengths being associated with greater degrees of cell 
death in the striatum and higher Vonsattel grades (for review see Vonsattel and 
DiFiglia, 1998). 
 
 
1.3. Huntingtin 
 
Huntingtin is a protein composed by more than 3100 amino acids and with a 
molecular mass of approximately 349 kDa, depending on the exact number of 
glutamine residues. A polymorphic proline-rich segment follows the 
polyglutamine tail (The Huntington’s Disease Collaborative Research Group, 
1993). Huntingtin does not show structural homology with any other known 
protein. 
The wild-type protein is widely expressed throughout the body, in both 
neuronal and non-neuronal cells, raising the question of how and why the 
disease mutation results in a selective neuronal loss. As mentioned above 
(section 1.2.2), in the HD brain, particularly in the two most affected regions, the 
striatum and cerebral cortex, an altered intracellular localization and perinuclear 
accumulation of mutant huntingtin is observed, with the formation of NIIs 
(DiFiglia et al., 1997a) and aggregates in dystrophic neurites (Sapp et al., 1999). 
However, the neurons bearing inclusions do not correspond to the most 
vulnerable ones. Indeed, the interneurons that are spared during the course of the 
disease are the ones that display the highest frequency of aggregates 
Eliminado: , 
Eliminado: with t
Eliminado: reminder being 
Eliminado: , as well as
Eliminado: -
Eliminado: usually cause the disease 
late in life
Eliminado: n
Eliminado: of the disease; a
Eliminado: -
Eliminado: ; 
Chapter 1 
Introduction 
 19 
(Kuemmerle et al., 1999), raising the question of whether inclusions are toxic, 
protective, or just an epiphenomenon of the disease mechanism. 
 
 
1.3.1. Proposed Functions of Wild-Type Huntingtin 
Pioneer studies have clearly shown that wild-type huntingtin is essential for 
normal embryonic development, since engineered knockout mutations that 
disrupt exon 4 (Duyao et al., 1995), exon 5 (Nasir et al., 1995), or the promoter 
(Zeithlin et al., 1995) of the mouse HD gene homolog Hdh leading to its 
complete inactivation, result in embryonic lethality. Interestingly, the HD 
mutation does not seem to abrogate the developmental functions of huntingtin, 
since HD patients appear to develop normally and the symptoms only start to 
manifest several years after birth. Nevertheless, normal huntingtin appears to be 
required not only during embryogenesis but also throughout life, since 
conditional knockout mice in which the Hdh gene is inactivated during 
adulthood are sterile and develop a progressive neuronal degenerative phenotype 
(Dragatsis et al., 2000). 
Within the cell, wild-type huntingtin is mainly localized in the cytoplasm 
associated with organelles such as mitochondria, the Golgi apparatus, the 
endoplasmic reticulum (ER), synaptic vesicles, and several components of the 
cytoskeleton. Wild-type huntingtin is also present inside the nucleus, although to 
a lesser extent (for review see Young, 2003; Landles and Bates, 2004). 
Yeast two-hybrid screenings, western-blotting, and immunoprecipitation 
studies have shown that wild-type huntingtin binds to several proteins. The latest 
review that was published on this subject listed 27 huntingtin-interacting 
proteins (Li and Li, 2004), and the list is continuously growing. Relevant 
examples include: (1) Huntingtin-Associated Protein 1 (HAP1), a novel protein 
with at least two isoforms (HAP1-A and HAP1-B) that is expressed in several 
tissues including the brain. HAP1 interacts with the p150 subunit of dynactin, 
thus being involved in intracellular transport; (2) Huntingtin Interacting Protein 
1 (HIP1), a protein implicated in cytoskeleton assembly as well as in 
endocytosis that binds to α–adaptin and clathrin; (3) Huntingtin Interacting 
Protein 2 (HIP2), an ubiquitin-conjugating enzyme that catalyzes the covalent 
attachment of ubiquitin units to intracellular proteins, tagging them for 
degradation by the proteasome; (4) Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH), a glycolytic enzyme; and (5) Microtubules and β-Tubulin, 
components of the cytoskeleton (for review see Gusella and MacDonald, 1998; 
Walling et al., 1998; Li and Li, 2004). 
In some cases, a functional relationship between wild-type huntingtin and its 
interacting proteins has also been established, as illustrated with the following 
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examples. (1) Postsynaptic Density 95 (PSD95) is a protein located in the 
postsynaptic membrane that is involved in the anchoring of NMDA and kainate 
(KA) receptors to the membrane. Wild-type huntingtin was shown to regulate 
these receptors through the binding of its Src homology-3 (SH3) sequence 
(proline-x-x-proline) to PSD95 (Sun et al., 2001). (2) Repressor-Element-1 
Transcription Factor (REST) / Neuron-Restrictive Silencer Factor (NRSF) is a 
transcriptional factor complex that binds to neuron-restrictive silencer elements 
(NRSEs) present in certain neuronal gene promoters, such as the Brain Derived 
Neurotrophic Factor (BDNF) promoter, inhibiting their expression. Wild-type 
huntingtin promotes BDNF expression by interacting with REST/NRSF in the 
cytoplasm and thus preventing this complex to translocate into the nucleus 
(Zuccato et al., 2003). (3) Vesicular transport of BDNF along the microtubules 
is also promoted by wild-type huntingtin and involves HAP1 and the p150 
subunit of dynactin (Gauthier et al., 2004). (4) HAP1 and Mixed-Lineage Kinase 
2 (MLK2) stimulate and modulate the activity of the helix-loop-helix 
transcription factor NeuroD (Marcora et al., 2003), which is crucial for the 
development of the dentate gyrus (DG) of the hippocampus (Liu et al., 2000), 
and for the morphogenesis of pancreatic islets (Huang et al., 2002). Interaction 
of wild-type huntingtin with both HAP1 and MLK2 was shown to promote the 
expression of this transcription factor (Marcora et al., 2003). (5) HIP1 
interaction with wild-type huntingtin prevents its binding to the HIP1-protein 
interactor (HIPPI) and the consequent activation of caspase-8 by this protein 
complex (Gervais et al., 2002). 
The anti-apoptotic function of wild-type huntingtin has also been 
corroborated with several in vitro studies. These have demonstrated that 
expression of the full-length protein protected conditionally immortalized 
striatal-derived cells from a variety of apoptotic stimuli. Wild-type huntingtin 
appeared to act downstream of mitochondrial cytochrome c release, preventing 
the formation of a functional apoptosome complex and the consequent activation 
of caspase-9 (Rigamonti et al., 2001) and caspase-3 (Rigamonti et al., 2000). 
Interestingly, huntingtin sequence has 10 HEAT (Huntingtin, Elongation 
Factor 3, Protein Phosphatase 2A, Target Of Rapamycin 1) repeats, which are 
conserved repeating segments of approximately 40 amino acids that form 2 
hydrophobic α-helices (Andrade and Bork, 1995). The function of these motives 
is still unclear, although they are found in a variety of proteins that are involved 
in intracellular transport and chromosomal segregation (Neuwald and Hirano, 
2000). 
Overall, these studies indicate that wild-type huntingtin may exert a variety 
of intracellular functions such as: (1) protein trafficking; (2) vesicle transport 
and anchoring to the cytoskeleton; (3) clathrin-mediated endocytosis; (4) 
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postsynaptic signaling; (5) transcriptional regulation; (6) and anti-apoptotic 
function (Figure 1.2). Thus, wild-type huntingtin is believed to have a pro-
survival role inside the cell (for review see Gusella and MacDonald, 1998; 
Walling et al., 1998; Landles and Bates, 2004; Li and Li, 2004). 
 
Figure 1.2. – Proposed functions of wild-type huntingtin. Based on the 
identification of several huntingtin-interacting proteins, it is believed that wild-type 
huntingtin may exert various intracellular functions that contribute to cell survival. 
 
 
 
1.3.2. Aggregation of Mutant Huntingtin 
Two non-mutually exclusive mechanisms have been suggested to explain the 
formation of aggregates of mutant huntingtin: 
1) The Polar Zipper Model. According to this theory, the normal tertiary 
protein conformation is destabilized by the presence of the expanded 
polyglutamine tract, leading to the establishment of abnormal protein-protein 
interactions with other polyglutamine-bearing proteins (including molecules of 
mutant and wild-type huntingtin). This results in the formation of insoluble β-
pleated sheets that form polar zipper structures via hydrogen bonding (Perutz et 
al., 1994; Stott et al., 1995). 
2) The Transglutaminase Model. Transglutaminases are enzymes that are 
involved in the cross-linking of glutamine residues and thus may also participate 
in the formation of aggregates. Indeed, in vitro studies have shown that 
huntingtin is a transglutaminase substrate and that the transglutaminase-mediated 
cross-linking increases with the length of the polyglutamine stretch (Kahlem et 
al., 1998). Hence, the expanded polyglutamine tract caused by the disease 
mutation could result in an increased transglutaminase-mediated cross-linking 
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with other molecules of mutant and wild-type huntingtin, as well as other 
polyglutamine-containing proteins, leading to the precipitation and intraneuronal 
accumulation of protein complexes. In support of this model, transglutaminase 
activity was shown to be increased in HD brains (Karpuj et al., 1999). 
Once formed, these aggregates of mutant huntingtin are transported by the 
microtubule organization center, or centrosome, to a perinuclear localization 
(Waelter et al., 2001; Hoffner et al., 2002). 
Because the formation of mutant huntingtin aggregates is regarded as a 
hallmark of HD, many hypothesize that aggregation of mutant huntingtin is the 
trigger point that eventually leads to cell demise in HD. Indeed, several proteins 
have been shown to abnormally interact and be recruited into the aggregates of 
mutant huntingtin, causing a severe dysregulation of several key intracellular 
pathways (see section 1.3.3). Nevertheless, mutant huntingtin inclusions may 
only represent a side effect of the ongoing cell dysfunction, or may even exert a 
protective role during the early stages of the disease. Indeed, it is possible that 
the inclusions represent a means for the cell to sequester the toxic N-terminal 
fragments and oligomers of mutant huntingtin as well as other misfolded 
proteins, which in the soluble form could cause a more rapid and severe damage 
(for review see Ciechanover and Brundin, 2003; Gunawardena and Goldstein, 
2005). 
 
 
1.3.3. Mutant Huntingtin & Intracellular Dysfunction 
The expanded polyglutamine is believed to confer a new function to 
huntingtin that is toxic to the cell (toxic gain of function). Indeed, the mutant 
protein (in either its soluble or insoluble/aggregate form) has been shown to 
disrupt several intracellular pathways by abnormally interacting and/or 
sequestering key components of these multiple pathways into the aggregates 
(Figure 1.3). On the other hand, several lines of evidence also suggest that a loss 
of function of wild-type huntingtin (due to its decreased expression and/or 
sequestration into the aggregates by interacting with the mutant protein) also 
contributes to the disruption of intracellular homeostasis, culminating in 
neuronal dysfunction and death (Figure 1.3). 
The contribution of both the toxic gain of function of mutant huntingtin and 
the loss of function of wild-type huntingtin for the dysregulation of relevant 
intracellular pathways that ultimately lead to cell loss in HD is summarized in 
Figure 1.3 and through the following sections. 
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Figure 1.3. – Both the loss of function of wild-type huntingtin and the toxic gain of 
function of mutant huntingtin contribute to the dysregulation of relevant intracellular 
pathways. These include: (1) activation of proteases such as calpains and caspases; (2) 
protein misfolding and inhibition of protein degradation (through the interaction with 
heat shock proteins and the proteasome); (3) transcriptional dysregulation (via abnormal 
interaction with numerous transcription factors); (4) disruption of axonal transport; and 
(5) synaptic dysfunction (by interfering with the expression and/or function of several 
synaptic proteins and neurotransmitter receptors). 
 
 
 
1.3.3.1. Activation of Proteases 
Protease cleavage sites for caspase-3 (Goldberg et al., 1996; Kim et al., 
2001; Sun et al., 2002) and calpain (Kim et al., 2001; Gafni and Ellerby, 2002; 
Sun et al., 2002) have been identified within the first 550 amino acids of 
huntingtin, and proteolysis has been shown to increase in the presence of longer 
polyglutamine tails (Gafni and Ellerby, 2002; Sun et al., 2002). Caspase-3 and 
calpain-mediated sequential proteolysis of mutant huntingtin was suggested to 
produce N-terminal fragments that are more toxic and prone to aggregate (Kim 
et al., 2001) and that diffuse passively into the nucleus due to its smaller size 
(Gafni and Ellerby, 2002; Sun et al., 2002). Moreover, these fragments can in 
turn recruit more proteases into the aggregates, favoring their subsequent 
Eliminado: was 
Eliminado: be 
Eliminado: d
Eliminado: than full-length 
huntingtin 
Eliminado: can 
Eliminado: It is suggested that
Chapter 1 
Introduction 
 24 
activation. This creates a positive feedback loop that results in further 
aggregation and proteolytic cleavage that may ultimately contribute to cell death. 
Furthermore, the expanded polyglutamine also reduces the binding of 
huntingtin to HIP1 (section 1.3.1), which is then free to associate with HIPPI and 
induce the activation of caspase-8, an initiator caspase that triggers the apoptotic 
cascade (Gervais et al., 2002). 
Finally, a very recent study has shown that yeast artificial chromosome 
(YAC) mice (see section 1.5.2) expressing a full-length mutant huntingtin 
construct that is resistant to cleavage by caspase-6, do not develop striatal 
neurodegeneration (Graham et al., 2006). These results strongly suggest that 
proteolysis of mutant huntingtin by caspase-6 is an important event in HD. 
 
 
1.3.3.2. Protein Misfolding and Inhibition of Protein Degradation 
Heat shock proteins (HSPs) like HSP40 and HSP70, which are chaperones 
involved in the refolding of misfolded proteins, are also sequestered into 
aggregates of mutant huntingtin in vitro (Wyttenbach et al., 2000). Since the 
abnormally long polyglutamine tract is likely to result in an overall misfolding of 
huntingtin, the interaction of HSPs with mutant huntingtin may represent an 
attempt of the cell to refold the mutant protein. However, by being sequestered 
into the aggregates, these chaperones will be prevented from exerting their 
normal protective functions and, over the years, this is likely to lead to an 
intracellular accumulation of misfolded proteins (for review see Ho et al., 2001). 
Furthermore, several components of the proteasome (the major intracellular 
system for degradation of misfolded and abnormal proteins), such as its 
regulatory and catalytic subunits and ubiquitin conjugation enzymes, are also 
sequestered into these aggregates in vitro (Wyttenbach et al., 2000). Again, the 
presence of ubiquitin residues in mutant huntingtin aggregates may be the result 
of an unsuccessful attempt of the cell to tag the mutated protein for degradation 
by the proteasome. Alternatively, the HD mutation may actually render the 
protein resistant to proteasomal degradation. Indeed, the mutant protein with its 
expanded polyglutamine tail may physically block the proteasome, preventing 
the entrance of further substrates into the proteasome complex. Yet another 
explanation is that the proteasome degradation system may become overloaded 
with an increasing number of misfolded and mutated proteins in the cell. As a 
consequence, the neurons may be progressively depleted of functional 
proteasomes, which will lead to a progressive accumulation of misfolded and 
abnormal proteins, further increasing the rate of protein aggregation (for review 
see Ho et al., 2001; Berke and Paulson, 2003; Ciechanover and Brundin, 2003). 
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1.3.3.3. Transcription Dysregulation 
Mutant huntingtin may also establishes abnormal protein-protein interactions 
with several nuclear proteins and transcription factors, recruiting them into the 
aggregates and inhibiting their transcriptional activity. Examples include 
tymidine-adenine-tymidine-adenine (TATA)-binding protein (TBP), CREB 
[cyclic-adenosine monophosphate (cAMP) response element (CRE) binding 
protein]-binding protein (CBP), specific protein-1 (Sp1), and the TBP associated 
factor (TAFII130); all of which interact with mutant huntingtin through the 
expanded polyglutamine tail. Other nuclear proteins, such as the pro-apoptotic 
transcription factor p53, also interact with mutant huntingtin via its SH3 
sequences, which are distal from the polyglutamine tract (for review see Tobin 
and Signer, 2000; Sugars and Rubinsztein, 2003; Landles and Bates, 2004).  
On the other hand, mutant huntingtin may also lose the ability to bind and 
interact with other transcription factors regulated by wild-type huntingtin, as is 
the case of the NRSE-binding transcription factors (section 1.3.1). In this 
particular case, the failure of mutant huntingtin to interact with REST/NRSF in 
the cytoplasm leads to its nuclear accumulation, where it binds to NRSE 
sequences and promotes histone deacetylation, leading to the remodeling of the 
chromatin into a closed structure. As a result, there is a suppression of NRSE-
containing genes, including BDNF (Zuccato et al., 2003). This is one case where 
the loss of the normal huntingtin function can have profound effects, leading to 
decreased levels of BDNF, an important survival factor for striatal neurons. 
 
 
1.3.3.4. Disruption of Axonal Transport 
The formation of neuropil aggregates of mutant huntingtin has lead to the 
hypothesis that axonal transport may be impaired in HD. Indeed, as stated above 
(section 1.3.1), it is believed that normal huntingtin can play a role during axonal 
transport, perhaps via association with HAP1, promoting both retrograde and 
anterograde transport. The expanded polyglutamine tract may inhibit this 
function, compromising the bidirectional transport of different cargoes along the 
axons, further implicating the loss of wild-type huntingtin function in HD (for 
review see Gunawardena and Goldstein, 2005). In fact, it was recently shown 
that mutant huntingtin is responsible for altering the wild-type 
huntingtin/HAP1/p150 complex (section 1.3.1), causing an impaired association 
between motor proteins and microtubules, and attenuating BDNF transport, 
which results in loss of neurotrophic support (Gauthier et al., 2004). 
Alternatively, aggregates may physically block transport within narrow 
axonal terminals (for review see Gunawardena and Goldstein, 2005). In fact, 
dystrophic striatal and corticostriatal neurites in HD brains exhibit several 
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characteristics of blocked axons, such as accumulation of vesicles and organelles 
in swollen axonal projections and multiple huntingtin aggregates (DiFiglia et al., 
1997a; Sapp et al., 1999). Interestingly, the appearance of striatal axonal 
inclusions are better correlated with striatal neuronal loss than the formation of 
NIIs (for review see Gunawardena and Goldstein, 2005). 
 
 
1.3.3.5. Synaptic Dysfunction 
A direct consequence of impaired axonal transport (section 1.3.3.4) is 
disruption of neuronal synaptic transmission. Specifically, this may occur by the 
depletion of synaptic vesicles and proteins involved in vesicle recycling and 
receptor endocytosis from the nerve terminals. 
Moreover, a number of studies suggest that mutant huntingtin can lead to 
synaptic dysfunction by altering the availability of various synaptic proteins (for 
review see Li JY et al., 2003; Smith et al., 2005). Examples include a 
progressive depletion of complexin II, a protein that regulates the fusion of 
synaptic vesicles with the presynaptic plasma membrane (Morton and 
Edwardson, 2001; Morton et al., 2001), a decrease of the SNARE (soluble N-
ethylmaleimide-sensitive factor [NSF] attachment protein receptor) protein 
synaptobrevin-2, and the G protein rabphilin 3A in the HD striatum (Morton et 
al., 2001). A depletion of PACSIN1/syndapin (a neurospecific phosphoprotein 
involved in receptor recycling) from synapses, due to its interaction with the 
mutant huntingtin SH3 domains, has also been demonstrated (Modregger et al., 
2002). 
These effects may result from a direct abnormal interaction between the 
mutant protein and some of the synaptic proteins (e.g., PACSIN1), which may 
lead to their sequestration into huntingtin inclusions. Alternatively, they may 
represent a consequence of the altered gene transcription (section 1.3.3.3), which 
may cause the down-regulation of some of these synaptic proteins. Moreover, 
wild-type huntingtin interacts with various vesicle proteins that are important for 
endocytosis (section 1.3.1). These interactions may be impaired in the presence 
of the mutation thus compromising the synaptic process, which emphasizes the 
importance of the loss of wild-type huntingtin function (for review see Li JY et 
al., 2003).  
Furthermore, mutant huntingtin can also induce synaptic dysfunction at the 
postsynaptic level by disrupting the expression and activity of several 
postsynaptic neurotransmitter receptors (for review see Li JY et al., 2003; Smith 
et al., 2005). Indeed, by interfering with Sp1-mediated transcription, mutant 
huntingtin can induce the down-regulation of D1, D2 and D3 dopamine (DA) 
receptors (Dunah et al., 2002). On the other hand, the expanded polyglutamine 
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interferes with the ability of huntingtin to bind to PSD95 and regulate the 
function of NMDA and KA receptors (section 1.3.1; Sun et al., 2001). Mutant 
huntingtin may also interfere with the recycling of membrane receptors through 
the interaction with several proteins that normally regulate this process 
(Modregger et al., 2002), further contributing to postsynaptic dysfunction. 
 
 
1.4. Mechanisms of Degeneration 
 
Over the course of HD, the intracellular dysfunction induced by mutant 
huntingtin (section 1.3.3) progressively leads to the degeneration of important 
neuronal pathways and cell loss in the striatum, select layers of the cerebral 
cortex, and other brain regions (section 1.2.2). 
 
Figure 1.4. – Intracellular dysfunction induced by mutant huntingtin progressively 
causes the degeneration of relevant neuronal pathways. A dysfunction of corticostriatal 
and nigrostriatal pathways can have deleterious consequences in the striatum. In 
particular, excitotoxicity and dysregulation of DA neurotransmittion can promote a 
cascade of events that ultimately contributes to the loss of striatal neurons. 
 
 
Although not necessarily a direct result of the mutant protein, various 
mechanisms such as glutamate-induced excitotoxicity, DA-mediated toxicity, 
metabolic impairment, mitochondrial dysfunction, oxidative stress, apoptosis, 
and autophagy have been implicated in the pathology of HD. Many of these 
mechanisms may slowly develop over time, becoming increasingly pronounced 
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by the late stages of the disease. Moreover, they are not mutually exclusive and 
are likely to occur in parallel and promote each other, ultimately culminating in 
neuronal loss (Figure 1.4). 
 
 
1.4.1. Corticostriatal Dysfunction & Excitotoxicity 
The striatum receives excitatory glutamatergic inputs from the entire cerebral 
cortex. Striatal neurons display selective vulnerability with HD and this may be 
due to the vast glutamatergic inputs they receive and/or the particular types of 
glutamate receptors expressed in these cells (section 1.2.2). Indeed, striatal 
interneurons, which are less affected in HD, have fewer excitatory inputs than 
striatal projection neurons. Moreover, most medium spiny GABAergic 
projection neurons express high levels of the NMDA receptor NR2B subunit 
(section 1.2.2), which increases the receptor channel permeability and 
determines its sensitivity to glycine, the Mg2+-blockage, and the channel 
deactivation time. Correspondingly, the spared interneurons express much lower 
levels of this subunit, which probably confers them a higher threshold for 
activation (for review see Sieradzan and Mann, 2001). Furthermore, the 
metabotropic glutamate receptor type 5 (mGluR5) is greatly expressed in the 
postsynaptic membranes of striatal projection neurons. The activation of these 
facilitatory receptors enhances the responses of NMDA receptors to glutamate 
activation, contributing to excitotoxicity (for review see Vonsattel and DiFiglia, 
1998). 
Therefore, dysfunctional cortical glutamatergic neurons may cause a 
sustained glutamate stimulation of the vulnerable striatal neuronal populations. 
Under conditions of chronic excitotoxicity, the intracellular Ca2+ concentration 
increases and can have deleterious consequences including mitochondrial 
dysfunction, activation of the Ca2+-dependent neuronal isoform of nitric oxide 
synthase (nNOS), generation of nitric oxide (NO•) and other reactive oxygen 
species (ROS), and activation of Ca2+-dependent proteases such as calpains. 
Importantly, mutant huntingtin can also sensitize the inositol (1,4,5)-triphosphate 
receptor type 1 (InsP3R1) located in the membrane of the ER, promoting a 
further increase in intracellular Ca2+ (Tang et al., 2003). Collectively, these 
events can contribute to the progressive neurodegeneration observed in the HD 
striatum. 
In further support of the excitotoxic hypothesis of HD neurodegeneration, 
intrastriatal injections of the NMDA agonist quinolinic acid (QA) induce a 
selective neuronal loss both in rats (Beal et al., 1986, 1991) and in primates 
(Ferrante et al., 1993) that resembles human HD. 
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1.4.2. Nigrostriatal Dysfunction & Dopamine Toxicity 
The striatum also receives dopaminergic input from the substantia nigra, 
which implicates this pathway in the selective striatal degeneration observed 
with HD (for review see Petersén and Brundin, 2002). In support, several studies 
have shown degeneration of nigrostriatal projections (Ferrante and Kowall, 
1987; Ginovart et al., 1997; Bohnen et al., 2000; Suzuki et al., 2001) and 
atrophy of dopaminergic neurons in the substantia nigra in HD brains (Oyanagi 
et al., 1989; Yohrling et al., 2003). Aggregates of mutant huntingtin were also 
found in this brain region (Gutekunst et al., 1999). Furthermore, a marked loss 
of tyrosine hydroxylase (TH; the rate-limiting enzyme for DA biosynthesis) 
(Yohrling et al., 2003) and down-regulation of the DA transporter (DAT) and 
the DA D1 and D2 receptors occur in HD brains (Augood et al., 1997; Ginovart 
et al., 1997), probably due to altered gene transcription induced by mutant 
huntingtin (section 1.3.3.5). Overall, these results suggest that both a presynaptic 
and a postsynaptic impairment may contribute to a dysfunctional nigrostriatal 
pathway. 
The nigrostriatal dysfunction may be involved in causing the motor and 
cognitive deficits observed with HD. In support, loss of both pre- and 
postsynaptic markers of DA neurotransmission is positively correlated with 
cognitive performance in asymptomatic and symptomatic HD patients (for 
review see Bäckman and Farde, 2001). Furthermore, as mentioned above 
(section 1.2.1), late stages of the disease are normally characterized by 
bradykinesia and rigidity, symptoms that may be directly caused by the 
progressive loss of DA receptors in the striatum. 
Importantly, DA itself can be a source of ROS and a trigger of oxidative 
stress. Under normal conditions, the enzyme monoamino oxidase converts DA 
into 3,4-dihydrophenylacetic acid (DOPAC) and hydrogen peroxide (H2O2). 
However, DA can also undergo a nonenzymatic process of auto-oxidation 
producing DA quinones and H2O2, and a DA semiquinone and superoxide (O2
•-). 
H2O2 and O2
•- can be further oxidized in the presence of transition metal ions, 
producing the extremely reactive hydroxyl radical (HO•) (for review see Sulzer 
and Zecca, 2000). 
 
 
1.4.3. Metabolic Dysfunction & Oxidative Stress 
Studies in HD patients and HD postmortem tissue have shown: (1) a 
significant reduction in aconitase activity in the caudate, putamen and cerebral 
cortex (Tabrizi et al., 1999); (2) a significant decrease in the activities of 
mitochondrial complexes II-III and IV in the caudate and putamen (Gu et al., 
1996; Browne et al., 1997) and of mitochondrial complex I in the muscle 
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(Arenas et al., 1998). Contradictory results have also been published regarding 
the activity of mitochondrial complex I in HD platelets, with an initial study 
showing a striking reduction of the activity of this complex (Parker et al., 1990), 
and a subsequent study reporting no deficiencies in platelet mitochondrial 
function (Gu et al., 1996); (3) increased lactate concentrations in the cerebral 
cortex (Jenkins et al., 1993); (4) an increase in the lactate/pyruvate ratio in the 
cerebrospinal fluid (CSF) (Koroshetz et al., 1997); (5) a reduced 
phosphocreatine/inorganic phosphate ratio in skeletal muscle (Lodi et al., 2000); 
and (6) a decreased resting membrane potential as well as a reduced threshold 
for Ca2+-induced depolarization in mitochondria from HD lymphoblasts (Panov 
et al., 2002). 
Taken together, these reports implicate mitochondrial dysfunction and 
metabolic impairment in HD pathology (for review see Sawa, 2001). Whether 
these energy deficits occur early on during the disease progress is still uncertain 
(for review see Davies and Ramsden, 2001; Petersén and Brundin, 2002). 
Nevertheless, systemic administration of the toxin 3-nitropropionic acid (3-NP; 
an irreversible inhibitor of mitochondrial complex II) causes striatal 
neurodegeneration in rats and primates. Intrastriatal injection of this toxin or 
malonate (a reversible mitochondrial complex II inhibitor) also leads to striatal 
neuronal loss (for review see Brouillet et al., 1999), further implicating 
mitochondrial dysfunction in HD. 
Importantly, mitochondrial dysfunction is also the major contributor to 
oxidative stress that along with the excitotoxic activation of nNOS (section 
1.4.1) and the metabolism of DA (section 1.4.2), can lead to a toxic increase in 
the levels of ROS. Susceptible neurons, as in the case of HD, may not be able to 
handle increased ROS production. High ROS levels may promote intracellular 
cascades of oxidative stress by oxidizing proteins and DNA, and triggering lipid 
peroxidation. Therefore, it is reasonable to speculate that oxidative stress might 
play a crucial role in the neurodegenerative process of HD. However, no 
alterations in the levels of lipid peroxides and no signs of major oxidative 
damage to DNA and proteins have been detected in the caudate nucleus, 
putamen, and frontal cortex of HD patients (Alam et al., 2000), casting doubt 
upon the oxidative stress hypothesis. 
 
 
1.4.4. Cell Death – Apoptosis & Autophagy 
As stated above, mutant huntingtin is a substrate for several caspases and 
calpains, which are believed to mediate the formation of the toxic N-terminal 
fragments. Moreover, sequestration of pro-caspases into the aggregates is 
thought to promote their activation, thus promoting an intracellular cascade of 
Chapter 1 
Introduction 
 31 
proteolytic events (section 1.3.3.1). Furthermore, calpain (Gafni and Ellerby, 
2002), caspases 1 (Ona et al., 1999), and caspase-8 (Sanchez et al., 1999) 
activity is increased in HD brains. These findings have led to the hypothesis that 
an apoptotic mechanism is responsible for HD neuronal loss. Indeed, early 
studies had identified apoptotic-like cells in the HD striatum with terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) 
(Dragunow et al., 1995; Portera-Cailliau et al., 1995; Thomas et al., 1995; 
Butterworth et al., 1998). However, no DNA laddering was observed after DNA 
electrophoresis, suggesting that the characteristic DNA fragmentation pattern of 
apoptosis does not occur (Dragunow et al., 1995; Portera-Cailliau et al., 1995). 
Furthermore, the detection of activated astrocytes in HD brains suggests 
inflammation (Hedreen and Folstein, 1995), which is generally absent in 
apoptotic conditions. Therefore, the evidence for a pure apoptotic process 
contributing to HD cell death is not convincing. Nevertheless, the activation of 
certain apoptotic pathways is likely to contribute to some degree to HD 
pathology (for review see Hickey and Chesselet, 2003a). 
Some evidence suggest that autophagy, a process by which lysosomes 
degrade cytoplasmic proteins and organelles, may mediate cell loss in HD. In 
support, HD brains display endosomal/lysosomal organelles, multivesicular 
bodies, and lipofuscin accumulation reminiscent of autophagy (for review see 
Petersén and Brundin, 2002). Furthermore, a positive correlation has been found 
between the number of autophagic vacuoles and the length of the polyglutamine 
expansion in HD lymphoblasts (Nagata et al., 2004). Moreover, several studies 
have also shown that expression of mutant huntingtin induces 
endosomal/lysosomal activity (Kegel et al., 2000) and sequestration of the 
mammalian target of rapamycin (mTOR, a protein kinase involved in the 
regulation of autophagy) into the aggregates of mutant huntingtin with 
subsequent inhibition of its kinase activity (Ravikumar et al., 2004). These 
events lead to autophagy, which in turn may promote huntingtin degradation and 
the clearance of aggregates (Ravikumar et al., 2002, 2004; Quin et al., 2003). 
This process may represent an initial attempt of the HD cell to eliminate the 
mutant protein that over the course of the disease becomes overloaded, 
insufficient and dysfunctional, eventually resulting in cell degradation. Indeed, 
the lysosomal proteases cathepsins D, B and L were recently shown to promote 
the generation and accumulation of mutant huntingtin fragments (Kim et al., 
2006). Furthermore, sequestration of Beclin 1 (a protein essential for autophagy) 
into NIIs might reduce the autophagic clearance of mutant huntingtin (Shibata et 
al., 2006). 
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1.5. Rodent Models of Huntington’s Disease 
 
Our understanding of HD pathogenesis, as well as the ability to develop 
novel therapies, depend on the availability of suitable models of the disease. 
Although in vitro cellular models are important for providing valuable insights 
into the molecular mechanisms of the disease, they cannot replace the need for in 
vivo models.  
 
Table II – Characteristics of the most used HD animal models. 
Transgenic 
Model 
Promotor CAG 
Repeats  
Expression 
Level 
Background 
Strain 
Age of 
Death 
Abnormal 
Behavior 
Neuropathology 
Knock-in Mice 
Hdh 94 Hdh 94 100% 129Sv x 
C57BL/6J 
Normal 
life 
span 
Hyperkinesia 
followed by 
hypokinesia 
NIIs; cell 
dysfunction; no 
cell loss or 
gliosis 
HdH 150 Hdh 150 n.d. 129/Ola x 
C57BL/6J 
> 12 
months 
Motor 
deficits 
NIIs; no cell 
loss; gliosis 
YACTransgenic Mice 
YAC 72 IT15 72 30-50% FVB/N > 12 
months 
Hyperkinesia 
followed by 
hypokinesia 
Selective 
striatal cell 
death; no NIIs 
YAC 128 IT15 128 75% FVB/N < 12 
months 
(males) 
Hyperkinesia 
followed by 
hypokinesia; 
cognitive 
deficits 
NIIs; Selective 
striatal and 
cortical cell 
death and 
atrophy  
Truncated Transgenic Mice 
R6/1 IT15 Approx. 
115 
31% CBA x 
C57BL/6J 
32-40 
weeks 
Behavioral 
and motor 
deficits 
NIIs; limited 
cell loss; brain 
atrophy; cell 
dysfunction 
R6/2 IT15 Approx.
145 
75% CBA x 
C57BL/6J 
10-16 
weeks 
Rapid 
deterioration 
of cognitive 
and motor 
functions 
NIIs; limited 
cell loss; brain 
atrophy; cell 
dysfunction 
N171-82Q Mouse prion 
protein 
82 10-20% C3H/HEJ x 
C57BL/6J 
24-30 
weeks 
Motor 
deficits 
NIIs; striatal 
neuronal 
degeneration 
HD94-Tet 
Regulated 
CMV; 
Tetracycline- 
responsive 
operator 
94 n.d. CBA x 
C57BL/6J 
Early 
death 
Motor 
deficits 
reversed by 
transgene 
inhibition 
NIIs and striatal 
atrophy 
reversed by 
transgene 
inhibition 
Transgenic Rats 
HD Tg 
Rat 
Hdh 51 22% Sprague 
Dawley 
24 
months 
Cognitive 
deficits and 
progressive 
motor 
dysfunction 
NIIs; specific 
striatal cell loss 
and atrophy; 
cell dysfunction 
(Adapted from Menalled and Chesselet, 2002; Hickey and Chesselet, 2003b). 
n.d., not determined. 
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In vivo non-mammalian HD models, such as those generated in Drosophila 
melanogaster, have proven to be valuable in studying important intracellular 
pathways involved in the disease process (e.g., aggregation, transcriptional 
regulation, proteasome-mediated protein degradation, etc.). These models are 
also useful for rapidly screening potential beneficial pharmacologic compounds 
(e.g., inhibitors of aggregation, and drugs that target cellular stress responses) 
(for review see Marsh et al., 2003). However, modeling HD in rodent models is 
useful for understanding the relation between neuronal dysfunction and/or death 
and the development of abnormal behaviours. Moreover, rodent models also 
provide excellent tools to further test the efficiency of new therapies and 
compounds, including those originally screened with the simpler Drosophila 
models (for review see Beal and Ferrante, 2004; Hersch and Ferrante, 2004; Li 
JY et al., 2005). 
There are several rodent models available for the study of HD. These models 
primarily differ in the size of the expressed huntingtin fragment, the number of 
CAG repeats, the promoter driving the transgene and consequently the 
expression of the mutant protein, the background strain, etc. As a consequence, 
each model exhibits unique phenotypes (for review see Menalled and Chesselet, 
2002; Hickey and Chesselet, 2003b). A summary of the most common used HD 
rodent models is presented in Table II. 
 
 
1.5.1. Knock-in Mice 
Knock-in mice were engineered by inserting elongated polyglutamine tracts 
into the mouse Hdh gene. Thus, the mutated gene is expressed under its natural 
promoter, in the appropriate genomic context of the Hdh gene, and the offspring 
are both heterozygous and homozygous for the mutation (for review see 
Menalled and Chesselet, 2002; Hickey and Chesselet, 2003b). In theory, these 
mice represent the most faithful reproduction of the human genetic condition, 
though no major behavioral deficits were observed in the initial reports 
(Shelbourne et al., 1999). Follow-up studies have subsequently shown that 
homozygous knock-in mice develop behavioral abnormalities at a very early 
stage, prior to any neuropathological change. Their abnormal behavior is 
characterized by a biphasic activity pattern (an initial marked increase in rearing 
followed by a period of hypoactivity) that resembles the progression of motor 
symptoms in HD patients (for review see Hickey and Chesselet, 2003b; Levine 
et al., 2004). 
Importantly, microaggregates of the mutant protein can be detected in the 
brains of four different HD knock-in models at an early disease stage (2-6 
months of age). However, NIIs are only present at later stages (10-18 months). 
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Furthermore, the degree of neuropathology is positively correlated with the 
number of CAG repeats. Mice carrying 94 CAG repeats (Hdh94) show 
aggregates and NIIs exclusively in the striatum; whereas, mice with 150 CAG 
repeats (Hdh150) show a more widespread distribution of aggregates throughout 
the brain. Interestingly, in most knock-in models, cell loss and gliosis are 
generally absent (for review see Menalled and Chesselet, 2002; Hickey and 
Chesselet, 2003b; Levine et al., 2004). 
Overall, the phenotype of HD knock-in mice supports the idea that neuronal 
dysfunction precedes cell death in HD, and might be the primary cause of the 
early functional abnormalities. 
 
 
1.5.2. Transgenic Mice – Full-Length Models 
Various transgenic mouse models have been generated using the full-length 
human IT15 gene with different CAG lengths as the transgene. 
Transgenic mice expressing the full-length IT15 gene with either 48 or 89 
CAG repeats under the control of the cytomegalovirus (CMV) promoter develop 
progressive motor impairments, which are accompanied by striatal neuronal loss 
as determined with TUNEL staining. However, NIIs are nearly absent in these 
transgenic mice (Reddy et al., 1998). 
YAC mice expressing the full-length IT15 gene with 72 (Hodgson et al., 
1999) or 128 (Slow et al., 2003) CAG repeats display a selective degeneration of 
striatal medium spiny neurons. Moreover, small nuclear aggregates of the mutant 
protein can be observed in YAC brains. Behaviourally, YAC mice also exhibit 
biphasic motor impairments with an initial period of hyperactivity followed by a 
hypoactive phase. (Hodgson et al., 1999; Slow et al., 2003). 
The YAC128 mice have been well characterized and a positive correlation 
between the onset of motor deficits and the extent of striatal cell loss had been 
documented (Slow et al., 2003). At 12 months of age, these mice show a 
significant atrophy of the striatum, globus pallidus and cortex with relative 
sparing of the hippocampus and cerebellum. Similarly, neuronal loss at this age 
is present in the striatum and cortex, the two brain regions most affected in HD 
patients, but not in the hippocampus. Moreover, nuclear accumulation of mutant 
huntingtin can be observed in the striatum as early as 2 months of age, 
coinciding with the onset of behavioral symptoms (Van Raamsdonk et al., 
2005a). Recent studies have also indicated that YAC128 transgenic HD mice 
develop mild cognitive deficits, which precede the onset of motor abnormalities 
and progressively deteriorate with age (Van Raamsdonk et al., 2005b).  
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1.5.3. Transgenic Mice – Truncated Models 
To address the question of CAG repeat stability in the mouse genome, 
Mangiarini and colleagues (1996) created transgenic mice with truncated 
fragments of the IT15 gene. They were surprised to find that these fragments 
were sufficient to generate a neurological phenotype similar to the human 
condition. These transgenic HD mouse models were referred to as the R6 lines 
(Mangiarini et al., 1996) and are represented in the majority of the studies in this 
thesis. As such, a thorough and extensive description of these models is 
presented in section 1.6. 
Other truncated transgenic mouse models exist that express a cDNA 
encoding an N-terminal fragment of huntingtin with 171 amino acids bearing 
either 18 (N171-18Q), 44 (N171-44Q), or 82 (N171-82Q) glutamine residues 
(Schilling et al., 1999). N171-82Q mice express relatively low steady-state 
levels of the transgene and show loss of body weight, behavioural abnormalities 
(loss of coordination, tremors, hypokinesis and abnormal gait), accumulate NIIs 
and neuritic aggregates of mutant huntingtin, and die prematurely (Schilling et 
al., 1999). 
Another valuable transgenic mouse model is the conditional model generated 
by Yamamoto and colleagues (Yamamoto et al., 2000). This HD mouse was 
engineered such that the expression of mutant huntingtin fragments is controlled 
by the tetracycline responsive system, allowing the gene to be turned off by oral 
administration of tetracycline derivatives. When the transgene expression was 
activated from birth (i.e., in the absence of any treatment), the mice 
progressively developed motor dysfunctions, neuronal inclusions both in the 
striatum and cortex, loss of striatal volume, and astrocytosis. Surprisingly, 
inhibition of transgene expression in symptomatic mice by antibiotic treatment 
ameliorated the behavioral deficits and abolished the inclusions (Yamamoto et 
al., 2000). These exciting findings suggest that the impact of the mutant protein 
can be arrested and even reversed, which can have tremendous implications for 
the development of therapies for HD. 
 
 
1.5.4. Transgenic Rats 
Recently, von Hörsten and collaborators developed the first transgenic rat 
model of not just HD but of any neurodegenerative disorder (von Hörsten et al., 
2003). This transgenic rat model express a 1962 bp IT15 cDNA fragment 
carrying 51 CAG repeats under the control of the endogenous rat Hdh promotor. 
These HD rats develop an adult-onset neurological phenotype characterized by 
reduced anxiety, cognitive impairment, and a progressive motor dysfunction. At 
the neuropathological level, the brains of these rats exhibit NIIs, striatal 
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shrinkage, and neuronal loss (von Hörsten et al., 2003; Kantor et al., 2006). 
Reduced brain glucose metabolism was also detected by high-resolution positron 
emission tomography (PET). In the late stage of the disease, the rats suffer from 
a rapid loss of body weight associated with a severe muscular atrophy, which 
invariably leads to death at around 24 months (von Hörsten et al., 2003). Both 
hetero- and homozygous animals also show decreases of the densities of several 
neurotransmitter receptors, including cholinergic muscarinic 1, 5-
hydroxytryptamine (5-HT), A2A adenosine, D1 and D2 DA, and GABA(A) 
receptors (Bauer et al., 2005). 
These transgenic rats may represent an accurate model of HD since they: (1) 
express a HD allele that is associated with the development of adult-onset HD 
(von Hörsten et al., 2003); (2) develop a striatum-restricted pathology (von 
Hörsten et al., 2003; Kantor et al., 2006); and (3) present a slow disease 
progression with deterioration of their motor performance and development of 
chorea-like symptoms (Cao et al., 2006). These HD transgenic rats are further 
characterized in Chapter 2 of this thesis. 
 
 
1.6. The R6 Transgenic Huntington’s Disease Mice 
 
Undoubtedly, the HD models that have been most extensively studied are the 
R6 transgenic mouse lines produced in 1996 by Gillian Bates and colleagues 
(Figure 1.5; Mangiarini et al., 1996). Currently there are about 270 publications 
describing the phenotype or the testing of novel treatments in these transgenic 
mice models. 
 
Figure 1.5. – A transgenic R6/2 mouse and a wild-type littermate control. Note that 
at 12 weeks of age, the R6/2 mouse is significantly smaller than its wild-type littermate 
control. Adapted from Mangiarini et al., 1996. 
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1.6.1. Characterization of R6 Mice 
 
1.6.1.1. Generation 
The R6 transgenic mice were generated by microinjection of a segment of 
the 5’-end of the IT15 gene, obtained from a single HD patient, into a single 
CBAxC57BL/J6 mouse embryo (Mangiarini et al., 1996). The transgene 
contained around 1 kb of the 5’-untranslated region, the exon 1 with around 130 
CAG repeats, and the first 262 bp of intron 1. Five lines with different CAG 
repeat lengths were originally generated: R6/0 (142 CAG repeats, showing no 
expression of the transgene), R6/1 (116 CAG repeats), R6/2 (144 CAG repeats), 
R6/5 (128-156 CAG repeats) and the control line HDex 6 (18 CAG repeats). The 
R6/1 and R6/2 lines have been the most commonly studied. Exon 1 of the IT15 
gene constitutes around 3% of the entire gene and is expressed under the human 
IT15 promotor in most tissues. Expression levels of the transgene are 
approximately 31% and 75% of the endogenous huntingtin level in the R6/1 and 
R6/2 models, respectively (Table II). Intergenerational instability has been 
found in the R6 lines, which is associated with paternal transmission (Mangiarini 
et al., 1997). No repeat instability was found in the R6/0 line, indicating that this 
effect is related to transcription (Mangiarini et al., 1997). Most R6/1 and R6/2 
females are infertile (Mangiarini et al., 1996; Papalexi et al., 2005), and males 
are used to breed the colonies. R6/2 males are ideally bred to first generation 
hybrids of CBAxC57BL/J6, a strategy that stabilizes the contribution of the two 
strain backgrounds across generations. This minimizes the risk of introducing 
new modifier genes that may differ between strains (Hockly et al., 2003; for 
review see Menalled and Chesselet, 2002). 
 
 
1.6.1.2. Neuropathology 
In R6/2 mice there is reduced neuronal loss in the striatum. To date, only one 
study reporting a 25% decrease in the total number of striatal cells in 12-week-
old transgenic mice (Stack et al., 2005) has been published. On the other hand, 
“dark cell degeneration” has been described in a small number of neurons in 12 
(Stack et al., 2005) and 14-week-old mice (i.e., at a very late stage in the 
development of the disease) (Iannicola et al., 2000; Turmaine et al., 2000; Yu et 
al., 2003). This “dark cell degeneration”, detected by toluidine blue- or osmium-
stained tissue by electron microscopy, is characterized by condensation but no 
fragmentation of both the cytoplasm and nucleus with ultrastructural 
preservation of intracellular organelles. Cells with these features are found in the 
anterior cingulate cortex, the dorsal striatum, the hippocampus, and in the 
Purkinje cell layer of the cerebellum of R6/2 mice. Similar features have been 
Chapter 1 
Introduction 
 38 
described in HD patients. The mechanism of cell death is thought to be neither 
classically apoptotic nor necrotic, and autophagy may be involved (Iannicola et 
al., 2000; Turmaine et al., 2000). Necrotic cell death markers are not evident and 
no substantial increase in striatal glial fibrilliary acidic protein (GFAP)-positive 
cells has been found in R6/1 or R6/2 mice (Hansson et al., 1999; Yu et al., 
2003). Nevertheless, a more pronounced age-related decline in the number of 
microglia in the R6/2 brains has been detected (Ma et al., 2003). 
Other HD neuropathological features are evident in R6 mice, such as the 
nuclear accumulation of truncated mutant huntingtin in ubiquitinated aggregates. 
The appearance of NIIs is an early event that can be detected in the striatum, 
cortex, and hippocampus of R6/2 mice as early as postnatal day 1 (Stack et al., 
2005). Between 3.5 to 4.5 weeks of age, NIIs are clearly evident in select 
neuronal populations in the CA1 region of the hippocampus, the periventricular 
nucleus of the hypothalamus (Morton et al., 2000), all layers of the cerebral 
cortex, and in 50% of the striatal neurons (Davies et al., 1997; Meade et al., 
2002). By 3.5 weeks these NIIs are already ubiquitin-positive (Meade et al., 
2002). Between 3 and 9 weeks of age, the number of neurons with inclusions 
and the inclusion size increase in all brain regions, and by 10 weeks of age, more 
than 80% of all neurons in the brain contain NIIs (Morton et al., 2000; Meade et 
al., 2002). The nuclear changes progress over time, and by 10 to 12 weeks 
invaginations of the nuclear membrane and an increase in the nuclear pore 
density occurs. It is important to note that NIIs are neuronal specific, since they 
have never been observed in glial cells (Davies et al., 1997). 
Not all neuronal populations acquire the same proportions of NIIs. In the 
striatum, the frequency of NIIs is lower in choline acetyltransferase-, nNOS- or 
calretinin-containing interneurons (around 10-20%) than in calbindin-positive 
projection neurons and parvalbumin-positive interneurons (around 90%) 
(Kosinski et al., 1999; Meade et al., 2002). In the cortex, essentially all 
pyramidal neurons of layers II-III and V-VI and all granule cells of layer IV 
develop NIIs by 9 weeks. However, some populations of cortical neurons (e.g., 
somatostatinergic and calbindinergic interneurons) develop NIIs more slowly 
and to a lesser extent (Meade et al., 2002). Neurons in the DG show NIIs 
significantly later than neurons in the CA1 and CA3 regions (Morton et al., 
2000; Hansson et al., 2001b). Only around 30% of the dopaminergic neurons in 
the substantia nigra contain NIIs (Petersén et al., 2002b). 
Aggregates of truncated mutant huntingtin have also been detected in 
neuronal processes (dendrites and axons) in R6 mice (Li H et al., 1999). These 
neuropil aggregates are smaller than NIIs, do not appear to contain ubiquitin, and 
co-localize with synaptic vesicles. Their formation highly correlates with the 
development of neurological symptoms in R6 mice (Li H et al., 1999), further 
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implicating an impaired axonal transport (section 1.3.3.4) and synaptic 
transmission (section 1.3.3.5) in HD neuropathology. 
Although there is no extensive neuronal loss in R6/2 mice, their brains 
weights decrease about 20% by the age of 12 weeks (Davies et al., 1997). The 
total striatal volume is reduced by 17% in 18-week-old R6/1 mice, with no 
corresponding cell loss, reactive astrocytosis or TUNEL-positive apoptotic 
neurons in the striatum (Hansson et al., 1999). Interestingly, the nigrostriatal 
(Petersén et al., 2002b) and corticostriatal (Puschban et al., unpublished 
observations) connections appear to be anatomically preserved. However, 
dopaminergic neurons of the substantia nigra of R6/1 mice show a 15% 
reduction in cross sectional area at the age of 16 weeks (Petersén et al., 2002b). 
In addition, the medium-sized striatal projection neurons display around 20% 
loss of soma area, as well as a decrease in their dendritic arborization and spine 
density (Klapstein et al., 2001), indicating that cell atrophy is responsible for the 
decreased brain weight observed in these mice. 
 
 
1.6.1.3. Behavior  
At birth, R6 mice are indistinguishable from their wild-type littermates. The 
first motor symptoms appear at 4 weeks of age in both R6/2 (Luesse et al., 2001) 
and R6/1 (Bolivar et al., 2004) lines, which are manifested as hyperactivity in 
the open field test. At 3.5 weeks of age R6/2 mice demonstrate a visual-spatial 
learning impairment and a memory deficit in the Morris water maze test that 
progress up to 7 weeks of age (Lione et al., 1999; Murphy et al., 2000), although 
cognition is difficult to properly assess when motor dysfunction is apparent and 
progressively deteriorates with age (Luesse et al., 2001). By 6 to 8 weeks of age 
R6 mice become hypoactive as assessed with the open field test (Carter et al., 
1999; Luesse et al., 2001; Bolivar et al., 2003, 2004). This hypoactivity is 
associated with a decline in motor coordination, as assessed by performance on a 
rotarod, and is detected by 5 to 6 weeks of age in R6/2 (Hockly et al., 2003) and 
at 8 weeks in R6/1 mice (Hansson et al., 2001b). The decline in rotarod 
performance in R6/1 mice is clearly correlated to an increased numbers of 
striatal neurons exhibiting NIIs (Hansson et al., 2001b). By 8 weeks of age, the 
R6/2 mice begin to exhibit other behavioral abnormalities, such as stereotypical 
hindlimb grooming, tremor, paw clasping when suspended by the tail (Figure 
1.6), dyskinesia and irregular gait. Handling or noise-induced convulsions may 
also appear at this time (Mangiarini et al., 1996; Gil et al., unpublished 
observations). Moreover, deterioration of the sleep-wake cycle and of the 
circadian rhythms of R6/2 mice is apparent at around 14 weeks of age (Morton 
et al., 2005). 
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Figure 1.6. – A 12-week-old R6/2 mouse adopting the feet-clasping posture. When 
suspended by the tail, a symptomatic R6/2 mouse will press both its front and hind 
limbs against the stomach. A normal mouse will hold its hind limbs outward in order to 
steady itself. Adapted from Mangiarini et al., 1996. 
 
 
Depending on the colony, death occurs at around 13 to 16 weeks of age in 
R6/2 mice (Carter et al., 1999), with the actual cause of premature death 
unknown. Undoubtedly, from a pathophysiological point of view and because 
the survival of R6/2 mice is often used as an outcome parameter when testing 
novel treatments, it would be extremely valuable to identify factors that are 
responsible for death. In some cases, it is clear that R6/2 mice succumb during a 
generalized convulsion (Mangiarini et al., 1996; Gil et al., unpublished 
observations). Interestingly, there is a marked difference in the R6/2 line life-
span (from 12 to 17 weeks of age) depending on the location of the colony. 
These differences are likely due to different procedures regarding breeding and 
animal welfare conditions. For example, variations in the number of mice per 
cage, enriched versus impoverished environment, accessibility to food and water 
at a symptomatic stage and background noise level (prone to elicit epileptic 
seizures) (Gil et al., unpublished observations) may play a role in the survival of 
the mice (for a detailed discussion see Hockly et al., 2003). 
 
 
1.6.1.4. Pathology outside the Central Nervous System 
Notably, huntingtin inclusions are found in islets of Langerhans, fibers of 
skeletal and cardiac muscle, in the medulla and reticular layer of the adrenal 
glands cortex, in kidney tubular/interstitial/glomerular cells, neuronal ganglion 
cells of the myenteric plexus of the stomach wall, and in the Meissners plexus of 
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the duodenum of 6-week-old R6/2 mice (Sathasivam et al., 1999). The mice also 
display NIIs in the retina that result in severe vision deficiencies by the age of 10 
weeks in R6/2 and at 32 weeks in R6/1 mice (Helmlinger et al., 2002). These 
tissues show a variety of other pathological changes but, similar to what happens 
in the central nervous system (CNS), it is not clear whether the inclusions are the 
cause, a consequence, or simply an epiphenomenon of these abnormal alterations 
(Sathasivam et al., 1999). 
Many of these tissues that exhibit mutant huntingtin inclusions also display a 
generalized atrophy. Thus, the liver, heart and kidney begin to atrophy in R6/2 
mice at 6 to 8 weeks of age and shrink to around 50% of normal sizes in late 
stages. 
At 4 weeks of age, testis size is decreased. This atrophy is gradual and 
continues throughout the life span of the mice (Sathasivam et al., 1999; Papalexi 
et al., 2005). The testicular atrophy is probably related to the sterility observed in 
50% of all R6/2 males and with the complete loss of fertility of all R6/2 males at 
8 weeks of age. This phenomenon may be caused by the reduction in 
gonadotrophin releasing hormone (GnRH)-expressing neurons in the 
hypothalamus of R6/2 mice and the consequent impairment of gonadotropic 
hormones (Papalexi et al., 2005). 
All skeletal muscle tissue begins to atrophy in R6/2 mice at 6 weeks of age 
(Sathasivam et al., 1999). Furthermore, age-dependent denervation-like 
abnormalities occur, and morphological alterations of neuromuscular junctions 
are observed in R6/2 skeletal muscles (Ribchester et al., 2004). Interestingly, 
these skeletal muscle abnormalities are accompanied by a progressive loss of the 
regenerative capacity of motor neurons in R6/2 mice (Ribchester et al., 2004). 
Moreover, dysregulation of gene expression is also detected in the R6/2 skeletal 
muscle, with an increased expression of ubiquitin-conjugating enzymes and 
DNA repair enzymes, which may be involved in a stress response to the toxic 
polyglutamines (Luthi-Carter et al., 2002). 
The weight loss typically seen in HD patients is reproduced in the R6 mice. 
The R6/2 mice begin to lose body weight at around 9 to 10 weeks of age 
(Hockly et al., 2003). Despite an increased accumulation of body fat and 
increased levels of leptin, a regulator of the fat metabolism (Fain et al., 2001), 
these mice still lose weight (Figure 1.5). 
Diabetes has been reported in some colonies of R6/2 mice (Hurlbert et al., 
1999; Luesse et al., 2001). However, no differences in survival, weight loss, 
motor coordination or activity occur between R6/2 mice with manifest or latent 
diabetes (Luesse et al., 2001). R6/2 mice of 12 weeks of age have dramatic 
reductions of glucagon in α-cells and of insulin in β-cells in the pancreas 
(Hurlbert et al., 1999). The accumulation of intranuclear inclusions in pancreatic 
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R6/2 islets correlates with impaired expression of transcriptional regulatory 
proteins essential for insulin gene expression and progressive reductions in 
insulin mRNA levels (Andreassen et al., 2002). Recently it has been shown that 
β-cell mass fails to increase normally with age in these mice (Björkqvist et al., 
2005). Although no abnormal cell death has been detected, cell replication is 
dramatically decreased in R6/2 islets. Also, despite an unaltered electrical 
activity, exocytosis is virtually abolished in β-cells, which may be due to a 
massive reduction in the number of insulin containing secretory vesicles 
(Björkqvist et al., 2005). 
Interestingly, many of these peripheral alterations, such as muscular atrophy, 
abdominal fat accumulation, insulin resistance, and reduced bone mineral 
density, are reminiscent of Cushing disease symptoms, which are caused by 
progressive alterations in the hypothalamic-pituitary-adrenal axis that lead to 
increased glucocorticoid levels (Björkqvist et al., 2006a). Indeed, we recently 
discovered that R6/2 mice show a hypertrophy of the adrenal cortex and a 
progressive increase in serum and urine corticosterone levels. In addition, the 
intermediate pituitary lobe was markedly enlarged and circulating adreno-
corticotrophic hormone (ACTH) was increased. Moreover, R6/2 mice 
demonstrate a 50% reduction in the expression of pituitary DA D2 receptors. 
Since DA transmission inhibits ACTH expression, this reduction in pituitary DA 
receptors may explain the observed increase in ACTH levels, and consequently, 
the increased production of glucocorticoids (Björkqvist et al., 2006a). 
To conclude, many non-CNS tissues are indeed affected in R6 mice and in 
certain cases dysfunction seems to occur independently of the presence of 
huntingtin inclusions. 
 
 
1.6.2. Dysfunction in R6 Mice  
 
1.6.2.1. Transcriptional Dysregulation 
Several changes in gene expression in the brains of R6/2 mice have been 
reported (Luthi-Carter et al., 2000, 2002, 2003; Zucker et al., 2005). In the R6/2 
striatum, 70 mRNAs out of 600 were differentially expressed at 6 weeks of age. 
The major alterations included a down-regulation of striatal genes involved in 
cAMP and retinoid signaling pathways, and up-regulation of genes indicative of 
stress and inflammation, including DNA repair enzymes (Luthi-Carter et al., 
2000). Similar alterations in gene expression have also been detected in the 
cerebral cortex, the cerebellum, and in muscle tissue, suggesting a lack of 
regional selectivity for this transcriptional dysregulation (Luthi-Carter et al., 
2002). 
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In an attempt to further characterize the striatal transcriptional dysregulation 
observed in the R6/2 striatum, a recent study demonstrated that both medium 
spiny projection neurons and nNOS-containing interneurons exhibit altered 
patterns of gene expression (Zucker et al., 2005). Within the nNOS-positive 
interneurons, mRNAs for nNOS, the NMDA receptor subunit NR2D, PSD95, 
and HAP1 were altered. This raises the possibility that these proteins confer 
protection against neurodegeneration in this interneuronal population (Zucker et 
al., 2005). 
Interestingly, transgenic HD mouse models that express either the full-length 
huntingtin (Hodgson et al., 1999) or one third of the protein (Laforet et al., 
2001) exhibit fewer transcriptional changes, and a slightly different 
transcriptional pattern as compared to R6 mice (Chan et al., 2002). The high 
number of gene expression changes in the R6 model suggests that short N-
terminal fragments of mutant huntingtin are particularly potent in eliciting 
transcriptional dysregulation (Chan et al., 2002). Furthermore, although 
emerging evidence suggests that protein context is crucial for determining 
toxicity of polyglutamine expansions (for review see La Spada and Taylor, 
2003), at least some of the transcriptional changes appear independent of the 
specific protein bearing the glutamine expansion, as similar changes have been 
found in transgenic mouse models for other CAG triplet repeat disorders (Luthi-
Carter et al., 2002). 
 
 
1.6.2.2. Dysfunction of the Corticostriatal Pathway  
The glutamatergic corticostriatal pathway has also been examined in the R6 
mice. However, contradictory results have been reported. Although whole tissue 
levels of glutamate are not altered in 12-week-old R6/2 mice (Reynolds et al., 
1999), microdialysis studies reveal reduced basal extracellular levels of 
glutamate and an increased release with KCl stimulation in R6/1 mice at 16 
weeks of age (Nicniocaill et al., 2001). However, in another microdialysis study 
extracellular glutamate levels were found to be unchanged in R6/2 mice 
(Behrens et al., 2002). Nevertheless, a partial inhibition of the glutamate 
transporter 1 (GLT 1) caused an age-dependent increase in extracellular 
glutamate levels in R6/2 mice, consistent with the idea of a dysfunctional 
glutamate transport capacity. This finding is consistent with the age-dependent 
down-regulation of GLT-1 mRNA and protein levels, which lead to a reduced 
function of the transporter (Lievens et al., 2001; Behrens et al., 2002). In these 
studies, a reduction in glutamate synthetase expression was also reported to 
occur in R6/2 mice, suggesting a perturbation of the glutamate-glutamine cycle 
(Lievens et al., 2001; Behrens et al., 2002). 
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Electrophysiological studies have also revealed a progressive decline in 
excitatory post-synaptic current frequency, which is specific to glutamatergic 
input, in R6/2 mice (Cepeda et al., 2003). These studies point to synaptic loss at 
the corticostriatal connections. However, isolated large-amplitude synaptic 
events from the cortex were found to occur frequently in 6-week-old R6/2 mice, 
which could account for the generalized convulsions observed in these mice 
(Cepeda et al., 2003). Interestingly, although GABA and glutamic acid 
decarboxylase (GAD) 67 mRNA levels are normal in the striatum of R6/2 mice, 
GAD67 expression is significantly reduced in the frontal and parietal cortex 
(Gourfinkel-An et al., 2003), which could lower the threshold for triggering 
seizures. 
 
 
1.6.2.3. Changes in Signalling Pathways and Intracellular Homeostasis  
At the single cell level, R6/2 striatal neurons demonstrate greater depolarized 
resting membrane potentials than wild-type neurons (Levine et al., 1999). 
Moreover, in striatal slices from 8-week-old R6/2 mice, a 5-fold increase in 
intracellular Ca2+ concentration was detected, indicating a fundamental alteration 
in Ca2+ homeostasis. Interestingly, intracellular Ca2+ dysfunction is supported by 
the observation that R6/2 striatal neurons can tolerate a dramatic overload of 
cytoplasmic Ca2+, induced by application of QA, which would normally lead to 
Ca2+ deregulation and cell death. The mechanism behind this Ca2+ tolerance is 
unknown but it may be related to either the capacity of these cells to remove 
intracellular Ca2+ , to sequester it into internal organelles, and/or  buffer it in the 
cytoplasm (Hansson et al., 2001b). 
Several lines of evidence suggest that a lack of trophic support can contribute 
to striatal neurodegeneration in HD. Indeed, normal huntingtin directly regulates 
the expression of BDNF (section 1.3.1; Zuccato et al., 2003), which appears to 
be reduced in the presence of mutant huntingtin (section 1.3.3.3; Zuccato et al., 
2001). By breeding R6/1 mice with BDNF+/- mice, and consequently disrupting 
the expression of BDNF, Canals and co-workers (2004) reported that a decrease 
in BDNF promotes the onset of motor symptoms, which happens to correlate 
with the loss of DARPP-32 (DA and cAMP regulated phosphoprotein of a 
molecular weight of 32 kDa)-positive striatal neurons in these mice. 
Interestingly, this accelerated neuronal dysfunction could be reverted by the 
exogenous administration of BDNF (Canals et al., 2004). R6/1-BDNF+/- double 
mutant mice also exhibit increased aggregates in the substantia nigra pars 
compacta, a decrease in retrograde labeling of dopaminergic neurons, a 
reduction in striatal DA content, and a reduced expression of DA receptors 
(Pineda et al., 2005). Finally, these double mutant mice exhibited lower 
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locomotor activity in response to amphetamine, further implicating BDNF in the 
motor disturbances associated with the dysfunction of the dopaminergic system 
(Pineda et al., 2005). 
 
 
1.6.2.4. Mitochondrial Dysfunction and Oxidative Stress 
A number of studies suggest that mitochondrial dysfunction and oxidative 
stress also play a role in R6 neuropathology. The evidence is outlined below. 
1) Increased concentrations of 8-hydroxy-2-deoxyguanosine, a marker for 
oxidative damage to DNA, have been found in the striatum of 12- to 14-week-
old R6/2 mice (Bogdanov et al., 2001). 
2) At the same age, there is a reduction in aconitase and mitochondrial 
complex IV activity in the striatum. There is also a decrease in complex IV 
activity in the cerebral cortex (Tabrizi et al., 2000). 
3) Up-regulation of caspases 1 and 3 (Chen et al., 2000) and activated 
caspase-9 and -3 (Kiechle et al., 2002) have been found in end stage R6 mice. In 
addition, a progressive increase in the cytoplasmic levels of cytochrome c 
occurs, suggesting the involvement of the mitochondrial apoptotic pathway. 
4) Increased immunolabelling for the inducible isoform of nitric oxide 
synthase (iNOS) and 3-nitrotyrosine was observed in R6/2 brains, which can be 
interpreted as a sign of increased NO• production and subsequent NO•-mediated 
oxidative stress (Tabrizi et al., 2000). Interestingly, in R6/1 mice, the NOS 
activity is increased at 19 weeks and then reduced at 32 weeks (Perez-Severiano 
et al., 2002); 
5) A biphasic change in the expression and activity of nNOS was also found 
in the striatum and cerebellum of R6/2 (Deckel et al., 2001) and R6/1 mice 
(Deckel et al., 2002b). Initially the expression and activity of this enzyme 
increases but then decreases as the disease state progresses. Furthermore, the 
decreased expression and activation of nNOS in the late stages of the disease 
correlate with body weight loss, abnormal clasping, and decreased performance 
on the rotarod task. Moreover, a biphasic change in the expression of the Ca2+-
calmodulin-dependent proteins calmodulin kinases II and IV (both of which are 
regulators of nNOS transcription and activation) has been proposed to underlie 
the alterations in nNOS expression and activity (Deckel et al., 2001, 2002a, 
2002b). 
6) Total superoxide dismutase (SOD) and Cu/Zn-SOD activity is increased 
in the striatum of young R6/1 mice and decreased in 35-week-old R6/1 mice 
(Santamaria et al., 2001). These authors suggest that the initially elevated 
enzymatic activity represents a compensatory mechanism against oxidative 
stress, which eventually breaks down in older mice (Santamaria et al., 2001); 
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7) Ascorbate (vitamin C), an extracellular non-enzymatic antioxidant, is 
reduced during periods of behavioral activity in R6/2 mice at 6 weeks, 
suggesting an impaired release of this vitamin and contributing to insufficient 
antioxidant protection (Rebec et al., 2002). 
Hence, R6 mice demonstrate increased markers for oxidative stress along 
with a compromised antioxidant capacity. With this in mind, it is important to 
point out that treating R6 mice with several antioxidant drugs (e.g., α-lipoic 
acid, ascorbate, co-enzyme Q10) can, to some extent, ameliorate the 
neuropathology and extend the survival of these mice (for review see Beal and 
Ferrante, 2004; Hersch and Ferrante, 2004; Li JY et al., 2005). However, these 
treatments only prolong the survival of R6 mice by 10 to 15%, which suggests 
that oxidative stress is not the major mediator in the disease process and/or that 
the treatments do not completely eliminate the production of free radicals. 
 
 
1.6.3. Therapeutic Strategies  
It is more likely that a combination of multiple factors is responsible for the 
severe pathology observed in R6/2 mice (section 1.6.2). As such, multiple 
approaches have been suggested to treat and reverse HD pathology in this model 
(for review see Beal and Ferrante, 2004; Hersch and Ferrante, 2004; Li JY et al., 
2005). These approaches can be classified according to their mode of action: (1) 
inhibition of histone deacetylation and methylation; (2) inhibition of protein 
misfolding and oligomerization; (3) transglutaminase inhibition; (4) caspase 
inhibition; (5) inhibition of excitotoxicity; (6) energy supplementation and 
rescue of metabolic impairment; (7) use of antioxidants; (8) genetic 
manipulations; (9) transplantation; and (10) environmental enrichment. Many of 
these treatment approaches have been found to exert ameliorative effects on the 
behavior and neuropathology of these transgenic mice and to increase their 
survival by up to 32% (for review see Li JY et al., 2005), demonstrating that the 
R6 mouse models are in principle amenable to therapy. Nevertheless, their 
accelerated progression of the disorder is not mimicked in the human condition, 
which may potentially reduce the ability to detect subtle improvements with a 
specific treatment. 
Furthermore, many studies with animal models are plagued by inconsistent 
experimental protocols (especially with behavioral tests) and inappropriate 
statistical analysis. Hockly and co-workers (2003) have shown that rotarod 
performance and weight loss produce quantitative, reliable and reproducible data 
that can be easily analyzed by standard parametric statistical methods and 
accurately predict the progressive nature of the disease in R6 mice (Hockly et 
al., 2003). However, one need to keep in mind that measuring behavioural 
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deficits such as rotarod performance may be influenced by other variables than 
pure motor functions. For example, in the case of R6 mice, muscle weakness, 
metabolic disruption, and hypothalamic dysfunction (see Chapter 4; Petersén et 
al., 2005) can influence rotarod performance. Moreover, although it has been 
reported that R6 mice can die suddenly during a convulsive attack (Mangiarini et 
al., 1996; Gil et al., unpublished observations), the actual cause of death of these 
mice is still unknown, which should be considered when anaysing survival data. 
 
 
1.7. Objectives 
 
As described above, HD is a multifactorial neurodegenerative disorder, 
characterized by a variety of symptoms that range from motor deficits, profound 
cognitive dysfunction, loss of body weight, to endocrine changes (section 1.2.1). 
However, much of the research has primarily focused on striatal degeneration, 
which mainly accounts for the motor impairment; whereas, other brain regions 
have received little attention. Moreover, even the striatal degeneration may result 
or be augmented by the impairment of other brain structures that directly or 
indirectly interact with the striatum (sections 1.4.1 and 1.4.2). 
Therefore, the two major themes that underly the work in this thesis are: 
1) To further elucidate the contribution of nonstriatal structures that directly 
interact with the striatum (i.e., the cortex and the substantia nigra) on 
striatal neurodegeneration; 
2) To explore the pathological changes of other nonstriatal brain regions 
(i.e., hypothalamus and hippocampus) that can contribute to other 
symptomologies of HD (peripheral and cognitive deficits). 
Bearing these two themes in mind, the specific objectives of this thesis are as 
follows: 
1) To evaluate the striatal response to an excitotoxic insult that mimicks an 
excessive activation of the glutamatergic corticostriatal pathway in the 
newly generated rat model (Chapter 2). 
2) To further characterize the impairment of the dopaminergic nigrostriatal 
pathway in the R6/1 mouse, by using in vivo microdialysis (Chapter 3). 
3) To determine whether the lateral hypothalamus, a structure involved in 
the regulation of several endocrine functions, is affected by HD 
pathology in both R6/2 mice and human HD brains (Chapter 4). 
4) To study the contribution of the DG of the hippocampus, a structure 
important for cognitive functioning, on the generation of new neurons 
and in HD pathology in R6/2 mice (Chapter 5 and 6). 
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5) To assess the effects of a novel neuroprotective compound 
(asialoerythropoietin; asialoEPO) on motor function, striatal 
neuropathology and hippocampal cell proliferation in R6/2 mice 
(Chapter 5). 
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Normal Sensitivity to Excitotoxicity in a 
Transgenic Huntington’s Disease Rat 
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2.1. Summary 
 
Excitotoxic cell damage by excessive stimulation of glutamate receptors has 
been hypothesized to contribute to the pathogenesis of HD. Transgenic mouse 
models of HD have shown variable sensitivity to excitotoxicity. The models 
differ in the genetic background, the type and length of the promoter driving the 
transgene expression, the CAG repeat length and/or the IT15 gene construct 
length. Furthermore, one has to differentiate whether transgenic or knock-in 
models have been used. All these factors may be crucial determinants in the 
responsiveness to an excitotoxic insult. Here, we explored the responsiveness to 
excitotoxic damage using a transgenic HD rat model carrying 22% of the IT15 
gene, which is driven by the rat Hdh promoter and harbors 51 CAG repeats. 
Transgenic HD rats received unilateral intrastriatal injections of the glutamate 
analogue quinolinic acid at 3 and 18 months of age. Lesion size was assessed 7 
days later using the degenerative stain Fluoro-Jade (FJ) and by counting 
surviving neurons that were immunolabeled with neuronal nuclei marker 
(NeuN). No difference in susceptibility to excitotoxicity was found between the 
HD rats and controls. Our study supports the mouse data that shows unaltered 
susceptibility to excitotoxicity with the expression of around 25% of the full 
IT15 gene. We conclude that differences in sensitivity to excitotoxicity between 
genetic animal models of HD may relate to the length of the expressed IT15 
gene. 
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2.2. Introduction 
 
With the generation of the R6 mouse lines a unique opportunity was 
established to assess the influence of expanded polyglutamine tracts on the 
susceptibility of striatal neurons to excitotoxicity. Unexpectedly, R6 mice were 
found to be practically resistant to damage induced by intrastriatal injection of 
QA, an NMDA receptor agonist that normally causes excitotoxic degeneration 
(Hansson et al., 1999). It was found that the resistance to QA developed 
gradually as the mice aged. Thus, at 3 weeks of age R6/1 mice displayed similar 
vulnerability to QA as wild-type control mice; whereas, 8- to 13-week-old R6/1 
began to demonstrate resistance that was fully developed by 18 to 36 weeks of 
age. R6/2 mice, which have a longer CAG repeat, developed complete resistance 
to QA as early as 6 weeks of age (Hansson et al., 2001b). This resistance was 
also observed after intrastriatal injections of NMDA (Hansson et al., 2001b), 
DA, 6-hydroxydopamine (6-OHDA) (Petersén et al., 2001), and malonate 
(Hansson et al., 2001a; Petersén et al., 2002b). Moreover, the resistance to QA 
was not limited to the striatum, as the hippocampus, in particular the CA1 region 
and to a lesser extent the DG, also demonstrate resistance to damage (Hansson et 
al., 2001b). Striatal and hippocampal resistance to excitotoxic damage also 
occurs following systemic injections of KA (Morton and Leavens, 2000) and 3-
NP (Hickey and Morton, 2000). It was also shown that R6/2 mice are partially 
resistant to hippocampal damage induced by a period of global cerebral ischemia 
(Schiefer et al., 2002). The glutamate agonist α-amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA) was the only toxin which R6 mice have 
been found not to be resistant to (Hansson et al., 2001b). 
Although the mechanism responsible for the observed resistance of R6 mice 
to these different toxins is not fully understood, it does not appear to be the result 
of a reduction in the number of NMDA receptors or a decreased receptor-
mediated influx of Ca2+ (Hansson et al., 2001b). It is possible that a reduction of 
the excitatory input to the striatum observed in older R6 mice (Cepeda et al., 
2001, 2003) can contribute to this resistance. Alternatively, the resistance 
phenomenon may be similar to pre-conditioning, as observed with ischemia, 
where permanent exposure to low levels of excitotoxicity and to changes in 
intracellular Ca2+ homeostasis (section 1.4.1) allows neurons to adpat to an even 
greater excitotoxic insult and sudden increase in intracellular Ca2+ concentration. 
On the other hand, the lack of resistance to AMPA-induced insults may be 
related with the fact that activation of these receptors is normally associated with 
an excessive influx of Na+ and consequent cell swelling. Therefore, it is 
reasonable to speculate that R6 mice have a better capacity to handle the 
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NMDA-induced Ca2+ overload than the AMPA-mediated Na+ influx (Hansson et 
al., 2001b). 
The work pioneered in the R6 mice has led others to study the phenomena in 
other HD mouse models, where at least 6 different genetic animal models of HD 
have so far been evaluated. Using a similar methodology of intrastriatal QA 
injections, the results have been mixed (Zeron et al., 2002; Jarabek et al., 2004; 
Slow et al., 2005). It appears that differences in the genetic background of the 
particular mouse strain, the promoter driving the transgene construct, the length 
of the IT15 gene, and the number of CAG repeats may explain these conflicting 
results (Petersén et al., 2002a). 
In order to further evaluate the role of glutamate-mediated excitotoxicity in 
HD striatal degeneration, we examined the response of the recently generated 
HD transgenic rat to intrastriatal QA injections. This transgenic rat model carries 
a truncated huntingtin cDNA fragment with 51 CAG repeats under the control of 
the native rat Hdh promoter that corresponds to 22% of the full-length IT15 gene 
(section 1.5.4; von Hörsten et al., 2003). Since previous studies in the R6 and the 
YAC mouse models have shown that excitotoxic susceptibility may develop 
over time (Hansson et al., 2001b; Zeron et al., 2002), we used both young and 
aged HD transgenic rats (3 and 18 months of age, respectively), and examined 
their responsiveness to intrastriatal injections of QA using a similar procedure to 
the one employed in the previous mouse studies. 
 
 
 
2.3. Materials and Methods 
 
 
2.3.1. Transgenic Animals 
Transgenic HD rats with 51 CAG repeats (section 1.5.4; von Hörsten et al., 
2003), and their wild-type littermates were used in this study. The transgenic HD 
rat expresses a cDNA (position 324–2321) corresponding to 22% of the full-
length IT15 gene under the control of the 886 bp rat Hdh promotor. The HD rat 
background strain is Sprague–Dawley strain derived. F10 rats were used for 
these experiments. Rats were housed under a 12 hours light/dark cycle with food 
and water ad libitum. Two time points were chosen, either 3 (n = 8 for wild-type 
rats; n = 10 for transgenic HD rats) or 18 (n = 6 for wild-type rats; n = 9 for 
transgenic HD rats) months of age. Previous research has shown that at 3 months 
of age these HD rats display signs of reduced anxiety, and at 9 to 18 months start 
exhibiting motor dysfunction and cognitive impairments (von Hörsten et al., 
2003; Nguyen et al., 2006). All research and animal care procedures were 
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approved by the District Government, Hanover, Germany, and performed 
according to international guidelines for the use of laboratory animals. 
 
 
2.3.2. Surgery 
QA (Sigma, Steinheim, Germany) was dissolved in 0.1 M phosphate 
buffered saline (PBS, pH 7.4). Under isoflurane anesthesia, the rats received a 
single unilateral intrastriatal injection of 80 nmol of QA in 1 μl at the following 
stereotactic coordinates using a 5 μl Hamilton syringe: 1.2 mm rostral to 
bregma, 2.7 mm right of the midline, and 4.5 mm ventral to the dural surface, 
with the incision bar set at zero. The injection rate was 0.2 μl/minute, and the 
cannula remained in place for an additional 3 minutes before being slowly 
retracted. 
 
 
2.3.3. Tissue Processing and Histology 
Rats were perfused with 4% paraformaldehyde (PFA) 7 days after the 
surgery. The brains were postfixed overnight in the same solution and 
dehydrated in 20% sucrose/0.1 M PBS. Serial coronal sections were cut on a 
freezing sliding microtome at 30 μm thickness and collected in PBS. Tissue 
from wild-type and transgenic rats was processed in parallel for 
immunohistochemistry to control for staining intensity. 
One series of rat brain sections was processed for Nissl stain (cresyl violet; 
ICN Biomedicals Inc., Aurora, OH, USA). Briefly, free-floating rat brain 
sections were mounted onto gelatin-coated slides and immersed in cresyl violet 
for 1 – 2 minutes (until the nuclei were clearly visible). After being immersed in 
a series of ethanol solutions of increasing concentrations (70%, 95% and 100%), 
the mounted sections were finally immersed in xylen and coversliped with DPX 
mounting medium (BDH Laboratory Supplies, Poole, UK). Another series of 
sections were processed for FJ (Histo-Chem, Jefferson, AR, USA), which is 
thought to stain for degenerating neurons (Schmued et al., 1997), as previously 
described (Hansson et al., 1999). Briefly, free-floating rat brain sections were 
mounted onto gelatin-coated slides and immersed in a series of ethanol solutions 
of decreasing concentrations (100% and 70%). The mounted sections were then 
incubated in 0.06% potassium permanganate (in distilled water) for 15 minutes 
and finally in FJ solution (0.001% FJ + 0.1% acetic acid in distilled water) for 30 
minutes in the dark. After rinsing and drying (at 60°C for 15 minutes), the 
mounted sections were immersed in xylen and coversliped with DPX mounting 
medium. 
A further series of brain sections was processed immunohistochemically for 
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the neuron-specific marker NeuN (Chemicon, Temecula, CA, USA). Briefly, 
free-floating sections were quenched (to block the endogenous peroxidases) in 
3% H2O2/10% methanol in 0.1 M PBS for 15 minutes. After rinsing in 0.1 M 
PBS, sections were incubated in a blocking solution containing 5% normal horse 
serum (NHS) and 0.25% Triton X-100 in 0.1 M PBS. They were then incubated 
for 48 hours at 4°C with a primary mouse monoclonal anti-NeuN antibody 
(diluted 1:1000) in blocking solution. After rinsing, sections were incubated for 
1 hour at room temperature with the secondary antibody biotinylated horse anti-
mouse IgG (diluted 1:200; Dakopatts, Copenhagen, Denmark) followed by a 
final rinse. The bound antibodies were then visualized with an avidin–biotin–
peroxidase complex system (Vectastain ABC Elite Kit; Vector Laboratories, 
Burlingame, CA, USA) using 3,3-diaminobenzidine (DAB) as the chromogen. 
 
 
2.3.4. Stereological Techniques  
All morphological analyses were performed on blind-coded slides, using a 
10x objective fitted on an Olympus BH2 microscope, a X-Y-Z step motor stage 
run by an IBM PC computer, a CCD-IRIS color video camera, and the CAST-
GRID software (Olympus Denmark A/S, Albertslund, Denmark). 
The striatal lesion area (defined by the presence of FJ-labeled cells or the 
lack of NeuN positive cells) was delineated in sections processed for either FJ-
staining or NeuN immunohistochemistry (distance between the sections: 210 
μm). The total striatal area at the non-injected side was delineated in 5 NeuN 
labeled sections (the level of these sections began 2 sections anterior to the 
appearance of the anterior commissure). The striatal lesion volume and the total 
striatal volume were calculated, taking into account the frequency of sections 
(1:8) and their thickness (30 μm), according to the Cavalieri principle 
(Gundersen et al., 1988). 
 
 
2.3.5. Statistical Analysis 
For group comparisons, data were subjected to a 2-factor analysis of variance 
(ANOVA) using the Statview 5.4 Package (Abacus Concepts, Berkeley, CA, 
USA). Data are presented as means ± standard error of the mean (S.E.M.). 
Statistical significance was set at p < 0.05. 
 
 
 
2.4. Results 
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The volume of the striatal lesion induced by the unilateral injection of QA in 
transgenic and wild-type rats of 3 and 18 months of age was analyzed 7 days 
post-surgery in sections stained for FJ (Figures 2.1.A–C) or processed for NeuN 
immunohistochemistry (Figures 2.1.D–F).  
 
Figure 2.1. - Striatal QA-induced lesions assessed with FJ staining and NeuN 
immunohistochemistry. Rats were subjected to an intrastriatal injection of 1 μl of QA 
(80 nmol) and the lesion volumes were assessed 7 days post surgery. Representative 
photographs showing QA-induced striatal lesions in a 18 month-old wild-type (A) and a 
HD transgenic (B) rats using FJ-staining. Higher magnification of FJ staining in a wild-
type rat (C). Representative photographs showing the adjacent sections processed for 
NeuN immunohistochemistry in a 18 month-old wild-type (D) and a HD transgenic (E) 
rats. Higher magnification of NeuN immunohistochemistry in a wild-type rat (F). Scale 
bar = 1 mm (A) and = 140 μm (C). 
 
Regions positive for FJ were immunonegative for NeuN, indicating loss of 
neurons. Within the FJ-positive areas vast numbers of degenerating cells 
exhibiting dense nuclei were observed, as confirmed with the cresyl violet stain 
Chapter 2 
 57 
(data not shown). In wild-type controls the striatal lesion volume amounted to 
approximately 43% of the total striatal volume, making it reasonable to detect 
subtle changes in the sensitivity to QA of the transgenic HD rats. However, there 
was no significant difference between the FJ-stained lesion volumes between 
groups (2-factor ANOVA; p = 0.91, F (1, 29) = 0.01), although a small 
difference between all rats of 3 and 18 months of age was detected (2-factor 
ANOVA; p = 0.02, F (1, 29) = 5.73) with no interaction between genotype and 
age (2-factor ANOVA; p = 0.43, F (1, 29) = 0.63) (Figures 2.1.A–C and 2.2.A). 
 
 
Figure 2.2. - No resistance to excitotoxic damage in HD rats. The striatal lesion 
volume following an injection of 80 nmol QA did not differ between 3 and 18 month-
old transgenic HD rats, or their wild-type littermates. The lesion volumes were assessed 
in sections stained with FJ (A) and processed for NeuN immunohistochemistry (B). 
There was no difference in the total striatal volumes between the genotypes of the 
different ages as assessed in sections processed for NeuN immunohistochemistry (C). 
Values represent means ± S.E.M. 
 
 
Correspondingly, no differences in lesion volumes were detected with NeuN 
processed sections between genotypes (2-factor ANOVA; p = 0.75, F (1, 29) = 
0.10), age groups (2-factor ANOVA; p = 0.62, F (1, 29) = 0.25), or any 
interaction between genotype and age (2-factor ANOVA; p = 0.93, F (1, 29) = 
0.01) (Figures 2.1.D–F and 2.2.B). 
After discovering no major differences in cell loss, we decided to examine 
whether the striatum had atrophied prior to the lesion by measuring total striatal 
volume at the non-injected side with NeuN immunohistochemistry (Figure 
2.2C). A 2-factor ANOVA revealed no differences in the total striatal volume 
between genotypes (p = 0.25, F (1, 29) = 1.37), age groups (p = 0.06, F (1, 29) = 
3.75), or any interaction between genotype and age (p = 0.45, F (1, 29) = 0.59). 
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2.5. Discussion 
 
In HD, there is a selective neuronal loss in the cerebral cortex and striatum, 
despite ubiquitous expression of the mutant huntingtin in all cells (section 1.2.2; 
for review see Vonsattel and DiFiglia, 1998). Interestingly, these afflicted 
regions are all densely innervated by glutamatergic input. Furthermore, 
intrastriatal injections of glutamate analogues both in rats (Beal et al., 1986, 
1991) and in primates (Ferrante et al., 1993) give rise to an HD-like 
neuropathology. These factors have led to the hypothesis that excitotoxicity 
plays a role in HD (section 1.4.1). 
In this study, neither young nor old transgenic HD rats (von Hörsten et al., 
2003) displayed altered sensitivity to excitotoxicity. 
Results ranging from reduced to increased sensitivity to excitotoxicity have 
been found in the various rodent models for HD. Although the animals vary in 
many parameters such as strain, transgene construct, promotor, CAG repeat 
length, and expression levels, most probably the length of the expressed IT15 
gene is crucial in determining the response to excitotoxicity. 
The HD rat expresses 22% of the full-length IT15 gene and displayed no 
altered susceptibility to excitotoxicity. This result is in agreement with a 
previous study that shows a maintained excitotoxic response in transgenic mice 
expressing around 30% of the full IT15 gene, independent of CAG repeat length 
and age of the mice (Petersén et al., 2002a). 
On the other hand, R6 mice express around 3% of the IT15 gene, with 117–
150 CAG repeats, and do demonstrate a profound resistance to excitotoxic 
insults (Hansson et al., 1999, 2001b). Similarly, other mouse models that also 
express only a small percentage of the full IT15 gene, such as the N171-82Q 
mouse (Jarabek et al., 2004) and the recently generated “shortstop” mouse 
expressing around 120 CAG repeats (Slow et al., 2005), demonstrate resistance 
to QA insults. A decrease in several proteins involved in the signaling pathways 
triggered by the activation of NMDA and DA D1 receptors (such as PSD95, 
nNOS, and the DA D1 receptor) has been suggested to account for the reduced 
sensitivity to an excitotoxic insult in N171-82Q mice (Jarabek et al., 2004). 
In contrast, in YAC72 (Zeron et al., 2002) and YAC128 (Graham et al., 
2005) mice, which express the full-length IT15 gene, a greater sensitivity to 
excitotoxicity has been reported. Interestingly, YAC mice expressing full-length 
mutant huntingtin resistant to proteolysis mediated by caspase-6 are protected 
against excitotoxicity induced by QA (Graham et al., 2006). This result suggests 
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that caspase-6-induced cleavage of full-length mutant huntingtin selectively 
mediates susceptibility to excitotoxic stress in YAC mice. 
To conclude, the data from these studies in HD mouse models, together with 
our results in the HD rat, suggest that the length of the expressed IT15 transgene 
should be considered when studying cellular responses to neurotoxins. 
Importantly, the diversity of results that have been obtained with intrastriatal 
injections of excitotoxins, ranging from resistance to enhanced susceptibility, 
makes it difficult to conclude on the actual impact of excitotoxic insults on HD 
striatal neurodegeneration. Moreover, in the human HD brain, the progressive 
dysfunction of the corticostriatal pathway is likely to result in chronic and 
sustained excitotoxicity. Given the fact that the intrastriatal injection of 
excitotoxins represents an acute model of excitotoxicity that artificially mimicks 
an over-stimulation of the corticostriatal glutamatergic pathway, one should be 
careful when drawing conclusions regarding the role of excitotoxicity in HD. 
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3.1. Summary 
 
Previous studies have implicated a dysfunction of the nigrostriatal 
dopaminergic system in the neuropathology of HD. In the present study we 
further characterized the deficits in the regulation of this pathway in R6/1 
transgenic HD mice using in vivo microdialysis. A set of R6/1 mice of 18 to 19 
weeks of age was examined regarding the maximum capacity of the nigrostriatal 
neurons to release DA in the striatum upon KCl-induced plasma membrane 
depolarization and amphetamine-mediated DA release through DAT. High 
performance liquid chromatography (HPLC) was used to measure the levels of 
DA and its metabolites, DOPAC and homovanillic acid (HVA). In adition to DA 
release, we also determined the total tissue DA levels. We found that intrastriatal 
infusion of both KCl and amphetamine rapidly increased the local dialysate DA 
levels in both R6/1 and wild-type mice. However, the absolute increase was 
attenuated in R6/1 mice as compared to wild-type mice. In accordance with 
these data, we observed a significant decrease in postmortem striatal DA tissue 
levels in R6/1 mice. In addition, there was a significant decrease in the baseline 
levels of DOPAC and HVA in dialysate samples from R6/1 mice. These results 
further implicate an impairment of the dopaminergic nigrostriatal pathway in the 
neuropathology of the R6/1 transgenic HD mice. 
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3.2. Introduction 
 
Several lines of evidence indicate that a dysfunction of the nigrostriatal 
dopaminergic pathway may contribute to the neuropathology of HD. Since the 
DA system plays an important function in the regulation of the striatum, it is 
plausible that some of the motor and cognitive symptoms that characterize HD 
may be due to DA (section 1.4.2). 
In R6 mice, multiple abnormalities of the dopaminergic nigrostriatal system 
have been reported. At the post-synaptic level (i.e., in striatal neurons), a 
reduced expression of DA D1 and D2 receptors can be detected as early as 4 
weeks in R6/2 mice (Cha et al., 1998). A reduced expression of DARPP-32 (a 
phosphoprotein that mediates DA signaling transduction pathways in striatal 
neurons) occurs at the same time point (Bibb et al., 2000; Luthi-Carter et al., 
2000; van Dellen et al., 2000b). Moreover, R6/2 mice exhibit defects in DA-
regulated ion channels (Bibb et al., 2000). Basal immediate early gene (IEG) 
expression, which is commonly used as an index of dopaminergic signal 
transduction, is also reduced in the R6/2 striatum at 12 weeks (Spektor et al., 
2002). Interestingly, DA D2 receptor antagonist-induced IEG mRNA levels 
were reduced in the R6/2 striatum; whereas, DA D1 receptor agonist-induced 
IEG mRNA levels were surprisingly increased. This increased IEG response 
after D1 receptor agonist stimulation may be due to D1 receptor super-
sensitization, which in turn is caused by a diminished dopaminergic input 
(Spektor et al., 2002). 
Furthermore, at the presynaptic level, the nigrostriatal terminals of 16-week-
old R6/1 mice were found to release reduced amounts of DA, both at baseline 
and after malonate stimulation, as measured by in vivo microdialysis (Petersén et 
al., 2002b). This may account for the reported D1 receptor super-sensitization. 
Moreover, 9-week-old R6/2 mice also display attenuated motor activation in 
response to cocaine (a DAT inhibitor that potentiates the action of 
physiologically released DA) (Hickey et al., 2002), further supporting the notion 
of an impaired capacity to release DA. 
In order to further characterize the dysfunction of the dopaminergic 
nigrostriatal pathway at the presynaptic level (i.e., at the level of DA synthesis 
and release), we performed in vivo microdialysis in 18- to 19-week-old R6/1 
mice. We infused KCl (which depolarizes plasma membranes inducing the 
release of DA from the vesicular pool), and amphetamine (which leads to a 
DAT-mediated efflux of DA) through the dialysis probe. This technique allowed 
us to evaluate the contribution of the 2 major DA releasing routes for the 
reduced release of DA that was previously reported (Petersén et al., 2002b). 
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3.3. Materials and Methods 
 
 
3.3.1. Transgenic Animals 
The heterozygous male R6/1 mice were purchased from Jackson 
Laboratories (Bar Harbor, ME, USA) and bred with wild-type females (F1 of 
CBA x C57BL/6J). DNA samples, derived from the tails of the offspring, were 
genotyped using a polymerase chain reaction (PCR) assay (Mangiarini et al., 
1996). The mice were housed under a 12-hour light-dark cycle with food and 
water ad libitum. All experimental procedures were conducted according to 
regulations set by the Ethical Committee for the use of laboratory animals at 
Lund University, Sweden. 
 
 
3.3.2. In vivo Microdialysis 
R6/1 (n = 7) and wild-type littermates (n = 8) of 18 to 19 weeks of age were 
anesthetized with a mixture of 1% halothane and O2/N2O. The anesthesia was 
maintained during microdialysis by free-breathing into a mask fitted over the 
nose of the mouse. Body temperature was maintained at 37°C using a 
temperature-regulating heating pad throughout the entire surgical procedure. A 
microdialysis probe of concentric design (CMA/11, Carnegie Medicin AB, 
Stockholm, Sweden; length = 2 mm; outer diameter = 0.24 mm) was inserted 
into the right striatum through a hole drilled in the skull, at the following 
stereotactic coordinates: 0.8 mm rostral to bregma; 2.2 mm lateral to the midline; 
2.8 mm ventral from the dural surface; with the tooth-bar set at zero. The probes 
were perfused at a rate of 2 μl/minutes with sterile Ringer solution (145 mM 
NaCl, 3 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, pH 6.0; Apoteksbolaget, Täby, 
Sweden) through the dialysis session. Perfusate samples were collected every 20 
minutes, starting 60 minutes after probe implantation (i.e., the first 120 μl were 
discarded). Subsequently, three stable basal values (60 minutes, with intervals of 
20 minutes) were obtained, after which the perfusion was switched to KCl (60 
mM), for 20 minutes. The perfusion medium was then switched back to normal 
Ringer solution and an additional three 20 minute-dialysate samples were 
collected. Amphetamine (10 μM) was then perfused through the microdialysis 
probe for 20 minutes, after which three more 20 minute-samples were collected 
in Ringer solution, yielding a total of 11 samples collected per mouse. Each 40 
μl sample was divided into 2 aliquots of 20 μl each, immediately frozen in liquid 
nitrogen and stored at –80°C until processed. 
 
Chapter 3 
 66 
3.3.3. Determination of the Dialysate DA, DOPAC & HVA Levels 
The quantification of the levels of the monoamine neurotransmitter DA and 
its acidic metabolites (DOPAC and HVA) in the dialysate samples was 
performed by HPLC separation and electrochemical detection, according to a 
method developed by Lagerkvist et al. (unpublished protocol; Carlsson Research 
AB, Göteborg, Sweden). The analytical method was based on 2 chromatographic 
separations dedicated for amines or acids, respectively. The 2 chromatographic 
systems shared a common auto-injector with a 10-port valve and 2 sample loops 
for simultaneous injection. The acids were separated by reverse phase 
chromatography; whereas, the amines were separated by reverse phase ion 
pairing preceded by a reverse phase separation in a column switching 
configuration. 
 
 
3.3.4. Analysis of Whole Tissue Striatal DA Levels 
Immediately after microdialysis, R6/1 and wild-type mice were sacrificed by 
cervical dislocation and the brains were rapidly removed on ice. The 2 
hemispheres were separated and the left striatum was dissected out and 
immediately frozen on dry ice and stored at –80°C until processing. 
Determination of whole tissue striatal DA levels was conducted at the Carlsson 
Research AB. Briefly, the striata were thawed and homogenized in 1 ml of 0.1 N 
perchloric acid containing 5% EDTA. After centrifugation at 14,000 g for 30 
minutes, 200 μl of the supernatant were filtered through a 0.22 μm glass filter 
and 20 μl were then injected into the HPLC equipment and the DA levels were 
determined as above (section 3.3.3). 
 
 
3.3.5. Evaluation of Microdialysis Probe Placement 
After dissecting out the 2 brain hemispheres, the right hemisphere (i.e., the 
one where the microdialysis probe was inserted) was fixed for 24 hours in 4% 
PFA and dehydrated in 20% sucrose/0.1 M PBS. Serial coronal sections were cut 
on a freezing sliding microtome at 30 μm thickness and collected in PBS. Tissue 
from wild-type and HD mice was processed in parallel to control for staining 
intensity. In order to evaluate the correct placement of the microdialysis probes 
inside the mice striata, one series of brain sections was processed for cresyl 
violet (ICN Biomedicals Inc.; procedure described in section 2.3.3). The brain 
sections of each mouse were analyzed with a 10x objective fitted onto a light 
microscope to confirm probe tip location. All microdialysis probes had been 
correctly placed within the striatum. 
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3.3.6. Statistical Analysis 
The data were analyzed with unpaired Student’s t tests or 2-factor ANOVA 
with repeated measures when appropriate, using the Statview 5.4 package 
(Abacus Concepts). Data are presented as means ± S.E.M. A p value of < 0.05 
was considered statistically significant. 
 
 
 
3.4. Results 
 
 
3.4.1. Whole Tissue Striatal DA Levels in R6/1 Mice 
Previous studies from our group have shown no significant differences in the 
whole tissue striatal levels of DA in 16-week-old R6/1 mice (Petersén et al., 
2002b). Interestingly, in the present study, the striatal DA tissue levels were 143 
± 11 nM for wild-type mice and 68 ± 11 nM for R6/1 mice (Student’s t test, p < 
0.05). Therefore, we conclude that a significant reduction in the whole tissue 
striatal DA levels can be detected at this age, possibly reflecting a progressive 
impairment of the dopaminergic nigrostriatal pathway. 
 
 
3.4.2. Dialysate DA Striatal Levels in R6/1 Mice 
In all samples collected during the microdialysis experiment the dialysate 
DA levels were consistently reduced in R6/1 as compared with wild-type mice 
(repeated measures 2-factor ANOVA; genotype p < 0.001, F (1, 130) = 24.95; 
time x genotype p <0.0001, F (10, 130) = 20.68) (Figure 3.1). Stable basal 
striatal dialysate DA levels were achieved 1 hour after probe implantation. Three 
basal fractions of 20 minutes each were collected during that period. Basal 
striatal dialysate DA levels were reduced by approximately 76% in R6/1 mice as 
compared with their wild-type littermate controls (during 20 minutes of sample 
collection: R6/1 = 0.610 ± 0.10 nM; wild-type = 2.49 ± 0.41 nM; Student’s t test, 
p < 0.01), which corresponds with previous results published by our group 
(Petersén et al., 2002b). Intrastriatal KCl (60 mM) injection during 20 minutes 
rapidly raised the local dialysate DA levels in all mice (Figure 3.1). However, 
the release of DA induced by KCl was significantly reduced in R6/1 mice (2.90 
± 0.42 nM) compared to wild-type animals (7.87 ± 0.99 nM; Student t test, p < 
0.001). After intrastriatal injection of amphetamine (10 μM), during 20 minutes, 
the local dialysate DA levels were 15.81 ± 1.31 nM in wild-type and 5.82 ± 0.83 
nM in R6/1 mice (Student’s t test, p < 0.0001) (Figure 3.1). These results 
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suggest that both routes of DA release (KCl-induced exocytosis and 
amphetamine-mediated DA release) are impaired in R6/1 mice. 
 
Figure 3.1 – Measurement of DA dialysate striatal levels before and after local  
infusion of KCl and amphetamine. Dialysate samples were collected every 20 minutes, 
starting 60 minutes after the implantation of the microdialysis probe. Basal levels were 
obtained during the first 3 samples after which KCl (60 mM) was perfused through the 
microdialysis probe during 20 minutes. After a recovery period of 60 minutes, 
amphetamine (10 μM) was perfused for 20 minutes and 3 more subsequent 20 minute-
samples were collected. There were significant reductions in DA dialysate levels at all 
time points in R6/1 mice as compared with their wild-type littermate controls. Data are 
presented as means ± S.E.M. 
 
 
 
3.4.3. Dialysate Basal Levels of DA Metabolites in R6/1 Mice 
We also determined the basal dialysate striatal levels of the DA metabolites 
DOPAC and HVA (Figure 3.2). Interestingly, we found a 67% reduction in the 
basal dialysate DOPAC levels (wild-type: 162.84 ± 20.01 nM; R6/1: 53.39 ± 
12.48 nM; Student’s t test, p < 0.001), and a 69% decrease in the basal dialysate 
levels of HVA (wild-type: 179.70 ± 20.07 nM; R6/1: 56.35 ± 13.36 nM; 
Student’s t test, p < 0.001). This significant reduction in the levels of both DA 
metabolites further supports the notion of an impaired dopaminergic nigrostriatal 
pathway in R6/1 mice. 
Chapter 3 
 69 
Figure 3.2 – Basal dialysate striatal levels of the DA metabolites DOPAC and 
HVA. Dialysate samples were collected every 20 minutes, starting 60 minutes after the 
implantation of the microdialysis probe. Basal levels of DOPAC and HVA were 
obtained during the first 3 samples and the respective averages were determined. Both 
DOPAC and HVA striatal basal dialysate levels were significant reduced in R6/1 mice 
as compared with their wild-type littermate controls (Student’s t test, *** p < 0.001). 
Data are presented as means ± S.E.M. 
 
 
 
3.5. Discussion 
 
In this work we extended previous observations from our group (Petersén et 
al., 2002b) and showed that both routes of DA release (membrane 
depolarization-induced exocytosis and DAT-mediated release) are impaired in 
18- to 19-week-old R6/1 mice. Furthermore, we detected a significant decrease 
in whole tissue striatal DA levels, which is in accordance with studies from 9- 
(Hickey et al., 2002) and 12-week-old (Reynolds et al., 1999) R6/2 mice. 
Furthermore, we found a significant reduction in the basal dialysate striatal 
levels of both DA metabolites, DOPAC and HVA. Overall, these results further 
implicate a dysfunction of the nigrostriatal dopaminergic pathway in the 
neuropathology of R6 transgenic mice. 
The cause for the impaired striatal DA release in these HD mice is not fully 
understood. One possibility could be the loss of dopaminergic neurons and/or a 
reduction in their striatal efferents. However, stereological counts revealed no 
differences in the total number of dopaminergic neurons in the R6/1 substantia 
nigra at 16 weeks of age, a time where a significant reduction in malonate-
induced DA release is detected. Furthermore, when injecting a retrograde tracer 
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into the striatum, the number of cells back-labeled in the substantia nigra is 
normal in 16-week-old R6/1 mice, suggesting that their axonal striatal 
projections are intact (Petersén et al., 2002b). 
Another possible explanation for the reduced DA release could be an 
impairment of DA synthesis. Although no differences in the protein levels of TH 
(the rate-limiting enzyme in the biosynthesis of catecholamines) were initially 
detected in 16-week-old R6/1 mice (Petersén et al., 2002b), recent evidence 
from our group suggest that this might not be the case (Smith et al., unpublished 
data). Indeed, a significant reduction of about 20% in TH protein levels was 
observed. Furthermore, this decrease progresses over the course of the disease, 
reaching 70% in 40-week-old R6/1 mice (Smith et al., unpublished data). 
Moreover, levels of TH mRNA are also decreased at both ages (Smith et al., 
unpublished data), suggesting that the observed decreased in TH protein levels 
could be a direct consequence of mutant huntingtin-mediated transcriptional 
dysregulation (section 1.3.3.3). In support of this hypothesis, reduced TH protein 
levels have also been reported in end-stage 12-week-old R6/2 mice as assessed 
by fluorescence immunohistochemistry (Ariano et al., 2002) and western-
blotting (Yohrling et al., 2003). Moreover, a similar TH decrease has been also 
observed in HD brains (section 1.4.2; Yohrling et al., 2003). 
Although an impairment of DA synthesis seems to be the likely cause of 
these pre-synaptic abnormalities, we cannot exclude the possibility that an 
impaired exocytotic process may also contribute to the observed reduced DA 
release, at least in basal conditions and after KCl-induced plasma membrane 
depolarization. Indeed, as discussed above (see section 1.3.3.5), mutant 
huntingtin is thought to abnormally interact with several different proteins 
involved in exocytosis, leading to the disruption of this process (for review see 
Li JY et al., 2003; Smith et al., 2005). 
Interestingly, we found that amphetamine evoked a greater release of DA 
than KCl in all mice. It was recently demonstrated that amphetamine induces 
DA release via 2 distinct DAT-mediated mechanisms: (1) a slow process 
consistent with an exchange mechanism due to the reversal of the transporter; 
and (2) a rapid efflux through a channel-like mode of DAT that accounts for the 
release of a large quantity of DA molecules (Kahlig et al., 2005). Therefore, it is 
possible that these two mechanisms can account for the massive DA release we 
observed upon amphetamine infusion. Nevertheless, the amphetamine-induced 
DAT-mediated DA release was significantly decreased in R6/1 mice as 
compared to wild-type controls. However, the protein levels of DAT seem to be 
unchanged in R6/1 mice both at 16 (Petersén et al., 2002b; Smith et al., 
unpublished data) and 40 weeks of age (Smith et al., unpublished data), 
suggesting that a decrease in DAT is unlikely to account for our results. 
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Therefore, a more likely explanation for the R6/1 mice reduced response to 
amphetamine is an impaired DA biosynthesis. 
In this study we also measured the basal dialysate striatal levels of the DA 
metabolites, DOPAC and HVA, and found that they too were significantly 
reduced in R6/1 mice. The observed decrease may reflect the reduced amount of 
DA that is available for catabolism in these mice. Interestingly, a reduction in 
whole tissue striatal DOPAC levels was also found in 9-week-old R6/2 mice 
(Hickey et al., 2002). 
It is important to point out that contradictory results showing no changes in 
the dopaminergic system of R6/2 mice have also been reported (Vetter et al., 
2003). By performing in vitro release experiments and in vivo microdialysis in 
freely moving 12-week-old mice, Vetter and colleagues (2003) failed to detect 
any significant differences at the level of electrically evoked release of [3H]DA 
and its modulation by DA D2 receptors, and of striatal DA levels in end-stage 
R6/2 mice (Vetter et al., 2003). The reasons for this discrepancy are currently 
unknown. It may be that differences between the transgenic mouse lines (R6/1 
versus R6/2), mice colonies, or in vivo microdialysis techniques are responsible 
for these discrepancies. It is interesting to point out that in our laboratory R6/2 
mice failed to survive during the long periods of anesthesia that were required to 
perform our particular microdialysis procedure. Nevertheless, our results 
correspond with the recent study by Johnson and colleagues (2006) who have 
demonstrated a progressive and significant reduction in DA release in brain 
slices from R6/2 mice (Johnson et al., 2006). Moreover, R6/2 mice showed an 
attenuated response to cocaine (Hickey et al., 2002; Johnson et al., 2006), and 
decreased activity in the open field when stimulated with a single dose of 
amphetamine (2.5 mg/kg) (Gil et al., unpublished observations), suggesting that 
an impaired release of DA indeed occurs in these mice. 
To conclude, we provide further evidence for an impaired release of DA and 
a corresponding reduction in striatal levels of this neurotransmitter and its 
metabolites in R6/1 mice. Since both pathways of DA release were markedly 
affected in R6/1 mice, we believe that this reduction is associated with a 
decrease in DA synthesis, which in turn is caused by a decrease in TH 
expression. Thus, a dysfunctional nigrostriatal pathway is likely to contribute to 
striatal degeneration and some of the symptoms of the disease, such as 
bradykinesia and rigidity, which are observed in both late-stage R6 mice and HD 
patients. 
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Dysfunction of the Lateral Hypothalamus in 
Huntington’s Disease 
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307:483 (2005)]. 
  74 
Chapter 4 
 75 
4.1. Summary 
 
Mutant huntingtin forms intracellular aggregates and is associated with 
neuronal death in select brain regions. Although R6/2 mice replicate many 
features of the disease, little neuronal death has been detected. Here we describe, 
for the first time, a dramatic atrophy and loss of orexin neurons in the lateral 
hypothalamus of R6/2 mice. Both the number of orexin neurons in the lateral 
hypothalamus and the CSF levels of orexin were reduced by about 72% in end-
stage R6/2 mice. Correspondingly, we detected a significant atrophy and loss of 
orexin neurons in the lateral hypothalamus of HD patients. The lateral 
hypothalamus plays an important role in sleep regulation. In support, R6/2 mice 
develop a narcoleptic-like behavior. In addition to orexin cell loss, we also 
detected a significant reduction (by 38%) of melanin-concentrating hormone 
(MCH) neurons in end-stage R6/2 mice. MCH is an important peptide involved 
in the maintenance of energy homeostasis and the regulation of food intake, and 
the implications of this finding deserve further investigations. Our results reveal 
a loss of hypothalamic orexin and MCH neurons, which is a novel and 
potentially very important pathological feature in HD that may explain some of 
the symptoms of the disease, namely sleep disturbances and weight loss. 
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4.2. Introduction 
 
The hypothalamus is one of the most functionally and neuroanatomically 
complex brain regions (Figure 4.1). It has long been recognized as a regulatory 
center that controls body homeostasis. Its functions include regulation of 
cardiovascular and autonomic functions, reproduction, body fluid homeostasis, 
energy metabolism, circadian rhythms, and the sleep-wakefulness cycle. A 
variety of studies suggest that multiple regions within the hypothalamus can 
regulate multiple physiological functions (for review see Hungs and Mignot, 
2001; Taheri et al., 2002). In particular, the lateral hypothalamus plays a critical 
role in the maintenance of wakefulness, and the regulation of the feeding 
behavior and energy homeostasis. Such disparate functions have been linked to 
distinct neuronal populations and their widespread axonal projections throughout 
the CNS, including the orexin (hypocretin) neurons, and the MCH-secreting 
neurons. 
 
Figure 4.1. – A schematic representation of the human hypothalamus and its 
nuclei, viewed from a coronal perspective. The three principal regions of the 
hypothalamus are the periventricular, lateral, and medial regions. Adapted from Kolb 
and Whishaw, 2006. 
 
 
Orexin neurons express the orexin gene, which codes for the precursor 
peptide prepro-orexin. Proteolytic cleavage of this precursor generates 2 orexin 
peptides: orexin-A (hypocretin 1; a 33 amino acid peptide) and orexin-B 
(hypocretin 2; a 28 amino acid peptide) (de Lecea et al., 1998; Sakurai et al., 
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1998). Orexin projections are particularly dense in monoaminergic centers and 
are thought to interact with the autonomic, neuroendocrine, and arousal systems 
(Date et al., 1999). This occurs through the activation of 2 closely related GTP-
binding protein (G protein)-coupled receptors, called orexin receptors 1 and 2 
(OX1R and OX2R). OX1R is relatively selective for orexin-A and is coupled to 
the activation of the excitatory Gq subtype of G proteins. Activation of Gq 
proteins leads to the stimulation of phospholipase C and the influx of 
extracellular Ca2+, which subsequently triggers the phosphatidylinositol cascade 
and the activation of protein kinase C. OX2R is a nonselective receptor for both 
orexin peptides and can be coupled either to excitatory Gq or inhibitory Gi/o 
proteins, depending on the target neuron (for review see Beuckmann and 
Yanagisawa, 2002; Mieda and Yanagisawa, 2002). 
Importantly, mice with a null mutation of either orexin (Chemelli et al., 
1999) or one of its receptors (Willie et al., 2003), and transgenic mice with a 
targeted ablation of orexin neurons (Hara et al., 2001) display severe 
disturbances in the sleep-wakefulness cycle. These sleep disturbances are similar 
to the symptoms observed in humans suffering from narcolepsy, a disease 
characterized by chronic sleepiness and a marked disorganization of the 
sleep/wake behaviour with abnormal manifestations of rapid eye movement 
(REM) sleep occurring during periods of wakefulness (for review see Siegel, 
1999; Taheri et al., 2002). Subsequent studies have shown that most human 
narcolepsy patients have reduced CSF levels of orexin (Ripley et al., 2001; 
Dauvilliers et al., 2003), and that in some cases a global loss of orexin is 
observed (Peyron et al., 2000). Furthermore, one mutation in the orexin gene 
that impairs the peptide trafficking and processing, was found in a single case of 
early onset narcolepsy (Peyron et al., 2000). Under normal conditions, orexins 
are thought to play a crucial role in sleep regulation by driving the cholinergic 
and monoaminergic tone throughout the sleep-wakefulness cycle. Furthermore, 
the suprachiasmatic nucleus (which contains neurons with a genetically 
identified biological clock that oscillates on a 24 hour cycle), projects to the 
orexin population in the lateral hypothalamus, explaining the occurrence of 
clock-dependent alertness (for review see Hungs and Mignot, 2001; Mignot et 
al., 2002; Taheri et al., 2002). 
Another important neuronal population within the lateral hypothalamus is 
formed by MCH-containing neurons. MCH is a cyclic peptide formed by 19 
amino acids that is generated via a proteolytic cleavage of its prepro-hormone, a 
process that also generates two additional peptides: neuropeptide E-I and 
neuropeptide G-E. Its biological functions are mediated through the activation of 
two G protein-coupled receptors: MCH-receptor 1 (MCHR1), which can be 
coupled to inhibitory Gi and excitatory Gq proteins and is expressed all over the 
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brain; and MCH-receptor 2 (MCHR2), which is exclusively coupled to 
excitatory Gq proteins and is only expressed in carnivores and primates. 
Although originally named due to its involvement in the regulation of skin color 
in fish, subsequent research showed that MCH plays a greater role in regulating 
various physiological functions. Indeed, MCH is believed to maintain energy 
homeostasis by regulating satiety, insulin and glucocorticoids levels, energy 
expenditure, and thermogenesis (for review see Jobst et al., 2004; Shi, 2004). 
MCH and MCHR1 expression is up-regulated by genetic obesity and food 
deprivation. Intracerebroventricular injection or chronic infusion of MCH 
stimulates food intake and body weight gain; whereas, continuous treatment of 
mice with a MCHR1 antagonist suppresses appetite and decreases adipocity (for 
review see Shi, 2004). 
Although the lateral hypothalamus has not been considered a major site for 
neurodegeneration in the human HD brain, several neuropathological studies of 
end-stage HD patients have demonstrated up to a 90% cell loss in the lateral 
tuberal nucleus of the hypothalamus (section 1.2.2; Kremer et al., 1990, 1991). 
Interestingly, in humans this region is particularly enriched with NMDA 
receptors (Kremer et al., 1993). Moreover, a recent study showed that in rat 
organotypic slice cultures of the lateral hypothalamus, orexin neurons are 
particularly susceptible to excitotoxic damage (Katsuri and Akaike, 2004). These 
observations suggest that excitotoxic cell death, which has been repeatedly 
suggested to play a role in the cell death observed in other brain regions (section 
1.4.1; for review see Beal, 2000; Petersén and Brundin, 2002), may also account 
for the loss of lateral hypothalamic neurons in HD patients. 
In this study we explore whether cell loss occurs in the lateral hypothalamus 
of R6/2 mice. We focused on orexin and MCH-secreting neurons, since the loss 
of these populations can have symptomatic implications in HD (namely, at the 
level of sleep disturbances and loss of body weight). Furthermore, we explored 
whether orexin neurons were also lost in the lateral hypothalamus of HD 
patients.  
 
 
 
4.3. Materials and Methods 
 
 
4.3.1. Transgenic Animals 
We used transgenic HD mice of the R6/2 line and their wild-type littermates 
(Jackson Laboratories) in this study. The colony was maintained by crossing 
transgenic males with females of their background strain (F1 of CBA x 
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C57BL/6J). Tails of the offspring were used to obtain DNA for determination of 
the genotype using a PCR assay (Mangiarini et al., 1996). The mice were housed 
in groups with ad libitum access to food and water at a 12-hour light/dark cycle. 
The experimental procedures were approved by the Ethical Committee for the 
use of laboratory animals at Lund University, Sweden. 
 
 
4.3.2. Human HD Brains 
We evaluated formalin-fixed brains of 5 HD patients (age 69 ± 6 years) and 
4 controls (age 64 ±10 years) from the Leiden University Hospital Brain Bank, 
Leiden, The Netherlands (Table IV).  
 
 
4.3.3. Tissue Processing and Histology 
R6/2 mice and wild-type littermates at 3.5, 7.5-8, 11.5-12 and 12.5 weeks (n 
= 4-9/genotype/age) of age were deeply anesthetized with pentobarbital and 
transcardially perfused with saline followed by 4% PFA in 0.1 M PBS. The 
brains were left in the fixative overnight and then dehydrated in 20% sucrose/0.1 
M PBS. Coronal sections were cut in 6 series throughout the brains on a freezing 
sliding microtome and collected in PBS. Tissue from wild-type/controls and 
R6/2/HD subjects was processed in parallel for immunohistochemistry to control 
for labeling intensity. 
Separate series of free-floating mouse sections were processed for detection 
of orexin-A, MCH, NeuN, and GFAP proteins. Briefly, the sections were 
quenched in 3% H2O2/10% methanol in 0.1 M PBS for 15 minutes, and 
preincubated with the proper sera. The sections were then incubated overnight at 
room temperature (or during 48 hours at 4°C) with a rabbit polyclonal antibody 
against orexin-A (diluted 1:700; Phoenix Pharmaceuticals Inc., Belmont, CA, 
USA), a rabbit polyclonal antibody against MCH (diluted 1:500; Phoenix 
Pharmaceuticals Inc.), a mouse monoclonal antibody against NeuN (diluted 
1:1000, Chemicon), and a rabbit polyclonal antibody against GFAP (diluted 
1:700; Dako, Glostrup, Denmark), respectively. The sections were then 
incubated for 2 hours with the respective secondary antibodies (biotinylated 
horse anti-mouse IgG, diluted 1:200, Vector Laboratories; and biotinylated 
swine anti-rabbit IgG, diluted 1:200, Dako), and visualized with an avidin–
biotin–peroxidase complex system (Vectastain ABC Elite Kit; Vector 
Laboratories) using DAB as the chromogen. A separate series of mice brain 
sections was also processed with cresyl violet (ICN Biomedicals Inc.), as 
described in section 2.3.3. 
To evaluate whether orexin-A-positive neurons possess NIIs of mutant 
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huntingtin, orexin-A/EM48 double-labeling was also performed. Briefly, after 
preincubation in blocking solution (in 1% bovine serum albumine, BSA/0.1 M 
PBS) containing NHS and normal donkey serum (NDS), the sections were 
incubated for 48 hours at 4°C with the mouse monoclonal anti-huntingtin 
antibody (EM48, diluted 1:500; Chemicon; which was shown to be specific also 
in mouse tissue; Yu et al., 2002) and the rabbit polyclonal anti-orexin-A 
antibody (diluted 1:700; Phoenix Pharmaceuticals Inc.). The sections were then 
incubated with the secondary antibodies: Texas Red dye-conjugated donkey 
anti-rabbit IgG (diluted 1:200, Jackson ImmunoResearch, West Grove, PA, 
USA) and biotinylated horse anti-mouse IgG (diluted 1:200; Vector 
Laboratories) for 2 hours, followed by incubation with Fluorescein (FITC)-
conjugated streptavidin (diluted 1:200, Dako) for 2 hours. 
Paraffin embedded human brain sections (15 μm thickness) were processed 
for orexin-A immunohistochemistry. Briefly, after de-waxing in xylen and 
rinsing in ethanol, the endogenous peroxidases were blocked in 0.3% hydrogen 
peroxide/methanol for 20 minutes. The sections were then incubated overnight at 
room temperature with the rabbit polyclonal antibody against orexin-A (diluted 
1:1500; Phoenix Pharmaceuticals Inc.), and finally with the secondary antibody 
biotinylated swine anti-rabbit IgG (diluted 1:600; Dako) for 1 hour. The bound 
antibodies were visualized as described above. 
 
 
4.3.4. Stereological Techniques and Cell Quantification 
All morphological analyses listed below were performed on blind-coded 
slides, using the stereological equipment described before (section 2.3.4) with a 
40x objective. 
Due to the low numbers of orexin neurons, we were unable to perform 
proper stereological quantification. Instead, the density of orexin neurons in the 
lateral hypothalamus of R6/2 and wild-type mice (n = 4-9/genotype/age) was 
assessed in the 3 sections with the largest number of orexin immunopositive 
neurons per brain (distance between the sections: 150 μm). The outer border of 
the lateral hypothalamus was determined by delineating the region just outside 
the location of the orexin-immunopositive neurons. Using a systematic random 
sampling technique, the number of labeled cells was assessed in 25% of the 
delineated area. Only profiles characterized by intense dark labeling throughout 
the cell body were counted. Note that significantly lighter profiles were not 
counted, since we were uncertain whether they represented true orexin-positive 
cells. Profiles were included independently of the size or shape of their soma, as 
some cells were atrophied (see section 4.4.1). The same technique was used for 
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all mice. The average density of orexin positive neurons in the 3 sections from 
each mouse was used in the statistical analysis.  
Due to sufficiently large enough numbers of MCH-positive neurons in the 
lateral hypothalamus of 8- and 12-week-old mice, their total numbers were 
assessed by stereological methods (Gundersen et al., 1988). For systematic 
sampling, the frame area (2437-2442 μm2) and the counting interval (x and y 
both 100 μ) were set to allow for at least a total of 200 cells to be sampled in 4 
sections of the lateral hypothalamus with the highest density of MCH-positive 
cells (distance between the sections: 150 μm). The outer border of the lateral 
hypothalamus was determined by delineating the region just outside the location 
of the MCH-immunopositive neurons. The optical dissector was set to sample all 
cells below the first 2.5 μm and above the last 2.5 μm of the top and bottom 
surfaces of the section. Only profiles characterized by intense dark labeling 
throughout the cell body were counted. Significantly lighter profiles were not 
counted, since we were uncertain whether they represented true MCH-positive 
cells. Profiles were included independently of the size or shape of their soma, as 
some cells were atrophied (see section 4.4.4). 
The cross-sectional soma area from 30 randomly selected orexin- or MCH-
immunopositive neurons was determined in 3 to 4 sections from 4 to 7 mice per 
genotype and age, by delineation of their soma circumference. Neurons were 
selected based on the intensity of their labeling throughout the cell body and 
regardless of their size and shape of their soma, as some cells were atrophied 
(see sections 4.4.1 and 4.4.4). Significantly lighter profiles were not counted, 
since we were uncertain whether they represented true orexin- or MCH-positive 
cells. 
In adjacent sections of the lateral hypothalamus, the density of cresyl violet 
stained cells, neurons (NeuN-labeled), and neurons containing NIIs (EM48-
positive) were assessed in 12.5-week-old mice. The procedure was identical to 
the one previously established to assess the number of orexin-positive neurons. 
Cell counts were performed in 3 sections per brain (distance between the 
sections: 150 μm). 
The presence of EM48-immunopositive NIIs in orexin-A-labeled neurons 
was analyzed in 100 randomly selected orexin-A-positive neurons in the 3 
mentioned sections from 4 mice per genotype at the ages of 3.5, 7.5 and 12.5 
weeks. 
In the human brains, we compared sections containing orexin-A-positive 
cells from each individual and selected the section that appeared to have the 
highest density of orexin-A-positive cells. In this section, orexin-A-positive 
neurons were counted in 4 different fields delineated by a 1 mm2 ocular grid. 
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The cross sectional soma area of 20 randomly selected orexin-A positive cell 
bodies/individual was also determined. 
 
4.3.5. Radioimmunoassay 
Hypothalami dissected from 12.5-week-old mice (n = 7 / genotype) or CSF 
withdrawn from the cisterna magna of 12-week-old mice (n = 4 / genotype) were 
used for peptide extraction. Using commercially available 125I 
radioimmunoassay (RIA) kits (Phoenix Pharmaceuticals), orexin-A (CSF and 
brain tissue) and orexin-B (brain tissue) were measured. Duplicate samples were 
assayed and levels were determined against a known standard. 
 
 
4.3.6. Electron Microscopy 
Mice of 12 weeks of age (n = 2/ genotype) were perfused with 0.075 M 
Sörensen buffer containing 3% paraformaldehyde and 1% glutaraldehyde. 
Hypothalami were dissected and fixed overnight in the same fixative, rinsed in 
Sörensen buffer, post-fixed for 1 hour with 1% OsO4 in the same buffer, 
dehydrated in acetone and embedded in Polybed 812. Ultra thin sections were 
cut and placed on copper grids before contrasted with 0.5% lead citrate and 4% 
uranyl acetate. Specimens were examined in a Philips CM10 transmission 
electron microscope. 
 
 
4.3.7. Scoring of Narcoleptic-Like Episodes 
We videorecorded and scored narcoleptic-like episodes in R6/2 and wild-
type mice at the following ages: 3.5 (n = 5), 7.5 (n = 5), 11.5 (n = 3), and 12.5 (n 
= 3) weeks, according to the procedure described by Chemelli and colleagues 
(Chemelli et al., 1999). Different mice were used for each age. Briefly, the mice 
were habituated for 3 hours in individual glass cylinders covered with bedding 
material before they were recorded during the first 4 hours of the dark cycle with 
a Sony CCD infrared videocamera. For each behavioral experiment, 1 R6/2 and 
1 wild-type mouse were videorecorded simultaneously. The scoring of the 
episodes was carried out by 2 investigators blinded to the mouse genotype. The 
episodes of behavioral arrest were classified into 3 different categories according 
to their severity: (1) periods of no movement; (2) periods of no movement with 
an abrupt and/or sudden change of posture in the beginning of the episode; and 
(3) episodes involving loss of muscular tone, and/or a sudden collapse of the 
head and neck, occasionally causing the mouse to fall completely onto its side. 
The same protocol was used to evaluate the behavior of 12-week-old R6/2 mice 
(n = 4) during the light-phase of the diurnal cycle. 
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4.3.8. EEG and EMG Recordings 
At 10 weeks of age, mice (n = 4 for R6/2; n = 2 for wild-type) were 
implanted with recording electrodes. One cortical screw electrode was attached 
to the right parietal bone to record the electroencephalogram (EEG) and a wire 
electrode (insulated copper, 250 µm in diameter, tip exposed to 1.5 mm, Belden, 
St. Louis, MI, USA) was attached between the occipital bone and the neck 
muscles to record the electromyography (EMG). Both electrodes were 
referenced to a frontal screw electrode. Two additional anchor screws were 
attached onto the left parietal and frontal bone, and a 3-way connector (Plastic 
One, Roanoke, VA, USA) fixed above the screws with dental acrylic cement. 
Twelve to 15 days following electrode implantation, pairs of mice (wild-type 
and R6/2) were videotaped and had the EEG and EMG recorded continuously 
(Chart 3.6.3, PowerLab/MacLab ADInstruments, Arhus, Denmark) during the 
first 4 hours of their dark cycle. Videotapes were scored for narcoleptic-like 
episodes (section 4.3.7) and EEG parameters were analyzed with Chart 3.6.3 
software. 
 
 
4.3.9. Statistical Analysis 
The data were analyzed with a 1- or 2-factor ANOVA when appropriate, or 
unpaired Student’s t tests, using the Statview 5.4 package (Abacus Concepts). 
Data were presented as mean or median ± S.E.M. A p value of < 0.05 was 
considered statistically significant. 
 
 
 
4.4. Results 
 
 
4.4.1. Orexin Loss in R6/2 Mice 
We observed a progressive reduction with age in the number of orexin 
neurons in the R6/2 lateral hypothalamus compared to wild-type mice (2-factor 
ANOVA; genotype p < 0.0001, F (1, 44) = 94.68; age p < 0.0001, F (3, 44) = 
40.10; age x genotype p < 0.0001; F (3, 44) = 28.12) (Figure 4.2). This 
reduction was not apparent at 3.5 weeks of age, but after 7.5 weeks orexin cell 
loss was clear (Figure 4.2.E). 
The surviving orexin neurons were significantly atrophied in R6/2 mice 
compared to wild-type, as assessed by measuring the cross sectional surface area 
of the cell bodies (2-factor ANOVA; genotype p < 0.0001, F (1, 24) = 23.50; age 
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p < 0.0001, F (3, 24) = 13.91; age x genotype p = 0.01; F (3, 24) = 4.49) (Figure 
4.2.F). 
Figure 4.2. - Progressive loss and atrophy of orexin neurons in R6/2 mice. Sections 
of lateral hypothalamus processed for orexin-A immunohistochemistry in wild-type (A, 
C) and R6/2 (B, D) mice at 12.5 weeks of age. Scale bar = 200 μm (A) and 20 μm (C). 
(E) Progressive reduction in the density of orexin-immunopositive neurons (n = 4 to 9 / 
genotype/age). (F) Progressive decrease of the cross-sectional surface area of the 
somata of the orexin-positive neurons (n = 4 / genotype) in R6/2 mice compared to 
wild-type littermates. Values represent means ± S.E.M. 
  
 
To further investigate whether reduction in orexin cells counts was due to 
actual cell loss rather than reduced orexin protein expression in surviving cells, 
adjacent sections were processed for cresyl violet and NeuN 
immunohistochemistry. At 12.5 weeks of age, we found a significant reduction 
of the number of cresyl violet stained cells (wild-type: 5363 ± 193 / mm2; R6/2: 
4381 ± 345 / mm2, Student’s t test, p < 0.05) and cells immunopositive for the 
neuron-specific marker NeuN (wild-type: 3704 ± 143 / mm2; R6/2: 3138 ± 167 / 
mm2, Student’s t test, p < 0.05) in R6/2 mice. 
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Although we did not use proper stereological methods to determine the total 
cell numbers in the lateral hypothalamus (section 4.3.4), we estimate that the 
percentage of orexin neurons (i.e., number of orexin-positive cells compared to 
the number of NeuN-positive neurons) in the lateral hypothalamus was around 
7% in wild-type mice and 2% in R6/2 mice of 12.5 weeks of age. Moreover, 
according to our estimations, end-stage R6/2 mice lost around 15% of neurons in 
the lateral hypothalamus, among which 72% were orexin-positive. However, we 
cannot completely exclude the possibility that this percentage may be 
overestimated since we excluded lightly labeled profiles (section 4.3.4), which 
may represent a down-regulation of orexin expression, from our quantification 
criteria. 
Using transmission electron microscopy, we observed frequent 
ultrastructural signs of neurodegeneration in the lateral hypothalamus of R6/2 
mice, with some neurons displaying “dark degeneration” (Figure 4.3) as 
previously described in other brain regions of R6/2 mice (section 1.6.1.2; 
Iannicola et al., 2000; Turmaine et al., 2000; Yu et al., 2003; Stack et al., 2005). 
No gliosis was apparent in 12.5-week-old R6/2 brains as assessed in 
hypothalamic sections processed for GFAP immunohistochemistry (data not 
shown). 
 
Figure 4.3. - Dark neuron degeneration in the R6/2 lateral hypothalamus. 
Transmission electron micrographs of lateral hypothalamus from a 12-week-old wild-
type (A) and R6/2 mouse (B) showing examples of dark degenerating nerve cell bodies 
in the R6/2 mouse. Scale bar = 5 μm. 
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We also studied the frequency of huntingtin inclusions in orexin 
immunopositive neurons in R6/2 mice. In 3.5-week-old R6/2 mice, none of the 
orexin neurons in the lateral hypothalamus contained EM48-immunopositive 
inclusions, while at 7.5 weeks 50 ± 6% of the orexin–positive neurons were 
EM48-positive. On average, 77.5 ± 5% of the NeuN-immunopositive neurons in 
the 12.5-week-old R6/2 lateral hypothalamus displayed EM48 immunoreactive 
inclusions, but only 57 ± 5% of the remaining orexin–positive neurons contained 
inclusions (Student’s t test, p < 0.05). 
Using RIA, we found a significant reduction of both orexin-A and orexin-B 
levels in R6/2 compared to wild-type mice at 12.5 weeks of age, both in the 
hypothalamus and in the remaining brain tissue (Table III). 
 
 
Table III - Orexin levels in R6/2 mice. 
Hypothalamus Brain 
(excluding the hypothalamus) 
 
Wild-type R6/2 Wild-type R6/2 
Orexin-A 
(ng/g tissue) 
28.0 ± 1.5 6.6 ± 1.3*** 17.9 ± 4.7 2.2 ± 1.5* 
Orexin-B 
(ng/g tissue) 
26.6 ± 1.3 2.8 ± 0.2*** 15.2 ± 1.3 2.8 ± 0.4*** 
RIA measurements in 12.5-week-old mice (n = 7). Student’s t test, *** p < 0.0001, * p 
< 0.05 as compared to wild-type. Values are presented as means ± S.E.M. 
 
 
 
Figure 4.4. - Photomicrographs of the pineal region around the third ventricle in a 
12-week-old wild-type (A) and R6/2 (B) mouse showing loss of orexin fibers in the 
R6/2 mouse. Scale bar = 100 μm. PC (posterior commissure), SCO (subcommisural 
organ), 3V (third ventricle). 
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The later result indicates that the projections of orexin neurons throughout 
the CNS are affected. Importantly, we found severe loss of orexin-
immunoreactive fibers around the third ventricle and the subcommisural organ, a 
region representative of the pineal gland (Mikkelsen et al., 2001), in 12.5-week-
old R6/2 mice (Figure 4.4). 
Using RIA, we also determined the levels of orexin in the CSF of 12-week-
old R6/2 mice and wild-type littermate controls. Compared to the wild-type 
orexin CSF levels (2070 ± 130 pg/ml), end-stage R6/2 mice showed a 72% 
reduction in the CSF levels of this peptide (590 ± 170 pg/ml, Student’s t test, p < 
0.001). 
 
 
4.4.2. Narcoleptic-Like Episodes in R6/2 Mice 
We performed infrared video recordings of mice at different ages during the 
first 4 hours of their dark cycle to analyze whether the orexin loss in R6/2 mice 
would result in the appearance of narcoleptic-like episodes (Chemelli et al., 
1999). At 3.5 weeks of age, R6/2 mice were indistinguishable from wild-type 
controls, with periods of hyperactivity and intense exploratory behavior 
intercalated by prolonged periods of rest and normal sleeping (Figure 4.5.A). 
However, at 7.5 weeks of age we observed several periods of brief behavioral 
arrest in R6/2 mice (n = 5; 1 to 8 episodes/mouse; median = 6) (Figure 4.5.A). 
These episodes were characterized by a sudden interruption of purposeful motor 
activity associated with a change of posture that was maintained throughout the 
episode. This resembles the narcoleptic episodes that have been described in 
orexin knockout mice (Chemelli et al., 1999). At 11.5 and 12.5 weeks, these 
episodes become even more frequent, and over 4 hours we observed 11 to 14 (n 
=3; median = 11), and 10 to 14 episodes of behavioral arrest per mouse (n = 3; 
median = 13), respectively (Figure 4.5.A). At 12.5 weeks of age, most of the 
episodes occurred during the first and the third hours of the dark phase, and their 
duration varied between 3 and 214 seconds (n = 3; mean = 62 seconds). An 
example of the episode distribution for one R6/2 mouse is illustrated in Figure 
4.5.B. 
To further characterize this behavior in end stage mice, we divided the 
episodes of behavioral arrest into 3 different categories according to their 
severity (section 4.3.7). All R6/2 mice examined (n = 3) showed episodes of no 
movement (5 to 9 episodes per mouse; median = 7). Two of the mice also 
exhibited abrupt and sudden changes of posture; and interestingly, all 3 mice 
displayed narcoleptic-like episodes with complete falls onto the side (4 to 5 falls 
per mouse; median = 4) (Figure 4.5.C). These episodes were followed by 
sudden bouts of locomotion with hyperactivity. 
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Figure 4.5.- Characterization of narcoleptic-like episodes in R6/2 mice. All 
analysis of narcoleptic-like episodes was performed during the first 4 hours of the dark 
phase, which is the active period for mice. (A) The total number of narcoleptic-like 
episodes increases with age in R6/2 mice. Different mice were used for each time-point. 
(B) The duration of the narcoleptic-like episodes for a 12.5-week-old R6/2 mouse and 
the period in which they occurred are illustrated by the vertical lines. (C) The total 
number of narcoleptic-like episodes per mouse divided into 3 different categories in 
12.5-week-old R6/2 mice (n = 3). Inserted table shows the mean duration of each of the 
different categories of narcoleptic-like episodes. (D) Typical EEG / EMG recording 
before and during a narcoleptic-like episode in a 12.5-week-old R6/2 mouse, showing 
reduced EMG activity and no epileptic activity in the EEG. Arrows indicate the 
beginning and the end of the narcoleptic-like episode. In contrast, the EEG / EMG 
recording of a resting wild-type mice display continued low level EMG activity also 
when the mouse is not ambulatory. Arrow indicates the beginning of the period. 
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Using the same criteria as above, we also evaluated the behavior of 12-week-
old R6/2 mice during the day, when mice are normally inactive. Interestingly, 
during the light-phase of their diurnal cycle, R6/2 mice generally spent less time 
sleeping than wild-type mice. However, they exhibited repeated, sudden 
episodes of behavioral arrest often associated with an abrupt change of posture. 
These kinds of episodes were never observed with wild-type littermate controls 
(data not shown). 
Since R6/2 mice are known to be convulsive-prone (Mangiarini et al., 1996; 
Gil et al., unpublished observations), we subjected a separate group of 12.5-
week-old R6/2 (n = 4) and wild-type (n = 2) mice to EEG / EMG recordings to 
determine whether the observed episodes of behavioral arrest, interpreted as 
narcoleptic-like, were instead caused by seizure activity. Mice were video 
recorded while the EEG / EMG activities were assessed, and the episodes of 
behavioral arrest were scored. Our video-EEG recordings revealed no 
epileptiform electrographic activity during episodes of motor arrest. Rather, the 
EEG was characterized by small amplitude theta activity and reduced EMG 
signal of the neck muscles (Figure 4.5.D). In contrast, when wild-type mice 
occasionally paused in their movements, EMG activity was not decreased 
(Figure 4.5.D). 
 
 
4.4.3. Orexin Cell Loss in HD Brains 
To ensure that loss of orexin containing neurons was also relevant to the 
human condition, we examined the lateral hypothalamus from HD patients. 
 
Figure 4.6. - Reduction in orexin neurons in HD patients. Representative 
microphotographs of orexin-A immunopositive neurons in the lateral hypothalamus of a 
control individual (A) and an HD patient (B). The illustration shows both atrophy of the 
individual neurons and a reduction in orexin immunopositive neurons in the HD patient 
brain compared to the control brain. Scale bar = 500 μm. 
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The mean number of orexin-positive neurons / mm2 in the section showing 
the highest density of orexin-positive neurons for each subject is given in Table 
IV. In control brains from healthy individuals, the mean number of orexin-
positive neurons / mm2 was estimated to be 62 ± 4 neurons. In corresponding 
areas in brains from HD affected individuals (grade II-IV) the mean number of 
orexin-positive neurons was 45 ± 1 / mm2 (Student’s t test, p < 0.005; Figure 
4.6.A-B, and Table IV). There seems to be no obvious relationship between the 
Vonsattel grade and the loss of orexin neurons (Table IV). 
 
 
Table IV - Data on HD patients and controls. 
 Brain Weight 
(g) & Fixation 
Time (months) 
Postmortem 
Interval 
(hours) 
Vonsattel 
Grade 
CAG 
Repeats 
No. Orexin 
Neurons/mm2 
HD      
1 1200 g /  
2 months 
unknown III 20/43 45 
2 - / 5 months < 24 hours III - 40 
3 - / 9 months 15 hours II - 47 
4 1175 g /  
15 months 
< 24 hours III 17/46 46 
5 - / 2.5 months 4 hours IV 16/39 49 
Controls      
1 1200 g /  
5 months 
15 hours - - 54 
2 1510 g / 
unknown 
13 hours - - 70 
3 - / unknown unknown - - 66 
4 1300 g / 
unknown 
6 hours - - 58 
 
 
There was also a significant neuronal atrophy in orexin cells of HD patients, 
detected as a reduction in the mean cross-sectional surface area of the orexin cell 
bodies in HD patients (230 ± 33 μm2) compared to controls (363 ± 8 μm2) 
(Student’s t test, p < 0.05). 
 
 
4.4.4. Loss of MCH-Containing Neurons in R6/2 Mice 
As stated above, we estimate that end-stage R6/2 mice lost around 15% of 
neurons in the lateral hypothalamus, among which 72% were orexin-positive 
(section 4.4.1). Therefore, the loss of orexin-containing neurons per se cannot 
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account for the total decrease in the estimated number of hypothalamic neurons. 
Thus, we sought to investigate MCH-secreting neurons, which constitute a 
separate neuronal population within the lateral hypothalamic region (section 4.2; 
Steininger et al., 2004). 
By performing MCH immunohistochemistry in brain sections from 8- and 
12-week-old mice, we observed a progressive reduction with age in the number 
of MCH-containing neurons in the lateral hypothalamus of R6/2 mice, as 
compared to their wild-type littermate controls (2-factor ANOVA; genotype p < 
0.01, F (1, 17) = 8.55; age p < 0.05, F (1, 17) = 8.01; age x genotype p = 0.12, F 
(1, 17) = 2.72) (Figure 4.7.A). We detected a 38% reduction in the number of 
MCH-positive neurons in 12-week-old R6/2 mice. The remaining neurons in 
end-stage R6/2 mice were significantly atrophied (2-factor ANOVA; genotype p 
< 0.0001, F (1, 17) = 65.58; age p < 0.001, F (1, 17) = 17.98; age x genotype p = 
0.21; F (1, 17) = 1.73) (Figure 4.7.B). Note that the decrease in MCH neurons 
was not as dramatic as for orexin-positive neurons. 
 
Figure 4.7. - Progressive loss and atrophy of MCH-containing neurons in R6/2 
mice. (A) Progressive reduction in the density of MCH-immunopositive neurons in R6/2 
mice compared to wild-type littermates (n = 4 to 7 / genotype/age). (B) Progressive 
decrease of the cross-sectional surface area of the somata of MCH-positive neurons in 
R6/2 mice compared to their wild-type littermates (n = 4 to 7 / genotype). Values 
represent means ± S.E.M. (Gil and Petersén et al., unpublished observations). 
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4.5. Discussion 
 
In HD there is pronounced neuronal death in select brain regions. Although 
transgenic HD mouse models have provided valuable insight into disease 
mechanisms, they have not reproduced the extent and specific patterns of cell 
death that occur in HD patients. This is true for the R6/2 mouse, which exhibits 
reduced cell loss in the striatum and the cerebral cortex (section 1.6.1.2; 
Iannicola et al., 2000; Turmaine et al., 2000; Yu et al., 2003; Stack et al., 2005). 
Now, for the first time, this study demonstrates progressive neuronal loss in 
the lateral hypothalamus of R6/2 mice. We have identified at least 2 neuronal 
populations that are lost in these mice: orexin and MCH-containing neurons. 
There was also a significant depletion of orexin in samples from hypothalamic 
tissue (that contain the cell bodies of the orexin neurons) and from the remaining 
regions of the brain (that receive orexin-projections). 
Moreover, we found that HD patients display loss and atrophy of orexin-
immunolabeled neurons in the lateral hypothalamus. There appears to be no 
obvious relationship between the Vonsattel grade and the loss of orexin neurons. 
This is most likely due to the fact that the Vonsattel scale is based on assessing 
striatal degeneration (section 1.2.2; Vonsattel et al., 1985; for review see 
Vonsattel and DiFiglia, 1998). Degeneration in the hypothalamus might not 
follow the same time course as in the striatum.  
Deficits in orexin neurotransmission result in narcoleptic-like behavior in 
mice (section 4.2; Chemelli et al., 1999; Hara et al., 2001; Willie et al., 2003), as 
well as dogs (Lin et al., 1999). In our study, the frequency, duration, and general 
appearance of the narcoleptic-like episodes in R6/2 mice are very similar to 
those observed both in orexin knock-out mice and mice with mutant orexin 
receptors (Chemelli et al., 1999; Hara et al., 2001; Willie et al., 2003). 
Furthermore, it appears to be a relationship between the loss of orexin neurons 
and the gradual onset of the narcoleptic-like phenotype in R6/2 mice. 
Interestingly, R6/2 mice exhibit a progressive disruption of the circadian rhythm 
caused by dysregulation of circadian rhythm genes in the suprachiasmatic 
nucleus of the hypothalamus (Morton et al., 2005). We have found that orexin 
fibers are lost in the R6/2 pineal region (Figure 4.4), which is involved in 
regulating the circadian rhythm via connections with the suprachiasmatic 
nucleus. Although no reports exist of HD patients actually suffering from 
narcolepsy, there is evidence that sleep patterns are disturbed (Petit et al., 2004). 
A thorough evaluation of their sleep/wakefulness cycle is therefore warrented. 
There is other evidence suggesting that orexin-containing neurons are 
sensitive to the expression of proteins with an expanded polyglutamine tail. 
Genetically engineered rodent models that express an ataxin-3 construct with a 
Chapter 4 
 93 
large number of CAG repeats (i.e., the gene responsible for the development of 
the polyglutamine disorder SCA3; section 1.1) in orexin neurons show 
hypothalamic degeneration (Hara et al., 2001; Beuckmann et al., 2004). Other 
studies demonstrate that null mutant mice for HAP1 exhibit hypothalamic 
degeneration and die early due to impaired feeding. As well, N171-82Q HD 
mice show a depletion of HAP1 and hypothalamic neuronal degeneration (Li SH 
et al., 2003). These results suggest that a disturbance in the function of critical 
huntingtin-interacting proteins (e.g., HAP1) may lead to neurodegeneration in 
the hypothalamus. 
Another explanation for the vulnerability of hypothalamic orexin-containing 
neurons may be related to the expression of NMDA receptors. Recently, it was 
shown that exposing rat hypothalamic organotypic slice cultures to an 
excitotoxic insult results in a specific loss of orexin neurons (Katsuki and 
Akaike, 2004). As previously discussed, excitotoxicity is a likely contributor to 
cell death in HD (section 1.4.1; for review see Beal, 2002; Petersén and Brundin, 
2002).  
Despite the loss of orexin neurons in the lateral hypothalamus, the NeuN cell 
counts suggest that more than just orexin cells are lost on R6/2 mice. Indeed, we 
also found a decrease in the number of MCH-containing neurons in this brain 
region (Figure 4.7; Gil and Petersén et al., unpublished observations). However, 
unlike the orexin neurons, this decrease appears later in the progression of the 
disease and the observed loss is not as severe. The later onset of the loss of MCH 
neurons may be partially due to the fact that MCH-containing neurons are more 
resistant to NMDA-induced excitotoxicity than orexin neurons. Indeed, it has 
been shown in rat organotypic hypothalamic slice cultures that MCH-containing 
neurons have a greater hyperpolarized resting membrane potential than orexin 
neurons. Therefore, when exposed to the same excitotoxic stimulus, the NMDA 
receptors present in orexin neurons may be more readily activated than those in 
MCH neurons (Katsuki and Akaike, 2004). 
Nevertheless, the loss of MCH-containing neurons is likely to have 
implications for the symptoms and the progression of HD. As mentioned above, 
MCH is a neuromodulator involved in the regulation of energy homeostasis and 
food intake. Indeed, recent studies in rodents have shown that central 
administration of MCH promotes feeding; whereas, fasting induces an increase 
in the expression of this peptide (section 4.2; for review see Shi, 2004). 
Furthermore, MCH knock-out mice are lean as a result of hypophagia and a 
slightly elevated metabolic rate (Shimada et al., 1998). Mice with a target 
deletion of the MCHR1 gene are resistant to obesity and show increased energy 
expenditure (Chen et al., 2002; Marsh et al., 2002). Moreover, a severe loss of 
body weight is observed both in end-stage R6/2 mice (section 1.6.1.4; 
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Mangiarini et al., 1996) and late stage HD patients (section 1.2.1). Whether there 
is a relationship between the loss of MCH-containing neurons in the lateral 
hypothalamus and the loss of body weight in R6/2 mice and HD patients is an 
exciting hypothesis that deserves further investigation. In this respect, it will be 
important to know if the loss of MCH-containing neurons is replicated in the 
human condition. 
Currently, there are no biomarkers available to evaluate the progression of 
HD and effectiveness of therapeutic interventions. Using plasma or CSF 
measurements of substances secreted from brain sites, such as the hypothalamus, 
offer a relatively rapid and cost effective strategy to identify neurodegeneration. 
In end-stage R6/2 mice, both the number of orexin neurons in the lateral 
hypothalamus and the levels of orexin in the CSF were reduced by 72%, 
suggesting that orexin could be used as a biomarker to detect for hypothalamic 
neurodegeneration in HD. Considering the corresponding loss and atrophy of 
orexin neurons in the human condition, it was reasonable to speculate that orexin 
CSF levels may be reduced in HD patients as well. Since the publication of our 
initial work, two small studies have extended our results and tested this 
hypothesis (Gaus et al., 2005; Meier et al., 2005). Each study compared the 
orexin CSF levels from about 10 patients with genetically validated HD. 
However, contrary to our expectations, no changes in CSF orexin levels were 
detected in these HD patients (Gaus et al., 2005; Meier et al., 2005). A recent 
collaboration involving our group and three other research centers also revealed 
no significant changes in orexin CSF levels in a larger sample of 37 HD patients 
(Björkqvist et al., 2006b). Moreover, in this study orexin CSF levels of 12 
month-old YAC128 mice were also determined and, despite a 10% reduction in 
orexin neurons in the lateral hypothalamus of these mice, no decrease in the CSF 
levels of this peptide was detected (Björkqvist et al., 2006b). Therefore, the 
moderate reduction in the number of orexin-positive neurons in the lateral 
hypothalamus of both HD patients (section 4.4.3) and YAC128 mice (Björkqvist 
et al., 2006b) is insufficient to cause significant changes in the CSF levels of this 
peptide. It can therefore be concluded that orexin CSF levels are not a useful 
clinical biomarker to monitor the progression of HD. 
Nevertheless, understanding the mechanisms underlying the loss of orexin 
and MCH neurons may shed light on the cellular events leading to neuronal 
death in HD. Moreover, the hypothalamic neurodegeneration may help to 
explain some of the non-motor symptomology of HD, such as sleep disturbances 
and weight loss. Finally, monitoring the loss of orexin neurons in the lateral 
hypothalamus may be useful for evaluating the therapeutic efficacy of novel 
drugs in R6/2 mice. 
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5.1. Summary 
 
No effective therapy is presently available for the treatment of HD. We 
designed this study to explore the therapeutic potential of erythropoietin (EPO), 
a cytokine that has been found to prevent excitotoxicity and to promote the 
generation of new neurons (neurogenesis). To avoid the side effects of a raised 
hematocrit, we used a variant of EPO, asialoEPO. R6/2 HD mice were treated 
with this cytokine from 5 to 12 weeks of age. We found for the first time that 
cell proliferation in the DG of the hippocampus was reduced by 70% in R6/2 
mice. Unfortunately, asialoEPO treatment did not influence the progression of 
motor symptoms, weight loss, and the neuropathology in R6/2 mice. 
Furthermore, the reduction in hippocampal cell proliferation was not reversed by 
this treatment. We conclude that the chosen protocol of asialoEPO treatment is 
ineffective in the R6/2 model of HD. We suggest that reduced hippocampal cell 
proliferation is a novel neuropathological feature in R6/2 mice that warrants 
further examination (see Chapter 6). 
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5.2. Introduction 
 
There is still no cure or satisfactory treatment for HD. Moreover, it is 
particularly challenging to perform therapeutic trials in HD patients for several 
reasons. First, the low prevalence of this disease in the general population often 
makes it difficult to recruit a sufficient number of patients for clinical trials. 
Second, due to the slow progression of the disease over a period of many years, 
treatments may require very long follow up periods. Third, there is substantial 
variability in the rate of progression, even in patients with similar numbers of 
CAG repeats. Fourth, there are no well-established objective surrogate 
biomarkers for HD (section 4.5), which means that clinical trials have to rely on 
cumbersome and subjective clinical rating scales as outcome parameters. The 
R6 mouse have served as a useful tool to evaluate new therapeutic strategies and 
is probably the most studied transgenic HD model in this respect (section 1.6.3; 
for review see Beal and Ferrante, 2004; Hersch and Ferrante, 2004; Li JY et al., 
2005). In particular, the R6/2 line has an early onset of symptoms and a fast 
progression of the disease, which allows for a more rapid evaluation of novel 
compounds. 
EPO was originally discovered as a kidney-produced cytokine that regulates 
haematopoiesis. It was then found to protect neurons from death in a variety of 
conditions. One of the advantages of this compound is that it can enter the brain 
with peripheral administration. Receptors for EPO have been identified in the 
brain (Digicaylioglu et al., 1995; Masuda et al., 1993). EPO has been shown to 
be neuroprotective in animal models of focal ischemia, spinal cord injury, retinal 
injury, brain trauma and subarachnoid hemorrhage (Brines et al., 2000; Siren et 
al., 2001; Celik et al., 2002; Gorio et al., 2002; Grasso et al., 2002; Junk et al., 
2002; Springborg et al., 2003). Promising results have also been demonstrated 
in a phase II clinical trial for stroke (Ehrenreich et al., 2002). One of the 
drawbacks of chronicly administrated EPO is an increase in the number of red-
blood cells (hematocrit). However, these side-effects can be overcome by using 
the natural EPO metabolite asialoEPO, a molecule that appears to have a 
neuroprotective potency similar to EPO (Erbayraktar et al., 2003; Wang et al., 
2004) and also has the capacity to cross the blood brain barrier (Erbayraktar et 
al., 2003). 
In addition to its neuroprotective properties, EPO seems to be essential for 
early embryonic neuronal development (Yu et al., 2002; Tsai et al., 2006) and to 
play an important role during adult neurogenesis (Shingo et al., 2001; Tsai et al., 
2006). Moreover, EPO has been shown to promote the regeneration and 
migration of neurons in several models of acute brain injury (Wang et al., 2004; 
Lu et al., 2005; Tsai et al., 2006). 
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On of the central dogmas of neuroscience has been the belief that 
neurogenesis only occurs during embryonic development. However, mounting 
evidence over the past 40 years has challenged that notion (for review see Gross, 
2000; Temple, 2001; Kempermann, 2002). In fact, proliferation and 
differentiation of new neurons are now known to occur in selective regions of 
the adult mammalian brain, primarily the subventricular zone (SVZ) of the 
lateral ventricles and the subgranular zone (SGZ) of the DG of the hippocampus. 
In the SVZ, neural stem cells give rise to committed progenitor cells that 
migrate through the rostral migratory stream (RMS) into the olfactory bulb (OB) 
where they differentiate into local interneurons (for review see Lie et al., 2004). 
 
Figure 5.1. – Hippocampal neurogenesis. The DG of the hippocampus is one of the 
two neurogenic regions in the adult mammalian brain. Hippocampal neurogenesis 
comprises at least four distinct stages: (1) proliferation, where stem cells in the SGZ 
give rise to transit proliferating cells; (2) fate determination, where proliferating cells 
differentiate into immature neurons; (3) migration, where immature neurons migrate 
into the granule cell layer of the DG; and (4) integration, where immature neurons 
mature into new granule neurons. Adapted from Lie et al., 2004. 
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In the SGZ of the DG, neuronal stem cells proliferate and differentiate into 
immature neurons. These migrate into the granule cell layer where they mature 
into new granule neurons, receiving inputs from the entorhinal cortex, and 
extending projections into the CA3 region of the hippocampus (Figure 5.1; for 
review see Lie et al., 2004). 
Although the functional impact of adult hippocampal neurogenesis is not yet 
known (for review see Kempermann et al., 2004), it has been suggested to be 
involved in learning and memory, thus contributing to cognitive functioning (for 
review see van Praag et al., 2002). It is a highly dynamic process that can be up-
regulated by environmental enrichment, exercise, learning, estrogen, 
antidepressant drugs, electroconvulsive therapy, and delivery of growth factors 
such as BDNF and insulin growth factor 1 (IGF1). It can also be down-regulated 
by stress, glucocorticoids, inflammation, excitotoxicity, opiate intake, and aging 
(for review see Duman et al., 2001a, 2001b; Kuhn et al., 2001; Kempermann, 
2002). The occurrence of neurogenesis in the adult brain provides a thrilling 
possibility to manipulate the endogenous restorative capacity in 
neurodegenerative disorders. Also, it is not fully explored what role 
neurogenesis may have in neurodegenerative diseases such as HD (for review 
see Armstrong and Barker, 2001). 
We studied the involvement of the hippocampus in the pathology of R6/2 
mice by evaluating hippocampal cell proliferation. We also tested whether 
stimulation of EPO-related signaling pathways would have beneficial effects in 
R6/2 HD mice. We used asialoEPO to selectively trigger the brain EPO 
receptors over a period of 7 weeks in R6/2 mice. We examined its effects on the 
development of motor symptoms, weight loss, striatal neuropathology and 
hippocampal cell proliferation.  
 
 
 
5.3. Materials and Methods 
 
 
5.3.1. Transgenic Animals  
Transgenic HD mice of the R6/2 line were originally purchased from 
Jackson Laboratories and the colony was maintained by breeding heterozygous 
R6/2 males with females from their background strain (F1 of CBA x C57BL/6J). 
Tails of the offspring were used to obtain DNA for determination of the 
genotype using a PCR assay (Mangiarini et al., 1996). The length of the CAG 
repeat in our R6/2 colony was analyzed, and was found to be stable at 142 ± 0.7 
CAG repeats (n = 18, from 2 different generations). The mice were housed in 
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groups with ad libitum access to food and water at a 12 hours light/dark cycle. 
The experimental procedures followed the guidelines set by the Ethical 
Committee for the use of laboratory animals at Lund University, Sweden. 
 
 
5.3.2. Administration of AsialoEPO and Body Weight Measurements 
Mice from the same litters were divided into 3 groups (n = 6 to 7 mice per 
group). AsialoEPO was synthesized from EPO as described elsewhere 
(Erbayraktar et al., 2003). One group of R6/2 mice was injected with asialoEPO 
(2.6 nmol/kg = 80 µg/kg; in PBS) intraperitoneally (i.p.) 3 times per week, 
starting from age 5 weeks (when the first motor symptoms appear) until age 12 
weeks. Another group of R6/2 mice and their wild-type littermates were injected 
(i.p.) with just the vehicle (PBS) following the same schedule. Mice were 
weighed once a week throughout the duration of the experiment. 
 
 
5.3.3. Behavioral Testing 
 
5.3.3.1. Rotarod 
Mice were pretrained on the rotarod for 2 days before the treatment began at 
5 weeks of age. On the first training day each mouse was placed on the rotarod 
for 120 seconds at a speed of 5 rpm. On the second day, mice were given 2 
separate 120 seconds sessions at 10 rpm followed by 1 at 15 rpm. The mice were 
tested on the following day with 3 trials of 180 seconds at 15 rpm. The mean 
value of the latency to fall for these 3 trials was compared between the mice. 
Mice were tested once a week using a similar block of 2 trials at the ages of 5, 6, 
7, 8, 10, 11 and 12 weeks. 
 
 
5.3.3.2. Paw Clasping  
One of the first symptoms displayed by R6/2 mice is limb dyskinesia when 
suspended by the tail. This symptom worsens over time until the mice clasp their 
paws together upon being picked up, and are unable to release this posture 
(section 1.6.1.3; Figure 1.6; Mangiarini et al., 1996). Paw clasping was 
evaluated prior to each rotarod session. Mice were suspended by the tail 10 cm 
above the cage for 20 seconds. The paw clasping was scored on a scale from 0 
to 2 points, where: absence of paw clasping or only the front paws pressed 
together yielded zero points; front paws pressed to the stomach yielded 1 point; 
and if front paws touched hind limbs, or both front and hind limbs were pressed 
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against the stomach, 2 points were noted. An individual blind to the genotype of 
the mice performed the assessment of paw clasping. 
 
 
5.3.3.3. Motor Activity in an Open Field 
The general motor activity of the mice was assessed in an open field. The 
open field apparatus was divided into 25 squares (5 x 5 cm each). The mice were 
analyzed at 10 and 12 weeks of age. They were allowed to habituate for 10 
minutes and afterwards their activity was recorded for the next 10 minutes. The 
number of squares entered during the last 2 minutes of the recording session was 
evaluated. This procedure was chosen in order to increase the habituation 
period, during which the activity of normal mice is increased due to their 
exploratory behavior. Previous studies have shown that this increase in activity 
is the greatest during the first 20 minutes in a new environment (Zhuang et al., 
2001). 
 
 
5.3.4. Administration of BrdU and Tissue Processing 
In order to assess the genesis of new cells in the brains of 12-week-old mice, 
we administered the thymidine analogue bromodeoxyuridine (BrdU), which 
incorporates into cells undergoing DNA synthesis, and therefore has been 
widely used as a proliferating marker (Cooper-Kuhn and Kuhn, 2001). All mice 
received i.p. injections of BrdU (50 mg/kg; in PBS, pH 7.2; Sigma), every 12 
hours for their last 6 days of survival. The mice were sacrificed 18 hours after 
the last BrdU injection. Mice were deeply anesthetized with pentobarbital and 
transcardially perfused with saline followed by 4% PFA in 0.1 M PBS. The 
brains were left in the fixative overnight and then dehydrated in 20% sucrose/0.1 
M PBS. Coronal sections were cut at 4 series throughout the brain on a freezing 
sliding microtome at a thickness of 40 μm and collected in PBS. 
 
 
5.3.5. Immunohistochemistry 
Tissue from wild-type and R6/2 mice was processed in parallel for 
immunohistochemistry in order to control for labeling intensity. One complete 
series of free-floating sections was processed for BrdU immunohistochemistry. 
Briefly, the sections were incubated in 1 M HCl at 65°C for 30 minutes in order 
to denaturate the DNA and allow the antibody to access the incorporated BrdU. 
The sections were then preincubated for 1 hour in 5% NHS and 0.25% Triton X-
100 in PBS. They then were incubated for 48 hours at 4°C with a mouse 
monoclonal antibody against BrdU (diluted 1:50; Dako) in PBS containing 2% 
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NHS. After incubation with the secondary antibody biotinylated horse anti-
mouse IgG (diluted 1:200; Dakopatts) for 2 hours, the bound antibodies were 
visualized with an avidin-biotin–peroxidase complex system (Vectastain ABC 
Elite Kit; Vector Laboratories) using DAB as the chromogen. 
Separate series of sections were also processed for the neuronal marker 
NeuN, the striatal marker DARPP-32, and EM48 (for detection of NIIs). Briefly, 
the sections were quenched in 3% H2O2/10% methanol in 0.1 M PBS for 15 
minutes, and preincubated with the proper sera (in the case of EM48 
immunohistochemistry, the blocking solution was prepared in 1% BSA/0.1 M 
PBS). The sections were then incubated overnight at room temperature (or 
during 48 hours at 4°C) with a mouse monoclonal antibody against NeuN 
(diluted 1:1000; Chemicon), a rabbit polyclonal anti-DARPP-32 antibody 
(diluted 1:1000; Chemicon), or the mouse monoclonal anti-huntingtin antibody 
(EM48, diluted 1:500; Chemicon). The sections were then incubated for 2 hours 
with the respective secondary antibodies (biotinylated horse anti-mouse IgG, 
diluted 1:200, Dakopatts; and biotinylated swine anti-rabbit IgG, diluted 1:200, 
Dako), and visualized as described above. 
BrdU/NeuN double labeling was also performed. Briefly, after DNA 
denaturation and preincubation in the proper sera, the sections were incubated 
for 48 hours at 4°C with monoclonal rat anti-BrdU (diluted 1:100, 
ImmunologicalsDirect, Oxfordshire, UK) and mouse anti-NeuN (diluted 1:100, 
Chemicon) antibodies. The sections were then incubated with the secondary 
antibodies Cy3-conjugated donkey anti-rat IgG (diluted 1:200, Jackson 
ImmunoResearch) and biotinylated horse anti-mouse IgG (Vector Laboratories) 
for 2 hours, followed by incubation with Alexa-488-conjugated streptavidin 
(diluted 1:200, Molecular Probes, Leiden, The Netherlands) for 2 hours. 
 
 
5.3.6. Stereological Techniques and Cell Quantification 
All morphological analyses were performed on blind-coded slides. The 
number of BrdU-immunopositive cells in the SGZ of the DG of the dorsal 
hippocampus was assessed by counting all positive cells in 7 to 9 sections per 
mouse (from –1.34 mm to –2.80 mm from bregma) using conventional light 
microscopy with a 40x objective. The distance between the sections was about 
120 μm. The total number of cells assessed in 7 to 9 adjacent sections per mouse 
was expressed as the average number of cells per section. 
Due to the large number of BrdU-immunopositive cells in the SVZ (located 
adjacent to the ventricle in the striatum), the total number of labeled cells in this 
region was assessed with stereological techniques (Gundersen et al., 1988). We 
used the stereological equipment described before (section 2.3.4) with a 100x 
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objective. For systematic sampling, the frame area (808 - 843 μm2) and the 
counting interval (x and y both 75 μ) were set to allow for at least a total of 200 
cells to be sampled in 5 adjacent sections (distance between the sections: 120 
μm) with the SVZ (five sections anterior to the appearance of the anterior 
comissure at +0.14 mm from bregma) and the optical dissector was set to 
sample all cells below the first 2.5 μm and above the last 2.5 μm of both 
surfaces of the section. 
For neuronal quantification in the DG, 4 mice from each group were 
randomly selected and the number of NeuN-positive neurons in the DG was 
determined. Since the DG is densely populated with neurons, we were able to 
use stereological techniques (100x objective; frame area: 187 - 249 μm2; 
counting interval: x and y both 150 μm). The number of neurons was 
determined in 7 adjacent sections (120 μm apart; from –1.34 mm to –2.80 mm 
from bregma). 
The number of EM48-immunopositive neurons in the striatum was assessed 
using the stereological equipment (with a 40x objective) and applying the same 
stereological principles (frame area: 2452 - 2498 μm2; counting interval: x and y 
both 500 μm). The number of EM48-positive neurons was determined in 5 
adjacent sections (120 μm apart) of the striatum beginning at the 2 sections 
anterior to the first appearance of the anterior commissure. 
The striatal volume was calculated in 4 randomly selected mice per group 
using the stereological equipment (with a 10x objective). The striatum was 
delineated in 5 adjacent sections (120 μm apart) processed for DARPP-32 
immunohistochemistry. The quantification began at 2 sections anterior to the 
appearance of the anterior commissure. Volume was calculated by taking into 
account the frequency of sections (1:4) and their thickness (40 μm), according to 
the Cavalieri principle (Gundersen et al., 1988). Using the stereological 
equipment (with a 40x objective), 45 randomly selected DARPP-32-positive cell 
bodies per striatum were delineated to assess their cross-sectional area (15 
neurons per section in 3 sections per mouse). 
 
 
5.3.7. Statistical Analysis 
The data were analyzed using the Statview 5.4 package (Abacus Concepts). 
Unpaired Student’s t, 1-factor ANOVA followed by the Bonferroni-Dunn post-
hoc test, and 2-factor ANOVA with repeated measures when appropriate were 
applied. Data are presented as means ± S.E.M. A p value of < 0.05 was 
considered statistically significant. 
 
 
Chapter 5 
 105 
5.4. Results 
 
 
5.4.1. AsialoEPO Does Not Reverse Motor Impairments in R6/2 Mice 
Mice were assessed weekly over 7 weeks on the rotarod task (2-factor 
repeated measures ANOVA; significant difference between the 3 groups: p = 
0.0001, F (2, 96) = 16.61; significant effect of time: p = 0.0009, F (6, 96) = 
4.16). There was no effect of asialoEPO on the development of motor deficits in 
the R6/2 mice as assessed by the time spent on the rotarod (Figure 5.2.A). 
 
Figure 5.2. - No effect of asialoEPO on the decline in rotarod performance or body 
weight in R6/2 mice. (A) Mice were tested weekly on the rotarod for 3 trials of 180 
seconds each, at the speed of 15 rpm. The mean latency to fall for the 3 trials was 
compared between mice. The testing began at 5 weeks and continued until 12 weeks of 
age. Administration of asialoEPO three times weekly from 5 to 12 weeks of age did not 
significantly affect the decline in rotarod performance in R6/2 mice. (B) Mice were 
weighed weekly during the treatment period. There was no effect of asialoEPO on the 
progressive reduction in body weight in R6/2 mice. Values are represented as means ± 
S.E.M. 
 
 
Open field was used to assess motor activity in mice at 10 and 12 weeks of 
age (Table V). The data were analyzed using 2-factor repeated measures 
ANOVA. There was a significant difference between the 3 groups (p = 0.0004, 
F (2, 15) = 13.7) and a significant time x group interaction (p < 0.05, F (2, 15) = 
4.30). AsialoEPO did not influence the decreased activity displayed by R6/2 
mice. 
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Table V - No effect of asialoEPO on open field activity in R6/2 mice.  
Age 
(weeks) 
wild-type 
(n = 7) 
R6/2 vehicle 
(n = 5) 
R6/2 asialoEPO 
(n = 6) 
10 weeks 66 ± 12 44 ± 14 20 ± 10 
12 weeks 75 ± 7 11 ± 5 12 ± 7 
The activity of the mice was assessed at 10 and 12 weeks of age in an open field. 
The open field was divided into 25 equal squares of 5 x 5 cm each. After 18 minutes of 
habituation to the new environment, the number of squares entered by the mice during 2 
minutes was determined as a measure of general activity. Data are presented as means ± 
S.E.M. 
 
 
In addition, all mice were assessed weekly with regard to their development 
of paw clasping. No wild-type mice ever showed clasping behaviour. Regardless 
of the treatment, around 80% of the R6/2 mice scored 1 point in the clasping 
scale at week 7. At week 10, all R6/2 mice scored 2 points. 
 
 
5.4.2. No Effect of AsialoEPO on Body Weight 
As mentioned above, an important symptom in R6/2 mice is progressive loss 
body weight (section 1.6.1.4; Mangiarini et al., 1996). The body weight was 
assessed weekly from 5 to 12 weeks of age (Figure 5.2.B). The data were 
analyzed using 2-factor repeated measures ANOVA. There was a significant 
effect of time (p < 0.0001, F (6, 96) = 1.55) and significant time x group 
interaction (p < 0.0001, F (12, 96) = 1.32). However, asialoEPO treatment did 
not affect the loss of body weight observed in R6/2 mice (p = 0.26, F (2, 96) = 
1.47). 
 
 
5.4.3. AsialoEPO Treatment Does Not Reverse Striatal Neuropathology in 
R6/2 Mice 
At 12 weeks of age, 5 striatal sections per mouse were assessed for NIIs. We 
detected 426000 ± 31000 NIIs in the vehicle-treated R6/2 mice and 407000 ± 
45000 NIIs in the asialoEPO-treated mice (Student’s t test, p = 0.73). 
To assess for atrophy we measured the striatal volume in striatal sections 
processed for DARPP-32. The striatal volume measured 8.23 ± 0.53 mm3 in 
wild-type mice, 5.14 ± 0.21 mm3 in vehicle-treated R6/2 mice, and 5.26 ± 0.07 
mm3 in asialoEPO-treated R6/2 mice (1-factor ANOVA; significant difference 
between the 3 groups: p = 0.0008, F (2, 6) = 29.01). As expected, there was a 
significant difference between both R6/2 groups as compared with the wild-type 
controls (Bonferroni-Dunn post-hoc test; wild-type versus vehicle-treated R6/2 
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mice: p = 0.0005; wild-type versus asialoEPO-treated R6/2 mice: p = 0.0006), 
and no difference between vehicle- and asialoEPO-treated R6/2 mice 
(Bonferroni-Dunn post-hoc test, p = 0.813). 
Moreover, the cross sectional analysis of striatal DARPP-32-
immunopositive neuronal area also demonstrated no changes in atrophy with 
asialoEPO treatment. Soma area was 78 ± 6 μm2 for wild-type mice, 55 ± 3 μm2 
for vehicle-treated R6/2 mice, and 59 ± 1 μm2 for asialoEPO-treated R6/2 mice 
(1-factor ANOVA; significant difference between the 3 groups: p = 0.013, F (2, 
6) = 9.64). Again, there was a significant difference between both R6/2 groups 
and the wild-type group (Bonferroni-Dunn post hoc test; wild-type versus 
vehicle-treated R6/2 mice: p = 0.006; wild-type versus asialoEPO-treated R6/2 
mice: p = 0.014) but not between asialoEPO- and vehicle-treated R6/2 mice 
(Bonferroni-Dunn post-hoc test, p = 0.504). 
 
 
5.4.4. AsialoEPO Administration Had No Effect on the Reduced BrdU 
Labeling in the R6/2 Mouse Dentate Gyrus 
EPO was shown to possess neurogenic properties (Shingo et al., 2001). 
 
Figure 5.3. - Reduced BrdU-labeling in the R6/2 DG with no influence by 
asialoEPO treatment. All mice were i.p. injected with 50 mg/kg of BrdU every 12 
hours for their last 6 days of survival to assess cell proliferation at 12 weeks of age. (A) 
The number of BrdU-labeled cells was assessed by stereological techniques in the SVZ 
in 5 striatal sections per mouse. In this region there was no significant reduction in the 
number of BrdU-labeled cells between the groups. (B) In the DG, BrdU-labeled cells 
were assessed in 7 to 9 sections per mouse as the mean number per section. There was a 
reduction in the number of BrdU-labeled cells in R6/2 mice compared to wild-type 
mice. The administration of asialoEPO was not able to reverse this reduced cell 
proliferation. Data are presented as means ± S.E.M. 
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Therefore, we sought to investigate whether cell proliferation in the 2 
neurogenic brain regions (subependymal layer of the SVZ and SGZ of the DG) 
was altered in R6/2 mice and whether asialoEPO treatment would impact this 
cell proliferation. We injected all mice with BrdU (50 mg/kg) during the last 6 
days before they were sacrificed. In the subependymal layer of the SVZ there 
was a slight trend towards a reduction in the number of BrdU labeled cells in 
R6/2 mice compared to their wild-type littermates at the age of 12 weeks (1-
factor ANOVA; p = 0.23, F (2, 16) = 1.63) (Figure 5.3.A). However, in the DG 
there was a significant difference between the groups (1-factor ANOVA; p < 
0.0001, F (2, 16) = 23.50). We found a profound reduction in the number of 
BrdU labeled cells in R6/2 compared to the wild-type mice (Bonferroni-Dunn 
post-hoc test, p < 0.0001) (Figures 5.3.B and 5.4). However, the administration 
of asialoEPO was not able to reverse this decreased hippocampal cell 
proliferation (Bonferroni-Dunn post-hoc test, p = 0.98). 
 
Figure 5.4. – BrdU-labeled cells in the DG of the hippocampus of wild-type and 
R6/2 mice. Hippocampal sections from 12-week-old R6/2 and wild-type mice were 
processed for BrdU/NeuN double-labeling. Photomicrographs showing representative 
NeuN labeling of the DG in a wild-type (A), a vehicle-treated R6/2 (B) and an 
asialoEPO-treated R6/2 (C) mouse. Photomicrographs showing representative BrdU-
labeling in the same sections of the DG in a wild-type (D), a vehicle-treated R6/2 (E) 
and an asialoEPO-treated R6/2 (F) mouse. Scale bar = 100 μm. 
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Finally, using stereological techniques, we calculated the total number of 
mature neurons (NeuN-positive) in the DG of 12-week-old mice. We found 
116967 ± 15056 neurons in wild-type mice, 141694 ± 4679 neurons in vehicle-
treated R6/2 mice, and 157301 ± 20065 neurons in asialoEPO-treated R6/2 mice 
(1-factor ANOVA; p = 0.20, F (2, 9) = 1.91). These results suggest that the 
reduction in cell prolifaration observed in R6/2 mice was not likely due to loss 
of neurons. 
 
 
 
5.5. Discussion 
 
The underlying mechanisms responsible for HD are still not fully 
understood, although excitotoxicity (section 1.4.1) and oxidative stress (section 
1.4.3) have been suggested to be involved in the pathogenesis of the disease (for 
review see DiFiglia, 1990; Davies and Ramsden, 2001; Petersén and Brundin, 
2002). Since administration of EPO has been shown to be protective against 
such insults (Siren et al., 2001; Celik et al., 2002; Ehrenreich et al., 2002; Junk 
et al., 2002; Erbayraktar et al., 2003), we tested whether asialoEPO, an EPO 
analogue, exerts beneficial effects in R6/2 HD mice. We injected R6/2 mice 3 
times weekly with asialoEPO, starting at five weeks of age (when symptoms 
begin to manifest) and ending at 12 weeks of age. We attempt to assess for the 
potential beneficial effects of this compound by measuring rotarod performance, 
paw clasping, open field activity, body weight changes, striatal huntingtin 
inclusions, striatal and neuronal atrophy, and cell proliferation. Despite all of 
these assessments, we were unable to find any beneficial effects of asialoEPO. 
 There may be several reasons why asialoEPO did not reverse the HD 
pathology and symptoms in R6/2 mice. It has been previously shown that EPO 
has neuroprotective effects in acute neurodegenerative paradigms characterized 
by extensive cell death, such as hypoxia and ischemia (Brines et al., 2000; Siren 
et al., 2001; for review see Cerami et al., 2002). The same is true for asialoEPO 
(Erbayraktar et al., 2003; Wang et al., 2004). However, the R6/2 HD mouse 
model is a chronic neuropathological model with reduced cell death (section 
1.6.1.2; Iannicola et al., 2000; Turmaine et al., 2000; Yu et al., 2003; Stack et 
al., 2005; Chapter 4). 
Moreover, one of the proposed neuroprotective mechanisms for EPO relies 
upon functional transcriptional machinery. EPO is thought to activate EPO 
receptors that are linked to the Janus kinase 2 (Jak2) pathway, where activation 
of this pathway promotes the nuclear translocation of nuclear factor-κB (NFκB). 
Once in the nucleus, NFκB up-regulates neuroprotective genes, such as the 
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caspase inhibitors X-linked inhibitor of apoptosis proteins (XIAP) and cellular 
inhibitor of apoptosis proteins-2 (c-IAP2) (Digicaylioglu and Lipton, 2001). 
Given that R6/2 mice display transcriptional abnormalities (section 1.6.2.1; 
Luthi-Carter et al., 2000, 2002, 2003; Zucher et al., 2005), it is possible that the 
EPO-mediated up-regulation of neuroprotective genes is compromised in these 
mice. Furthermore, since most of these genes have anti-apoptotic functions, their 
effects are likely to be minimal in the R6/2 brain, where little apoptosis has been 
documented (section 1.6.1.2; Iannicola et al., 2000; Turmaine et al., 2000; Yu et 
al., 2003; Chapter 4). 
This study is the first to demonstrate an impairment of cell proliferation in 
the hippocampus of R6/2 mice. In this region, the majority (approximately 80%) 
of the surviving BrdU-labeled cells are known to mature into neurons (for 
review see Duman et al., 2001a, 2001b; section 6.4.2). Interestingly, during the 
process of submitting this work for publication, another study was published 
showing reduced cell proliferation in the DG of R6/1 mice (Lazic et al., 2004), 
indicating that compromised DG cell proliferation is a novel feature of the R6 
lines. 
The underlying mechanism for the reduced cell proliferation in the R6/2 
mice is not yet determined. Various factors may be responsible, including stress, 
increased levels of glucocorticoids, or an accelerated aging process. A more 
detailed discussion of these mechanisms can be found in the next chapter 
(section 6.5). Suffice to say, the mice in the present study were subjected to 
much handling stress with the weekly injections and behavioral testing and 
stress can have a negative impact on cell proliferation (for review see Duman et 
al., 2001a). Therefore, in this study it would have been appropriate to have a 
non-handled control group to assess for the influence of stress. Furthermore, 
future studies need to determine whether the decrease number of hippocampal 
proliferating cells in R6/2 is due to increased death of the proliferating cells or to 
impaired cell proliferation. Our results suggest the latter since we did not find a 
loss in the total number of neurons (NeuN-positive cells) in the DG of R6/2 
mice. 
Neurogenesis has been suggested to play an important role in hippocampal 
function, which could explain some of the cognitive deficits characteristic of 
HD. Therefore, treatments aimed at restoring hippocampal neurogenesis are 
likely to have beneficial effects. In support of this hypothesis, a recent study has 
shown that fluoxetine (a serotonin-reuptake inhibitor commonly used for the 
treatment of depression) administration to R6/1 mice reversed the neurogenesis 
deficits in the DG and improved hippocampal-dependent cognitive impairments 
(Grote et al., 2005). Moreover, environmental enrichment, which can slow the 
disease progression both in R6/2 (Hockly et al., 2002) and R6/1 (van Dellen et 
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al., 2000a) mice, was recently shown to partially restore the deficit in DG cell 
proliferation in R6/1 mice (Lazic et al., 2006). These results demonstrate that a 
restoration of hippocampal neurogenesis may ameliorate some of the symptoms 
of R6 mice. 
Unfortunately, in this study we were unable to restore hippocampal cell 
proliferation with asialoEPO administration in the R6/2 mice. Interestingly, all 
studies reporting the neurogenic properties of EPO were performed in acute 
animal models of neurodegeneration, such as stroke (Wang et al., 2004; Tsai et 
al., 2006) and traumatic brain injury (Lu et al., 2005). Again, it might be the 
case that EPO (and its derivative asialoEPO) are not so effective in promoting 
neurogenesis in chronic degeneration models. Furthermore, in this study 
asialoEPO treatment was initiated when the mice were 5-week-old, which might 
be too late in the disease process to obtain an effect at the level of DG cell 
proliferation. The evaluation of DG cell proliferation and neurogenesis 
throughout the lifespan of R6/2 mice will be the focus of Chapter 6. 
 
  112
Chapter 6 
 113 
 
 
 
 
 
 
 
Chapter 6 
 
 
Reduced Hippocampal Neurogenesis in R6/2 
Transgenic Huntington’s Disease Mice 
 
 
 
Chapter based on the following publication: 
 
Gil J, Mohapel P, Araújo IM, Popovic N, Li JY, Brundin P, and Petersén Å 
(2005): “Reduced hippocampal neurogenesis in R6/2 transgenic Huntington’s 
disease mice”. Neurobiol. Dis. 20:744-751. 
 
  114
Chapter 6 
 115 
6.1. Summary 
 
In this study we extended our previous findings (Chapter 5; Gil et al., 2004) 
and investigated to what extent cell proliferation and neurogenesis are altered in 
R6/2 transgenic HD mice. Using the thymidine analogue BrdU, we found a 
decrease in the number of proliferating cells in the DG of R6/2 mice over the 
course of the disease progression. This reduction was first detected in pre-
symptomatic mice, and by 11.5 weeks R6/2 mice had 66% fewer newly born 
cells in the hippocampus. These results were confirmed by 
immunohistochemistry for the cell cycle markers Ki-67 (11.5 weeks: 72% 
reduction), proliferating cell nuclear antigen (PCNA; 11.5 weeks: 36% 
reduction), and for the transcription factor NeuroD (11.5 weeks: 79.5% 
reduction). We did not observe changes in cell proliferation in the R6/2 SVZ, 
indicating that the decrease in cell proliferation is specific for the hippocampus. 
This decrease corresponded to a reduction in neuronal production, as assessed by 
double immunolabeling for BrdU and the neuronal marker NeuN and by 
immunohistochemistry for the neuroblast marker doublecortin. We conclude that 
diminished hippocampal neurogenesis is a novel neuropathological feature in 
R6/2 mice that occurs early in the disease process, and therefore could be 
assessed when evaluating potential therapies. 
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6.2. Introduction 
 
Given the capacity of the adult brain to generate new neurons, adult neuronal 
stem cells have been proposed as an endogenous cellular source for the treatment 
of various neurodegenerative diseases (for review see Lie et al., 2004; Mohapel 
and Brundin, 2004). However, there is still controversy whether neurogenesis is 
compromised with neurodegenerative conditions, with different groups reporting 
contradictory results in animal models and patients of Alzheimer’s disease (AD) 
(Haughey et al., 2002a, 2002b; Jin et al., 2004a, 2004b) and Parkinson’s disease 
(PD) (Fallon et al., 2000; Hoglinger et al., 2004; Zhao et al., 2003; Frielingsdorf 
et al., 2004). 
It is possible that altered neurogenesis is an important pathological hallmark 
in HD. It was recently reported that there is an increased number of proliferating 
cells in the subependymal layer of the SVZ adjacent to the striatum of human 
HD brains (Curtis et al., 2003, 2005a, 2005b, 2006). These newborn cells were 
identified with the cell cycle marker PCNA and half were found to coexpress the 
glial marker GFAP while only 5% expressed the neuronal marker βIII-tubulin 
(Curtis et al., 2003). However, in this study hippocampal neurogenesis was 
never examined. We have shown that cell proliferation is reduced in the DG of 
end-stage R6/2 mice (Gil et al., 2004; Chapter 5), a study that is in agreement 
with the work of Lazic and colleagues (2004, 2006) that demonstrated a 
reduction in hippocampal cell proliferation in R6/1 transgenic HD mice (Lazic et 
al., 2004, 2006). 
In order to further characterize the involvement of hippocampal 
neuropathology in R6/2 mice, in this study we extend our previous observations 
and used several markers to evaluate cell proliferation and neurogenesis 
throughout the lifespan of R6/2 mice. 
 
 
 
6.3. Materials and Methods 
 
 
6.3.1. Transgenic Animals 
Transgenic HD mice of the R6/2 line were originally purchased from 
Jackson Laboratories and the colony was maintained by breeding heterozygous 
R6/2 males with females from their background strain (F1 of CBA x C57BL/6J). 
Tails of the offspring were used to obtain DNA for determination of the 
genotype using a PCR assay (Mangiarini et al., 1997). The mice were housed in 
groups with ad libitum access to food and water at a 12 hours light/dark cycle. 
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The experimental procedures followed the guidelines set by the Ethical 
Committee for the use of laboratory animals at Lund University, Sweden. 
 
 
6.3.2. Administration of BrdU and Tissue Processing 
Generation of newborn cells was assessed by injecting 50 mg/kg of the 
thymidine analogue BrdU (in PBS, pH 7.2; Sigma) i.p. every 12 hours for 3 
consecutive days. Note that administration of BrdU over a period of 6 days 
(section 5.3.4) was more than sufficient to detect proliferating cells. Therefore, 
in order to minimize the handling of mice, we were able to reduce the number of 
BrdU injections and still detect changes in cell proliferation. At the age of 3.5, 
7.5 and 11.5 weeks of age, mice were sacrificed 18 hours after the last BrdU 
injection. To analyze the neuronal differentiation of the newborn cells that 
incorporated BrdU, a separate set of mice at the age of 5.5 and 10 weeks were 
sacrificed 2 weeks after the last BrdU injection, which was administered at 3.5 
and 8 weeks of age, respectively. Mice at 2 weeks of age were sacrificed without 
prior BrdU injection due to their young age. Mice were deeply anesthetized with 
pentobarbital and transcardially perfused with saline followed by 4% PFA in 0.1 
M PBS. The brains were left in fixative overnight and then dehydrated in 20% 
sucrose / 0.1 M PBS. Six series of coronal sections were cut throughout the brain 
on a sliding freezing microtome at a thickness of 30 μm and collected in PBS.  
 
 
6.3.3. Immunohistochemistry 
Tissue from wild-type and R6/2 mice was processed in parallel for 
immunohistochemistry to control for labeling intensity. One series of free-
floating sections was processed for BrdU immunohistochemistry exactly as 
described in section 5.3.5. 
Separate series of sections were also processed for the proliferative marker 
Ki-67, the neural-specific intermediate filament nestin, the transcription factor 
NeuroD, and doublecortin, a marker for newly differentiated and migrating 
neuroblasts. Briefly, after quenching in 3% H2O2/10% methanol in 0.1 M PBS 
for 15 minutes, and preincubation with the proper sera, the sections were 
incubated for 48 hours at 4°C with a mouse monoclonal antibody against Ki-67 
(diluted 1:120, Novocastra, Newcastle, UK), a monoclonal mouse anti-rat nestin 
antibody (diluted 1:200, BD Biosciences Pharmingen, Heidelberg, Germany), a 
polyclonal goat antibody against NeuroD (diluted 1:200, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), or a polyclonal goat anti-doublecortin 
antibody (diluted 1:400, Santa Cruz Biotechnology), respectively. The sections 
were then incubated for 2 hours with the respective secondary antibodies 
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(biotinylated horse anti-mouse IgG, diluted 1:200; Dakopatts, and biotinylated 
horse anti-goat IgG, diluted 1:200; Vector Laboratories), and visualized with an 
avidin-biotin–peroxidase complex system using DAB as the chromogen 
(Vectastain ABC Elite Kit, Vector Laboratories). 
Immunohistochemistry for the cell cycle marker PCNA was also performed. 
A separate series of brain sections were first incubated in 10 mM sodium citrate 
buffer (in PBS, pH 6.0) at 95°C for 5 minutes. This step was repeated twice in 
order to unmask the antigens. After quenching and preincubation with 5% 
normal swine serum (NSS) for 1 hour, the sections were incubated with a rabbit 
polyclonal antibody against PCNA (diluted 1:200, Santa Cruz Biotechnology) 
for 48 hours at 4°C. The sections were then incubated with the secondary 
antibody biotinylated swine anti-rabbit IgG (Dako), and visualized as described 
above. 
Neuronal differentiation was also assessed by BrdU/NeuN double labeling, 
exactly as described in section 5.3.5. 
 
 
6.3.4. Stereological Techniques and Cell Quantification  
All morphological analyses were performed on blind-coded slides. The 
number of BrdU-immunopositive cells in the SGZ of the DG of the dorsal 
hippocampus was assessed as described on section 5.3.6 (the distance between 
the sections was 150 μm). The same procedure was also used to determine the 
numbers of Ki-67-, PCNA-, nestin-, NeuroD-, and doublecortin-labeled cells 
within this region. 
The total number of BrdU-labeled cells in the SVZ was estimated by 
stereological techniques (frame area: 163 μm2; counting interval: x and y both 
75 μ), as described on section 5.3.6 (the distance between the sections was 150 
μm). The total number of PCNA-positive cells in this region was also 
determined by stereological techinques, using the same method. The total 
volume of the SVZ was calculated taking into account the frequency of sections 
(1:6) and their thickness (30 μm), according to the Cavalieri principle 
(Gundersen et al., 1988). 
For the sections that were processed for BrdU/NeuN immunohistochemistry, 
50 BrdU-labeled cells per mouse were analyzed for co-labeling with NeuN, 
using a confocal laser-scanning microscope (Leica DM IRE3 microscope, Leica 
Confocal Software Version 2.77, Wetzlar, Germany) at 1 μm optical thickness. 
BrdU and NeuN were considered to be co-localized if nuclear co-localization 
was observed over the extent of the nucleus in consecutive 1 μm z-stacks, 
profiles of green and red fluorescence coincided, and when co-localization was 
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confirmed in x-y, x-z, and y-z cross-sections produced by orthogonal 
reconstructions from z-series. 
 
6.3.5. Statistical Analysis 
The data were analyzed with a 2-factor ANOVA or unpaired Student’s t 
tests, when appropriate, using the Statview 5.4 package (Abacus Concepts). Data 
are presented as means ± S.E.M. A p value of < 0.05 was considered statistically 
significant. 
 
 
6.4. Results 
 
6.4.1. R6/2 Mice Exhibit Decreased Hippocampal Cell Proliferation With 
the Progression of the Disease 
Using BrdU to label dividing cells we observed an age-related decline in 
the number of proliferating cells in mice of both genotypes (2-factor ANOVA; 
genotype p < 0.0001, F (1, 38) = 46.97; age p < 0.0001, F (2, 38) = 80.93; age x 
genotype p = 0.50, F (2, 38) = 0.71) (Figure 6.1).  
Figure 6.1. - Progressive reduction in the number of proliferating BrdU-
labeled cells in the DG of R6/2 and wild-type mice. There was an age related decline in 
the number of BrdU-labeled cells in the DG of all mice (A). Compared to wild-type 
littermates, R6/2 mice displayed significantly less BrdU-labeled cells at all ages 
examined. Values represent means ± S.E.M. Representative sections of the DG 
processed for BrdU immunohistochemistry in wild-type (B) and R6/2 mice (C) at 11.5 
weeks of age. Scale bar = 50 μm. 
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However, compared to wild-type littermates, R6/2 mice exhibited 
significantly fewer BrdU-labeled cells. Already by 3.5 weeks, R6/2 mice 
displayed a significant 21% reduction in the number of BrdU-positive cells 
compared to their wild-type littermate controls. Nestin is an intermediate 
filament protein that is expressed in neural progenitor/stem cells in the CNS, 
thus being widely used as a marker for cell proliferation (for review see Wiese et 
al., 2004). When examining for nestin labeling we were able to confirm the 
results obtained with BrdU. We found a trend for a similar degree of reduction 
(19%) in the number of nestin-positive cells in 3.5-week-old R6/2 mice (wild-
type: 377 ± 25 cells/section; R6/2: 304 ± 24 cells/section, Student’s t test p = 
0.057). At 7.5 weeks, an age at which motor symptoms are present, BrdU cell 
numbers further declined to 43% compared to wild-type mice. At 11.5 weeks, at 
a more advanced stage of motor deterioration, R6/2 mice showed a reduction of 
66% in BrdU-labeled cells compared to wild-type mice (Figure 6.1). 
Ki-67 is a nuclear protein that is expressed in all phases of the cell cycle 
except during the resting phase, and thus can be used as a marker for cell 
proliferation during the initial phase of adult neurogenesis (Kee et al., 2002). 
 
Figure 6.2. - Reduced cell proliferation in the R6/2 DG as assessed with the 
endogenous cell proliferation marker Ki-67. There was a progressive reduction in Ki-67 
positive cells in the DG of both R6/2 and wild-type mice (A). The R6/2 mice displayed 
significantly fewer Ki-67-positive cells. Values represent means ± S.E.M. 
Representative photomicrographs of the DG processed for Ki-67 immunohistochemistry 
in wild-type (B) and R6/2 mice (C) at 11.5 weeks of age. Scale bar = 50 μm. 
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Ki-67 was used to assess cell proliferation in 2- and 11.5-week-old mice 
(two-factor ANOVA; genotype p < 0.05, F (1, 22) = 6.83; age p < 0.0001, F (1, 
22) = 198.97; age x genotype p = 0.44, F (1, 22) = 0.61) (Figure 6.2.A). We 
found a non-significant trend towards a decrease in the number of Ki-67-positive 
cells (20% reduction) in 2-week-old R6/2 mice. Assessment of Ki-67-positive 
cells at 11.5 weeks of age confirmed the BrdU analysis, with 72% fewer Ki-67-
labeled cells in R6/2 mice compared to wild-type littermates (Figure 6.2). 
Since the cell cycle marker PCNA has been used in previous studies 
assessing cell proliferation in human HD tissue (Curtis et al., 2003, 2005a, 
2005b, 2006), we also used this marker to evaluate cell proliferation in 2- and 
11.5-week-old R6/2 mice (2-factor ANOVA; genotype p < 0.005, F (1, 22) = 
11.04; age p < 0.0001, F (1, 22) = 84.09; age x genotype p = 0.65, F (1, 22) = 
0.21). 
 
Figure 6.3. - Reduced cell proliferation in the R6/2 DG as assessed with the cell 
cycle marker PCNA. There was a progressive decrease in the number of PCNA-
immunopositive cells with increasing age in the DG of both R6/2 and wild-type mice 
(A). Significantly fewer PCNA-positive cells were found in R6/2 mice. Values represent 
means ± S.E.M. Representative sections of the DG processed for PCNA 
immunohistochemistry in wild-type (B) and R6/2 mice (C) at 11.5 weeks of age. Scale 
bar = 50 μm. 
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Again, we observed a non-significant trend towards a decrease in the number 
of PCNA-labeled cells at the early age of 2 weeks in R6/2 mice (10% reduction) 
(Figure 6.3.A). However, this marker was less sensitive at detecting decreases in 
cell proliferation at 11.5 weeks of age, since we only observed about a 36% 
decrease in the number of PCNA-labeled cells (Figure 6.3), compared to 66% 
and 72% with BrdU and Ki-67, respectively. 
Neuro D is a helix-loop-helix transcription factor that is expressed during 
development in the mammalian brain. Mutant mice homozygous for a deletion at 
the NeuroD locus fail to develop a granule cell layer within the DG, which is due 
to a severe defect in the proliferation of hippocampal precursor cells and to a 
delayed differentiation of these precusor cells into granule cells (Liu et al., 
2000). Interestingly, a recent study has also shown that NeuroD interacts with 
both normal and mutant huntingtin (section 1.3.1; Marcora et al., 2003). When 
we labeled for NeuroD, we observed a significant 79.5% reduction in the 
number of NeuroD-positive cells in the DG of 11.5-week-old R6/2 mice 
(Student’s t test, p < 0.01) (Figure 6.4). 
 
Figure 6.4. - Reduced cell proliferation in the DG of R6/2 mice as assessed with the 
transcription factor NeuroD. (A) There was a significant decrease in the number of 
NeuroD-immunopositive cells in the DG of 11.5-week-old R6/2 mice as compared with 
wild-type mice (Student’s t test, ** p < 0.01). Values represent means ± S.E.M. 
Representative photomicrographs of the DG processed for NeuroD 
immunohistochemistry in wild-type (B) and R6/2 mice (C) at 11.5 weeks of age. Scale 
bar = 50 μm. (Gil and van der Burg et al., unpublished observations). 
 
 
 
6.4.2. Decreased Hippocampal Neurogenesis at Both Early and at End 
Stage of Disease in R6/2 Mice  
Three and a half and 8-week-old mice were injected with BrdU (every 12 h, 
during 3 days) and allowed to survive for an additional 2 weeks before being 
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sacrificed. The total number of BrdU-labeled cells 2 weeks after the last BrdU 
injection was significantly lower in R6/2 as compared to wild-type mice at both 
ages (2-factor ANOVA; genotype p < 0.0001, F (1, 17) = 52.75; age p < 0.0001, 
F (1, 17) = 72.46; genotype x age p < 0.005, F (1, 17) = 12.99) (Figure 6.5.A). 
 
Figure 6.5. - Decreased hippocampal neurogenesis in R6/2 mice. To study whether 
the reduced cell proliferation reflected a decrease in neurogenesis, 5.5- and 10-week-old 
mice were sacrificed 2 weeks after the last BrdU injection to allow for differentiation of 
the proliferating cells that incorporated BrdU. (A) A significant reduction in BrdU-
labeled cells was found in the DG of R6/2 mice at both ages compared to wild-type 
mice. (B) In the DG of both 5.5- and 10-week-old wild-type and R6/2 mice, around 80-
90% of the BrdU-labeled cells were NeuN-positive. Values represent means ± S.E.M. 
(C) A representative confocal image of a cell immunopositive for both BrdU (red) and 
NeuN (green) in the DG of a 10-week-old R6/2 mouse. Scale bar = 8 μm.  
 
 
Interestingly, if the average number of BrdU-labelled cells at 5.5 weeks (2 
weeks post-injection; Figure 6.5) was compared with the cell proliferation 
numbers at 3.5 weeks (18 h post-injection; Figure 6.1), there were 35% less 
BrdU-positive cells in wild-type and 69% less BrdU-positive cells in R6/2 mice 
at 5.5 weeks of age. Similarly, if one compares the BrdU numbers at 10 weeks (2 
weeks post-injection; Figure 6.5) with the cell proliferation numbers at 7.5 
weeks (18h post-injection; Figure 6.1), one finds 73% less BrdU-positive cells 
in wild-type and 84% less BrdU-positive cells in R6/2 mice at 10 weeks of age. 
Therefore, waiting 2 weeks after the last BrdU injection allowed us to determine 
the survival rate of newly born precursor cells. 
We also evaluated the proportion of precursor cells that become neurons by 
confocal analysis. We estimated that about 80-90% of the BrdU-labeled cells co-
expressed the specific neuronal marker NeuN at both 5.5 and 10 weeks of age 
(2-factor ANOVA; genotype p = 0.08, F (1, 17) = 3.50; age p < 0.01, F (1, 17) = 
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9.85; age x genotype p < 0.05, F (1, 17) = 6.87) (Figures 6.5.B and C). In order 
to determine the nature of the remaining BrdU-positive cells, we performed a 
double-abeling for BrdU and the glial marker GFAP (data not shown). However, 
due to the fact that the DG is a very dense and compact cell layer and BrdU is 
localized in the nucleus whereas GFAP is present in the cytoplasm, it was 
virtually impossible to conduct a proper double-labeling determination with the 
confocal microscope. 
Doublecortin is a microtubule binding protein that is expressed in newly 
differentiated and migrating neuroblasts (Brown et al., 2003). In 10-week-old 
R6/2 mice, we also observed a significant 65% reduction in the number of 
doublecortin-labeled cells (Student’s t test, p < 0.01), further indicating a 
reduction in hippocampal neurogenesis (Figure 6.6). 
 
Figure 6.6. - Decreased number of neuroblasts in the DG of R6/2 mice. (A) The 
reduced hippocampal neurogenesis in R6/2 mice was confirmed by a significant 
decrease in the number of doublecortin-immunopositive neuroblasts in the DG of 10-
week-old R6/2 mice as compared to wild-type controls (Student’s t test, ** p < 0.01). 
Values represent means ± S.E.M. Representative photomicrographs of the DG 
processed for doublecortin immunohistochemistry in wild-type (B, C) and R6/2 mice 
(D, E) at 10 weeks of age. Scale bar = 50 μm (B, D) and = 20 μm (C, E). 
 
 
6.4.3. R6/2 Mice Exhibit Normal Proliferation in the SVZ 
We evaluated the volume of the SVZ, the other neurogenic zone in the adult 
brain, in young and old R6/2 and wild-type mice. The total volume of the SVZ 
was 0.072 ± 0.004 mm3 in wild-type and 0.072 ± 0.003 mm3 in R6/2 mice at 3.5 
weeks, and 0.071 ± 0.003 mm3 in wild-type and 0.057 ± 0.003 mm3 in R6/2 mice 
at 11.5 weeks of age. Two-factor ANOVA revealed a significant difference 
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between the age groups (p < 0.05, F (1, 26) = 5.28). However, no difference 
between the genotypes (p = 0.051, F (1, 26) = 4.17), or any interaction between 
age and genotype (p = 0.054, F (1, 26) = 4.08) were detected. 
 
Figure 6.7. - No difference in cell proliferation in the SVZ of R6/2 mice. Cell 
proliferation in the SVZ of 3.5- and 11.5-week-old R6/2 mice and wild-type littermates 
was examined using stereological assessment of BrdU-labeled cells (A). Representative 
sections of the SVZ processed for BrdU immunohistochemistry in wild-type (B) and 
R6/2 mice (C) at 11.5 weeks of age. The cell cycle marker PCNA was also used to 
assess cell proliferation in the SVZ of 11.5-week-old R6/2 mice (D). Again, no 
significant difference in the number of PCNA-positive cells was detected between the 
two genotypes (Student’s t test, n.s., non-significant). Representative photomicrographs 
of the SVZ processed for PCNA immunohistochemistry in wild-type (E) and R6/2 mice 
(F) at 11.5 weeks of age. Scale bar = 100 μm. Values represent means ± S.E.M. 
 
 
We then examined the total number of BrdU-labeled cells in this region and 
found no significant differences between R6/2 and wild-type mice at both ages 
(2-factor ANOVA; significant effect of age: p < 0.04, F (1, 26) = 4.98; no 
significant effect of genotype: p = 0.43, F (1, 26) = 0.64; no significant 
interaction age x genotype: p = 0.84, F (1, 26) = 0.04). (Figures 6.7.A-C). 
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Furthermore, the total number of PCNA-labeled cells in the SVZ did not differ 
between 11.5-week-old R6/2 and wild-type mice (Student’s t test, p = 0.56) 
(Figures 6.7.D-F). 
These results further confirm our previous published observations of 
reduced cell proliferation that is restricted to the DG and does not affect the SVZ 
in 12-week-old R6/2 mice (Gil et al., 2004; Chapter 5). 
 
 
 
6.5. Discussion 
 
In this study we report an age-related decline in hippocampal cell 
proliferation, both in R6/2 HD mice and in wild-type littermate controls. The 
reduction in hippocampal cell proliferation with aging in wild-type mice is in 
agreement with previous studies (Bizon and Gallagher, 2003). Nevertheless, 
R6/2 mice exhibited a greater reduction in the number of BrdU-positive cells 
than that expected with normal aging. This reduction can be detected as early as 
2 weeks of age, before any behavioral or widespread neuropathological features 
have been reported in R6/2 mice. Therefore, reduced neurogenesis may 
constitute one of the initial pathological steps in the disease process. 
Our study is the first to systematically investigate progressive changes in 
neurogenesis in a HD model. We previously showed a reduction in cell 
profileration in R6/2 mice (Gil et al., 2004; Chapter 5), which has been 
confirmed by Lazic and coworkers in R6/1 mice (Lazic et al., 2004, 2006). In 
the present study we extended our knowledge of this deficit by showing the 
progressive nature of the reduced cell proliferation using a variety of different 
cell cycle markers; i.e. BrdU, Ki-67, and PCNA. Furthermore, we demonstrate 
that 80-90% of the surviving proliferating cells became neurons in both wild-
type and R6/2 mice, a similar percentage to what has been reported previously 
(for review see Duman et al., 2001a, 2001b). We also found a reduction in the 
survival rate of newly born precursor cells both in wild-type and R6/2 mice. In 
agreement, a massive reduction in the number of BrdU-labeled cells is 
commonly reported during the first days up to more than two weeks after the last 
administration of BrdU and is thought to be due to cell death (Gould et al., 1999; 
Dayer et al., 2003). 
Several recently published studies have failed to replicate our findings, in 
that no differences in basal cell proliferation were detected in the DG of R6/1 
(Grote et al., 2005) or R6/2 mice (Jin et al., 2005; Phillips et al., 2005). The 
reasons for these discrepancies are currently unknown. They may be attributable 
to differences between different mice colonies, protocols of BrdU administration 
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or the methods used to quantify BrdU-labeling. It is interesting to note that in all 
these reports stereological counting methods were used to determine the total 
number of DG proliferating cells (Grote et al., 2005; Jin et al., 2005; Phillips et 
al., 2005); whereby, in our hands we are unable to use this technique due to the 
inability to count at least 200 labeled cells, which is one of the basic tenants of 
stereological principles (sections 5.3.4 and 6.3.4; Gundersen et al., 1988). These 
authors do not state whether or not they met this basic stereological requirement; 
but, if they did not, a great bias would be introduced into their counting 
procedure. 
Nevertheless, in the study by Phillips and colleagues (2005), R6/2 mice 
failed to up-regulate DG neurogenesis in response to KA-induced seizures (a 
very robust method of inducing DG neurogenesis), confirming that indeed these 
mice show a compromised neurogenic process (Phillips et al., 2005). These 
authors also speculate that the reduced cell proliferation in response to seizures 
is attributed to the surrounding environment in which these progenitor cells are 
located, rather than any intrinsic impairment of the precursor cells itself (Phillips 
et al., 2005). However, this hypothesis was based on the fact that neurospheres 
derived from the SVZ of 8-week-old R6/2 and wild-type mice have the same 
proliferative capacity (Chu-LaGraff et al., 2001; Phillips et al., 2005), which is 
in agreement with the normal cell proliferation observed in the R6/2 SVZ. Since 
neurospheres derived from the adult DG are difficult to maintain in culture 
(Phillips et al., 2005), one should be careful when speculating about the actual 
intrinsic proliferative capacity of the precursor cells in this neurogenic brain 
region. 
Classically, HD is considered a neurodegenerative disease in that 
dysfunction and death of neurons underlie most, if not all, of the symptoms. 
Although the cerebral cortex, the striatum and the hypothalamus are the major 
sites for neuropathology in HD (section 1.2.2), some studies have reported cell 
loss also in the hippocampus of HD patients (Rosas et al., 2003; for review see 
Vonsattel and DiFiglia, 1998). Keeping in mind that R6/2 mice show reduced 
neuronal death (section 1.6.1.2; Iannicola et al., 2000; Turmaine et al., 2000; 
Helmlinger et al., 2002; Yu et al., 2003; Stack et al., 2005; Chapter 4), we have 
shown no neuronal loss in the DG of the hippocampus with NeuN 
immunohistochemistry (Gil et al., 2004; Chapter 5) and FJ staining (Gil et al., 
unpublished observations). Nevertheless there is strong electrophysiological and 
behavioral evidence for hippocampal dysfunction (Murphy et al., 2000) in these 
mice. It remains to be seen if the disturbed neurogenesis in R6 mice participates 
in hippocampal dysfunction. Nevertheless, Grote and colleagues (2006) have 
recently shown an improvement of the cognitive function in R6/1 mice upon 
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recovery of DG cell proliferation followed by fluoxetine treatment (Gore et al., 
2006). 
Given that expanded CAG repeats in huntingtin can lead to the dysregulation 
of transcription, intracellular trafficking and metabolism (section 1.3; for review 
see Li and Li, 2004), it is plausible that they may also interfere with the 
proliferative capacity of progenitor cells. Indeed, huntingtin is known to interact 
with the cell cycle machinery (for review see Li and Li, 2004). Huntingtin can 
also become associated with the centrosome and microtubules (Gutekunst et al., 
1995; Hoffner et al., 2002), the latter through interaction with β-tubulin (section 
1.3.1; Hoffner et al., 2002). Interestingly, the HEAT repeat motifs present in the 
huntingtin sequence (Andrade and Bork, 1995) are also found in a number of 
proteins that are involved in mitotic progression, chromosomal dynamics and 
segregation (section 1.3.1; Neuwald et al., 2000) and several of these proteins 
exert their functions via microtubules. Dysfunctional microtubule dynamics 
caused by mutant huntingtin may be a more broad phenomenon in HD, since a 
reduced proliferative capacity is not only found in the brain but also in the 
pancreas of end-stage R6/2 mice (Björkqvist et al., 2005). 
As stated above (section 1.3.1), normal huntingtin and the huntingtin-
associated proteins HAP1 and MLK2 modulate and stimulate the activity of 
NeuroD (Marcora et al., 2003), a transcription factor that is crucial for the 
development of a functional DG (Liu et al., 2000). NeuroD is also expressed in 
the pancreas, where it plays an important role in the morphogenesis of normal 
islets (Huang et al., 2002). The relationship between normal huntingtin, NeuroD 
and genesis of new cells (both in the DG and in the pancreas) raises the exciting 
possibility that an abnormal interaction between mutant huntingtin and NeuroD 
could contribute, at least in part, for the compromised generation of new cells 
observed both in the DG and in the pancreas of R6/2 HD mice. Arguing against 
this hypothesis, the study of Marcora and co-workers (2003) showed that 
NeuroD activity could also be stimulated by mutant huntingtin in vitro (Marcora 
et al., 2003). However, as the authors suggested, the aggregates of mutant 
huntingtin that are formed in vivo may interfere with NeuroD activation. 
Interestingly, we found a drastic decrease in the number of NeuroD-positive 
cells in the DG of R6/2 mice (Figure 6.4; Gil and van der Burg et al., 
unpublished observations). Whether this decrease is a cause or a consequence of 
the observed reduced cell proliferation remains to be elucidated. Further 
experiments are needed in order to conclude if a compromised NeuroD pathway 
(due, for instance, to its sequestration into NIIs of mutant huntingtin) is 
contributing to a reduction in the generation of new cells (neurons and pancreatic 
cells), or if this decrease in the number of NeuroD-positive cells simply reflects 
the down-regulation of another cell proliferation marker. 
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Interestingly, a disturbed NeuroD function would also explain the down-
regulation of certain genes that are regulated by this transcription factor. One 
example is the neurotrophin BDNF, whose expression is regulated by huntingtin 
and NeuroD, and that has been shown to be down-regulated in HD (sections 
1.3.1 and 1.3.3.3; Zuccato et al., 2001; Luthi-Carter et al., 2002; Canals et al., 
2004; Spires et al., 2004). BDNF has also been shown to stimulate cell 
proliferation in the neurogenic zones and to promote migration of progenitor 
cells from the SVZ to non-neurogenic regions like the striatum and septum, the 
thalamus and the hypothalamus (Benraiss et al., 2001; Pencea et al., 2001; 
Mohapel et al., 2005). Therefore, one can speculate that the down-regulation of 
BDNF observed in HD (Zuccato et al., 2001; Luthi-Carter et al., 2002; Canals et 
al., 2004; Spires et al., 2004) can also contribute to the decrease in cell 
proliferation. 
A recent study showing a reduction in cell proliferation, both in the DG and 
the SVZ, in PD brains has also implicated the dopaminergic system in the 
regulation of neurogenesis (Hoglinger et al., 2004). In this paper the authors also 
show that experimental depletion of DA in rodents decreases precursor cell 
proliferation in both the DG and the SVZ. Moreover, a selective agonist of D2-
like receptors is enough to completely restore proliferation, further supporting 
the idea that DA can promote cell proliferation (Hoglinger et al., 2004). As 
stated above, several studies have shown that a dopaminergic dysfunction may 
also be implicated in HD (section 1.4.2). In fact, R6 mice display a deficient 
dopaminergic neurotransmission (Bibb et al., 2000; Petersén et al., 2002b; 
Chapter 3). Whether this dysfunction in the dopaminergic neurotransmission is 
contributing to the observed compromised neurogenesis in R6/2 mice, is a 
hypothesis that needs to be further evaluated. 
Still another factor that can account for these results is an increase in the 
levels of glucocorticoids, which are known to down-regulate neurogenesis 
(section 5.2; Cameron and McKay, 1999). Importantly, we have recently shown 
a progressive increase in the serum and urine levels of corticosterone in R6/2 
mice (section 1.6.1.4; Björkqvist et al., 2006a). Therefore, it is possible that the 
alterations in the hypothalamic-pituitary-adrenal axis (Björkqvist et al., 2006a) 
may contribute to the progressive decrease in cell proliferation and neurogenesis 
in R6/2 mice. 
In contrast with the decrease observed in the DG, in the SVZ we found no 
difference between R6/2 and wild-type mice in the number of proliferating cells. 
This is in agreement with our previous examination of BrdU-labeled cells in the 
SVZ in 12-week-old R6/2 mice (Gil et al., 2004; Chapter 5). We also assessed 
the total number of PCNA-positive cells in the SVZ of 11.5-week-old mice and 
found again no differences. Phillips and colleagues (2005) have recently 
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extended these results and demonstrated that the number and migration of 
neuroblasts generated in the SVZ is not altered in R6/2 mice (Phillips et al., 
2005). Similar findings in the R6/1 model were also recently published (Lazic et 
al., 2006). However, contradictory results were reported in HD human tissue, 
where an increased cell proliferation in the SVZ (estimated by assessing the 
number of PCNA-positive cells) was described (Curtis et al., 2003, 2005a, 
2005b, 2006).  
The discrepancy between the results in R6 mice and HD patients could be 
due to several factors. For instance, the R6 mice express a higher number of 
CAG repeats and display a greater frequency of inclusions than HD patients. 
Alternatively, as suggested by Phillips and co-workers (2005), it may be the case 
that R6 mice simply do not live long enough for that phenomenon to be detected 
(Phillips et al., 2005). 
On the other hand, it has been suggested that PCNA can also be expressed in 
cells undergoing DNA repair (Tomasevic et al., 1998), and therefore caution 
should be taken when evaluating cell proliferation results that are exclusively 
based on PCNA immunohistochemistry. Although in theory BrdU could also 
label cells undergoing apoptosis and DNA repair, this is unlikely to be the case 
whith the low BrdU concentration used in our study. Indeed, several 
experimental data have shown that BrdU-positive cells mature into neurons in 
the rodent DG, that irradiation reduces the amount of BrdU labeling while 
increasing DNA repair and apoptosis, and no BrdU labeling has been detected in 
cells undergoing apoptosis (Cooper-Kuhn and Kuhn, 2002). Nevertheless, the 
validation of the results obtained with BrdU labeling with 
immunohistochemistry for endogenous cell cycle markers like Ki-67 and PCNA 
is the best option in order to draw definite conclusions regarding changes in cell 
proliferation. 
Finally, one can speculate that cell loss in the caudate nucleus of HD patients 
is the actual trigger for the increased SVZ cell proliferation reported by Curtis 
and colleagues (Curtis et al., 2003, 2005a, 2005b, 2006). In agreement with this 
scenario, an increased neurogenesis was also observed in the striatum of the QA-
lesion rat model of HD (Tattersfield et al., 2004), where an excitotoxicity-
induced striatal lesion was enough to promote SVZ neurogenesis. Similar results 
were also obtained with other lesion paradigms, such as rat models of stroke 
(Arvidsson et al., 2002; Parent et al., 2002) and PD (Fallon et al., 2000). On the 
other hand, the cell death occurring in the striatum of R6/2 mice (section 1.6.1.2; 
Iannicola et al., 2000; Turmaine et al., 2000; Yu et al., 2003; Stack et al., 2005) 
may not be enough to stimulate cell proliferation in the adjacent SVZ. 
Interestingly, R6/2 mice failed to up-regulate cell proliferation in the SVZ in 
response to QA-induced excitotoxic striatal lesions (Phillips et al., 2005), in 
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agreement with the well documented striatal resistance to excitotoxic insults 
(Hansson et al., 1999, 2001b), and further supporting the hypothesis of an overt 
striatal cell death as being the actual trigger for SVZ proliferation in HD 
patients. Nevertheless, treatment of R6/2 mice with fibroblast growth factor 2 
(FGF2) stimulated SVZ cell proliferation (by 150%), as well as the migration of 
new neurons from this region into the cerebral cortex and striatum (where they 
differentiate into DARPP-32-expressing medium spiny neurons) (Jin et al., 
2005). Furthermore, FGF2 treatment reduced the number of NIIs, improved 
motor function, and increased the life span of these animals by 20%, suggesting 
that potentiation of SVZ neurogenesis may be used for the treatment of HD (Jin 
et al., 2005). 
We conclude that the progressive decline in hippocampal cell proliferation 
observed in R6/2 HD mice is a novel neuropathological feature that occurs early 
in the progression of the disease, before the appearance of any other HD 
symptoms. Therefore, cell proliferation might be assessed when evaluating the 
efficacy of potential therapies in this HD mouse model. Nevertheless, future 
studies are still needed in order to evaluate hippocampal neurogenesis in the 
human HD brain. 
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7.1. Final Conclusions 
 
The work presented in this thesis has broadened our understanding of the 
varied neuropathology associated with HD. We attempted to evaluate the impact 
of nonstriatal brain regions on striatal degeneration. We also looked to other 
brain structures to understand how they could contribute to a wide array of HD 
symptoms. We utilized several different rodent models of HD to address these 
questions. Due to the diverse nature of the final conclusions of the studies 
included in this thesis, each are summarized under a separate and specific aim 
(section 1.7): 
 
1) To evaluate the striatal response to an excitotoxic insult that mimicks an 
excessive activitation of the glutamatergic corticostriatal pathway in the newly 
generated rat model (Chapter 2). 
We conclude that the newly generated transgenic HD rat model, which 
expresses a huntingtin fragment of intermediate size bearing 51 CAG repeats 
under the control of the rat Hdh promoter (von Hörsten et al., 2003), was not 
resistant to QA-induced excitotoxic striatal lesions. By comparing our results 
with those obtained with different HD transgenic mouse models, we hypothesize 
that sensitivity/resistance to striatal excitotoxic insults is a function of the length 
of the expressed mutated huntingtin gene. Moreover, since the intrastriatal 
injection of excitotoxins represents an acute insult, they may not model well the 
more chronic dysfunction of the corticostriatal pathway associated with 
sustained excitotoxicity that occurs in the human HD brain. 
 
2) To further characterize the impairment of the dopaminergic nigrostriatal 
pathway in the R6/1 mouse, by using in vivo microdialysis (Chapter 3). 
We present further evidence implicating a dysfunction of the dopaminergic 
nigrostriatal pathway in the neuropathology of R6 mice. By performing in vivo 
microdialysis in R6/1 mice, we were able to detect several disturbances of this 
pathway at the presynaptic level, namely a reduction of striatal DA release (both 
by exocytosis and through an efflux via the DAT). This decrease was 
accompanied by a reduction in the striatal levels of this neurotransmitter and its 
metabolites (DOPAC and HVA). A disturbance in the synthesis of DA (due to a 
reduction of TH expression) (Ariano et al., 2002; Yohrling et al., 2003; Smith et 
al., unpublished data) is likely to be the underlying cause of the impairment of 
both DA release routes. We speculate that the dysfunction of the dopaminergic 
nigrostriatal pathway may in fact contribute to the neurodegeneration of striatal 
neurons. Moreover, the deficient dopaminergic neurotransmission is likely to be 
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responsible for some of the motor symptoms of the disease (e.g., bradikynesia 
and rigidity), especially in late-stage HD patients and transgenic HD mice. 
 
3) To determine whether the lateral hypothalamus, a structure involved in 
the regulation of several peripheral and endocrine functions, is affected by HD 
pathology in both R6/2 mice and human HD brains (Chapter 4). 
We report, for the first time, loss of specific neuronal populations in the 
lateral hypothalamus of R6/2 mice. These populations express either orexin 
(involved in the regulation of the sleep/wakefulness cycle), or MCH (which 
controls energy homeostasis and food intake). Importantly, reduction in the 
number of orexin neurons was also observed in human HD brains, extending 
initial studies that indicated loss of somatostatin-positive neurons in another 
region of the hypothalamus, the lateral tuberal nucleus (Kremer et al., 1990, 
1991). Moreover, loss of orexin in the R6/2 mice is accompanied by the 
development of a narcoleptic-like phenotype resembling orexin knockout mice 
(Chemelli et al., 1999). Evaluating the implications of loss of MCH neurons is 
beyond the scope of this thesis. However, it is likely that loss of these neurons 
do contribute, at least in part, to the reduced body weight observed in both 
human HD patients and R6/2 mice. 
 
4) To study the contribution of the DG of the hippocampus, a structure 
important for cognitive functioning, on new neuron production and in HD 
pathology in R6/2 mice (Chapters 5 and 6). 
We discovered a progressive and specific impairment of neurogenesis in the 
DG of the hippocampus in R6/2 mice. The decrease in cell proliferation was first 
observed at a time when no widespread neuropathological, motor, or cognitive 
symptoms are known to occur. As the HD mice age and the disease symptoms 
and pathology increasingly manifest, there is an even further decline in DG 
neurogenesis. Interestingly, the decrease in neurogenesis appears to be restricted 
to the hippocampus, since we observed no evidence of reduced cell proliferation 
in the SVZ of R6/2 mice. Importantly, one of the mechanisms that can account, 
at least in part, for these observations is a reduction in dopaminergic 
neurotransmission, in accordance with the results presented on Chapter 3. Since 
a similar reduction in cell proliferation was reported to occur in the DG of R6/1 
mice (Lazic et al., 2004, 2006), we conclude that a reduced neurogenesis is a 
common feature of the R6 lines, constituting a novel neuropathological feature 
of these transgenic models. A reduced neurogenesis may have functional 
implications in HD, for instance at the cognitive level. 
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5) To assess the effects of a novel neuroprotective compound (asialoEPO) on 
motor function, striatal neuropathology and hippocampal cell proliferation in 
R6/2 mice (Chapter 5). 
Evaluation of hippocampal cell proliferation in R6 mice is a potential 
method for determining the efficacy of new therapeutic strategies. Therefore, we 
evaluated whether asialoEPO, an EPO analogue, has any beneficial effects on 
motor symptoms, neuropathology, or cell proliferation in R6/2 mice. In our 
hands this compound had no benefits on any of the outcome variables, including 
hippocampal cell proliferation. We conclude that this compound is not an 
effective candidate for the treatment of HD-related symptomology. 
 
To conclude, we provide further evidence implicating the involvement of 
brain regions that directly interact with the striatum (i.e., the substantia nigra) in 
striatal degeneration, which may impact the development of motor symptoms in 
HD. Moreover, we also demonstrate that other nonstriatal brain regions, 
specifically the lateral hypothalamus and the DG of the hippocampus, are also 
afflicted in R6/2 HD mice and, in the case of the lateral hypothalamus, in HD 
human brains. The observed alterations (loss of orexin- and MCH-containing 
neurons in the lateral hypothalamus and decreased neurogenesis in the DG) are 
likely to have significant functional implications. These may include 
disturbances of the sleep/wakefulness cycle and development of a narcoleptic-
like behaviour, loss of body weight, and cognitive impairment. 
 
 
7.2. Future Directions 
 
The field of HD has been the focus of intensive research during the past 
decade, especially after the identification of the gene and the mutation 
responsible for the disease (The Huntington’s Disease Collaborative Research 
Group, 1993). This discovery lead to the generation of the R6 lines, the first HD 
transgenic mouse models (Mangiarini et al., 1996). Despite the efforts of a 
multidisciplinary approach from a broad array of researchers, a cure for this 
devastating neurodegenerative disorder still eludes us. A cure for HD will 
depend on our ability to understand the mechanisms underlying the 
neurodegeneration caused by the expression of mutant huntingtin. 
The research presented in this thesis, as is often the case in science, leave 
many more questions unanswered and deserving further investigation. More 
specifically, it will be important to further characterize the sleep disturbances in 
HD patients. Furthermore, the impact of loss of MCH-containing neurons in the 
lateral hypothalamus of R6/2 mice deserves further attention, and a relationship 
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between loss of MCH and the decreased body weight observed in R6/2 mice is 
currently under investigation. Moreover, a validation of these results in human 
HD samples is of primary importance. Finally, assessing hippocampal 
neurogenesis in HD human brains will be important. Determining the exact 
mechanisms responsible for the reduced neurogensis may shed some more light 
on the pathogenesis of HD. Ultimately, the answer to these questions will clearly 
define the importance of these nonstriatal brain regions for the pathology of HD. 
The development of new therapies specifically designed to ameliorate the 
nonstriatal symptoms is likely to improve the quality of life as well as increase 
life expectancy of patients afflicted with this devastating disorder. 
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